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Abstract 
Gardnerella vaginalis is the etiological agent of bacterial vaginosis (BV), a chronic vaginal 
infection that affects women globally. Increasing antibiotic resistance and failing treatment 
options has resulted in chronic BV, demonstrating a need for novel alternative therapeutics. A 
total of 34 environmental bacterial isolates with antimicrobial properties against a G. vaginalis 
collection (n=17) were isolated and characterized for their antagonistic effects against G. 
vaginalis isolates and for their production of antimicrobial active agents. The G. vaginalis 
collection was shown to be diverse by genotyping and by their antibiotic susceptibility profiles. 
Anti-G. vaginalis (αGV) isolates were identified and phylogenetically clustered following full 
genome sequencing and their antiGV target range specificities were investigated. A subset of the 
αGV collection (n=20) were shown to produce and export active antimicrobial agents with 
molecular sizes of 4.6-35kD, which showed specific lethal effect on G. vaginalis isolates (target 
ranges of 5-100%). Cocktail formulations consisted of promising representatives from αGV 
clusters, with overlapping complimentary properties and specificity to G. vaginalis were 
identified for further study as the antimicrobial candidates for BV.   
Keywords 
Gardnerella vaginalis, Bacterial vaginosis, Antimicrobial peptides, Antibiotic Resistance, Host 
Range, Alternative Therapeutics, Genome, Clinical isolates, Bacteriocin 
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1 Introduction 
1.1 Gardnerella vaginalis 
Gardnerella vaginalis, the etiological agent of bacterial vaginosis (BV), was first observed by 
Leopold in 1953 and later identified and characterized as Haemophilus vaginalis (Gardner and 
Dukes, 1954; Dukes and Gardner, 1961). G. vaginalis  grows as circular, convex, small grey 
colonies on human and rabbit blood agar plates and produces β-hemolysis with diffused edges, 
with no effect on sheep blood (Leopold, 1953; Gardner and Dukes, 1954; Greenwood and 
Pickett, 1980; Piot et al., 1982).  G. vaginalis is a Gram-variable, coryneform, nonmotile, 
nonsporulating, facultative anaerobe of approximately 0.8-1.2 µm in size, containing a fibrillar 
nucleoid and volutin metaphosphate granular development in the cytoplasm in stationary and 
death phases of growth (Leopold, 1953; Gardner and Dukes, 1954; Dukes and Gardner, 1961; 
Criswell et al., 1972; Wells and Goei, 1981; Sadhu et al., 1989). Its pleomorphic properties have 
led to a great debate over the Gram classification and taxonomy of the bacterium. It was 
suggested that the bacterium be classified as part of the genus Haemophilus based on the 
organism being Gram-negative (Dukes and Gardner, 1961). This was supported by the low 
peptidoglycan content (about 20% of the cell wall), lack of teichoic acids, and an amino acid 
composition of cell wall preparations of 11-14 amino acids that resemble that of Escherichia coli 
but not Gram-positive Bacillus megaterium.  Cell membrane/cell wall fine electron micrographs 
were also used to identify the microorganism (Criswell et al., 1971, 1972). In 1966, Ryen et al. 
had produced electron microscopic data for Haemophilus vaginalis 594, the same strain that was 
used later in 1972 by Criswell et al., and compared it to other Gram-positive bacteria. It was 
shown that G. vaginalis had resemblance to low mucopeptide containing Corynebacterium 
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diphtheriae and Butyribacterium retgerri, but none of the Gram-positive Lactobacillus 
acidophilus and the Gram-negative Haemophilus influenza (Ryen et al., 1966). This lead Ryen et 
al. (1966) to suggest that the G. vaginalis be classified under either of genera Corynebacterium 
or Butyribacterium but not Haemophilus. The taxonomic state of G. vaginalis claimed by 
Criswell et al (1971, 1972) was further called into question when several groups showed the 
resemblance of the amino acid composition of the peptide bridge of its cell wall to that of Gram-
positive bacteria (Ryen et al., 1966; Harper and Davis, 1982). In contrast to Criswell’s findings it 
was shown that the cell wall amino acid composition of G. vaginalis isolates was limited in 
diversity, with the most common amino acids being alanine, lysine, glutamic acid and glycine, 
consistent with the majority of Gram-positive bacteria, having a range of 4 to 6 major amino 
acids in their peptidoglycans (Schleifer and Kandler, 1972; Harper and Davis, 1982; O’Donnell 
et al., 1984). In addition, the cell division processes described by electron microscopy resembles 
Gram-positive bacteria with the development of a thick septa (Ryen et al., 1966; Sadhu et al., 
1989). The lack of an outer membrane and LPS furthermore supported Gram-positive properties 
of G. vaginalis (Sadhu et al., 1989). However, Criswell et al. reported that visualization of a 
layered cell wall was dependent on the angle at which the wall was dissected for imaging. An 
oblique angle was the culprit for this illusion of a Gram-negative cell wall structure for G. 
vaginalis (Criswell et al., 1971, 1972; Greenwood and Pickett, 1980). Other components of the 
cell wall found in lesser amounts included glucose, galactose and 6-deoxytalose (Harper and 
Davis, 1982). It was then suggested that the bacterium was in fact Gram-positive but assembled a 
thinner cell wall than normal, resulting in growth dependent Gram-variable staining properties 
(Sadhu et al., 1989).  
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Nevertheless, the taxonomic deliberation could not be put to rest due to finding that the 
bacterium lacked requirements for specific growth factors, X (hemin) and V (NAD), associated 
with the genus Haeomophilus and thus was reclassified as a member of genus Corynebacterium, 
more specifically Corynebacterium vaginale (Edmunds, 1960; Zinnemann and Turner, 1963; 
Dunkelberg and McVeigh, 1969; Greenwood and Pickett, 1980). Its microscopic morphology 
may present similarities to the genera Haemophilus and Corynebacterium, however, through 
DNA-DNA hybridization no genetic association between G. vaginalis to Corynebacterium or 
Haemophilus was observed resulting in the current classification of G. vaginalis as the only 
species of the genus Gardnerella, named after Gardner, and the species name as vaginalis 
referring to the vagina as the location of bacterial isolation (Leopold, 1953; Gardner and Dukes, 
1954; Dukes and Gardner, 1961; Zinnemann and Turner, 1963; Greenwood and Pickett, 1980). 
Numerical taxonomy analysis additionally illustrated that 78 G. vaginalis isolates and several 
reference strains including ATCC 14018 had a relatedness exceeding 95% (Greenwood and 
Pickett, 1980).  
1.2 Diversity among G. vaginalis isolates  
Besides structural peculiarities, the G. vaginalis isolates show phenotypic and genotypic 
diversities. Discovery of biological markers and developing typing schemes are important in 
understanding the diversity among G. vaginalis isolates. Molecular typing methodologies have 
been developed based on biochemical/metabolic properties (Biotyping), serological properties 
(Serotyping), and genomic sequence properties (Genotyping and oligotyping).  The biotyping 
scheme relies on three biochemical tests; hippurate hydrolysis, β-galactosidase activity and the 
presence of lipase (Piot et al., 1984). At the present, there are eight biotypes to distinguish G. 
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vaginalis isolates (Piot et al., 1984). Biotype 1 (hippurate +, β-galactosidase +, lipase +), biotype 
2 (hippurate +, β-galactosidase -, lipase +) and biotype 5 (hippurate +, β-galactosidase -, lipase -) 
are the most commonly isolated biotypes from women who suffer from BV, while hippurate 
hydrolysis negative biotypes 3, 4, 7 and 8 having the lowest occurrence rates (Piot et al., 1984; 
Briselden and Hillier, 1990; Pleckaityte et al., 2012). A modified biotyping scheme was 
developed based on the addition of sugar fermentation tests for arabinose, galactose and xylose 
to the standard hippurate, β-galactosidase and lipase tests (Piot et al., 1984; Benito et al., 1986). 
This modified scheme resulted in 4 groups I, II, III and IV, which was further subdivided into a 
total of 17 biotypes (Benito et al., 1986).  
Serological typing is another method that has been used to characterize G. vaginalis isolates.  
This method relies on immunologic responses to bacterial antigenic determinants that aid in 
clustering bacteria to serotypes. Edmunds (1962) originally identified seven serotypes based on 
precipitin tests that used antisera produced against 13 strains of G. vaginalis. Thirty-six of the 
fifty (72%) G. vaginalis isolates where sorted into these serotypes (Edmunds, 1962). The method 
was deemed unsatisfactory and provided difficulty in standardization of antigenic determinants 
(Edmunds, 1962). Due to the weak responses observed in this time-extensive detection method, 
this system may lack sufficiency to be used as a standard method of G. vaginalis classification 
(Ison et al., 1987).  In addition, cross-reactivity of G. vaginalis antiserum against other bacteria 
including Neisseria gonorhoeae and Haemophilus influenzae has been observed in several other 
studies (Vice and Smaron, 1973; Boustouller et al., 1986). 
Genotyping methods aim at identifying and grouping the bacterial strains on the basis of their 
unique genomic sequence and genomic organization differences. Unlike serotyping and 
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biotyping methods, genotyping is independent from external variables such as the diversity of 
host immune responses and does not rely on phenotypic detection of enzymatic pathways that is 
limited by the number of tested traits and might be influenced environmentally. Therefore, 
genotyping methods offer uniquely strain-specific resolution. Southern blot-based classical 
typing (RFLP) were not successful, and PCR ribotyping using intergenic regions of the16S and 
23S ribosomal RNA operons of G. vaginalis did not produce diverse banding patterns (Ingianni 
et al., 1997). Genotyping based on amplified ribosomal DNA restriction analysis (ARDRA) and 
random amplified polymorphic DNA analysis (RAPD) of the 16S rRNA gene of G. vaginalis 
have been developed, which were able to resolve the genomic differences between subgroups of 
G. vaginalis. ARDRA was utilized to originally group G. vaginalis isolates into 3 to 4 genome 
types (Ingianni et al., 1997). It is important to note that the current molecular taxonomic 
classification of bacteria is based on the 16S rRNA sequence. Digestion of the 16S rRNA gene 
amplicon with restriction enzyme TaqI produced distinct banding patterns resulting in genotypes 
A, B, and C, while digestion with HpaII, categorized the G. vaginalis isolates into 4 genotypes 
(Ingianni et al., 1997). No specific correlation was observed between the above genotypes and 
the symptomatic manifestation of bacterial vaginosis. However, distribution of prevalent 
genotypes was shown to be unique to the places that G. vaginalis isolates were originated from, 
validating ARDRA as a powerful epidemiologic study tool. RAPD uses a fluorescently labeled 
single primer to randomly amplify segments of the chromosomal DNA to generate amplicons of 
variable sizes resulting in a species-specific banding fingerprint (El Aila et al., 2009; Lopes dos 
Santos Santiago et al., 2011). An assessment of RAPD as a genotyping technique for G. 
vaginalis was completed for 134 G. vaginalis isolates. In this study one-hundred and fifteen 
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(86%) isolates were originated from 10 Kenyan women and the remaining 19 isolates (14%) 
were from 16 Belgian women (Lopes dos Santos Santiago et al., 2011). Each of the 134 isolates 
had one of three DNA fingerprinting patterns, hence genotypes 1-3,  where genotype 3 was the 
resultant of the combined patterns of genotypes 1 and 2 (Lopes dos Santos Santiago et al., 2011). 
Confirmation of the diversity observed by DNA fingerprinting was further established by 
ARDRA Taq1 procedure, demonstrating that both techniques were reliable methods of genetic 
typing of G. vaginalis clinical isolates (Lopes dos Santos Santiago et al., 2011). Pleckaityte et al. 
(2012) subsequently identified 17 G. vaginalis clinical isolates with the previously described 
TaqI ARDRA technique, as being either genotype 1 or 2, which furthermore corresponded to 
Ingianni et al (1997) genotypes B and A, respectively (Ingianni et al., 1997; Lopes dos Santos 
Santiago et al., 2011). Direct sequencing of the 16S rRNA gene corresponding to genotypes 1 
and 2, followed by digestion with HindIII and BamHI, resulted in the subtyping of genotype 2 
(Ingianni et al., 1997). G. vaginalis isolates were consequently assigned into three genotypes; 
genotype 1, genotype 2 (subtypes 2A, 2B, 2C) and genotype 3 or B, A and C respectively 
(Ingianni et al., 1997; Lopes dos Santos Santiago et al., 2011; Pleckaityte et al., 2012). Since a 
standard naming scheme is absent for TaqI G. vaginalis genotyping we propose a unified naming 
scheme consistent with Ingianni et al. (1997) original scheme along with a modification to the 
subtyping nomenclature of Pleckaityte et al. (2012). This unified scheme results in genotypes; A 
(A1, A2, A3), B and C. Additionally, reference to ARDRA genotypes by HpaII digestion of G. 
vaginalis isolates will be indicated as genotypes 1, 2, 3, and 4 as stated previously by Ingianni et 
al. (1997).  
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Genotype prevalence with geographical bias has been detected among diverse populations as 
seen in the lack of genotype 3 G. vaginalis isolates acquired from Lithuania (Ingianni et al., 
1997; Pleckaityte et al., 2012). Additionally, no genotypic bias was observed among isolates 
acquired from Rome, Italy; however, in Cagliari, a municipality of Italy with a significantly 
lower population than Rome, genotype 2 was prevalent (Ingianni et al., 1997). TaqI genotype 2 
(i.e. genotype A) was also the most common genotype discovered in the Lopes dos Santos 
Santiago et al. study, making up to 49% of the isolates. Nevertheless, genotype 1 (26%;  i.e. 
genotype B) and genotype 3 (25%; i.e. genotype C) were both represented in this study as well 
(Lopes dos Santos Santiago et al., 2011). These observations suggested that G. vaginalis isolates 
may differ between geographic regions.  In addition, HpaII genotype 2 and TaqI genotype 2 (i.e. 
genotype A)  may be more pathogenically relevant (Ingianni et al., 1997; Lopes dos Santos 
Santiago et al., 2011).  
Oligotyping, is another genotyping scheme that was used to demonstrate diversity among G. 
vaginalis isolates. This high throughput technique was used to demonstrate low level taxonomic 
differences among 65,710 pyrosequencing reads of 16S rRNA gene segments in V4-V6 region of 
16S rRNA gene from 53 monogamous women and their male partners (Eren et al., 2011). The 
highly variable nucleotides within these segments were identified by Shannon entropy analysis 
that was translated to a total of 46 oligotype clusters. The oligotypes were demonstrated to be 
strongly correlated between monogamous couples providing evidence for sexual transmissibility 
of this pathogen (Eren et al., 2011). Further exploration into the validity of oligotyping as a 
method of high resolution subtyping and as a reliable epidemiological tool has to be established. 
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However, oligotyping has been utilized in the typing of the human oral microbiome, as well as in 
ecological studies (Eren et al., 2013, 2014; Kleindienst et al., 2016).  
In summary, typing methods have been invaluable in providing detailed insight into the 
biological diversity among G. vaginalis isolates, nevertheless, more important areas of future 
studies must focus on establishing link between the biological diversity and pathophysiology, 
prognosis of BV and antibiotic susceptibility. This will lead to effective preventative and 
treatment strategies, improved patient care and reduced demand on the healthcare system. 
1.3 Pathogenesis  
Bacterial vaginosis occurs when the balance of the vaginal microflora is disrupted resulting in a 
decline in natural vaginal Lactobacilli. Colonization of  vagina  by G. vaginalis leading to 
recruitment of other anaerobic bacteria by 100- to1000-folds displace the Lactobacillus species 
resulting in a polymicrobial establishment of bacterial vaginosis (reviewed in: Bautista et al., 
2016).  
A healthy vaginal environment is predominantly comprised of Lactobacilli including L. 
crispatus, L. gasseri, L. iners, L. plantarum, L. rhamnosus and L. suntoryeus (Swidsinski et al., 
2005; Anukam et al., 2006). Lactobacillus spp are known as a protective members of the vaginal 
microflora through competitive exclusion of pathogenic species by producing antimicrobials 
such as hydrogen peroxide (H2O2) and lactic acid (Patterson et al., 2007). Moreover, their 
competitive exclusion of G. vaginalis is facilitated by producing surface ligands and adhesions 
(Ojala et al., 2014). The type of lactobacillus species tested, however, shows variance in their 
protective nature against BV biofilm production (Castro et al., 2013).  L. crispatus was shown to 
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reduce the adhesion percentage of BV and non-BV associated strains to a lesser extent than L. 
iners; however, L. iners required a higher dosage to cause a significant decline in adhesion of the 
non-BV associated strain (Castro et al., 2013).   
G. vaginalis strains can also counteract Lactobacillus spp competitive exclusion capacities to 
differing degrees depending on the nature of the G. vaginalis isolates. For example, BV 
associated strains had a L. crispatus displacement rate of 63.8% while non-BV strains 
displacement rate was 19.0% (Castro et al., 2015). L. crispatus was also equally displaced by the 
addition of non-BV and BV associated G. vaginalis strains by up to 88% whereas L. iners 
displacement range was 8.6-11.4% from the non-BV associated G. vaginalis and 30.6-81.0% 
from the BV associated strain; where 81% displacement was induced with a high dosage of G. 
vaginalis (Castro et al., 2013).  
G. vaginalis initiates a BV infection partially due to its capability of inducing cytotoxicity and 
adhering to vaginal epithelial cells. Of the 30 BV associated bacteria (BVAB), isolated from BV- 
positive women in Alves et al.’s (2014) in vitro study, it was discovered that G. vaginalis had the 
highest cytotoxicity level whereas 80% of remaining 29 isolates had low cytotoxicity (Alves et 
al., 2014). It was determined to have the highest initial adhesion ability to Hela cells (Alves et 
al., 2014). This was supported by G. vaginalis adherence to an inert glass surface, which was 
pre-coated with L. crispatus, more efficiently than other BVAB: Fusobacterium nucleantum, 
Provetella bivia, Atopobium vaginae and Mobiluncus mulieris. The other BVAB adherence 
capacity is indicative of which stage of BV biofilm colonization they partake in (Machado et al., 
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2013). F. nucleatum was identified as an intermediate colonizer, while P. bivia, A. vaginae and 
M. mulieris as late colonizers (Machado et al., 2013). 
As well as displacing Lactobacillus spp and initiating biofilm, G. vaginalis has also been shown 
to enhance the growth of BVAB, P. bivia and F. nucleatum providing further support for G. 
vaginalis as the major etiological agent of BV (Machado et al., 2013). Furthermore, it has been 
established that G. vaginalis biofilm grows when an indiscriminate secondary BV-associated 
bacterium is established within the biofilm (Machado et al., 2013). Specifically, for P. bivia this 
symbiotic relationship occurs due to G. vaginalis production of amino acids that are utilized by 
P. bivia (Pybus and Onderdonk, 1997). The cycle continues as P. bivia produces ammonia that 
G. vaginalis utilizes further perpetuating an abundance of G. vaginalis and amino acid 
production (Pybus and Onderdonk, 1997).  
Other known BVAB, Brevibacterium mcbrellneri, Enterococcus faecalis, Mycoplasma hominis 
and Staphylococcus hominis have been shown to be capable of producing a biofilm, which 
contributes to the polymicrobial BV infection (Alves et al., 2014). Atopobium spp have 
additionally been observed to form biofilms and even generate up to 40% of a BV biofilm mass 
(Swidsinski et al., 2005).  
M. hominis is a BV-associated bacterium that has significant increased prevalence and elevated 
bacterial load in BV compared to non-BV afflicted women (Cox et al., 2016). M. hominis also is 
positively correlated with G. vaginalis prevalence and bacterial load in co-infections indicating a 
symbiotic relationship conducive to the development of a BV infection (Cox et al., 2016).  
Ureaplasma parvum prevalence rates were also increased in BV relative to intermediate and 
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non-BV subjects (Cox et al., 2016). Additionally, co-infection with G. vaginalis in BV positive 
women was 78.6% suggesting a possible link between U. parvum and BV (Cox et al., 2016). 
Atopobium vaginae and G. vaginalis may also have a symbiotic relationship as a higher Nugent 
score was more likely when both species were present in BV associated biofilms and through 
95.5% of samples containing A. vaginae also contained G. vaginalis (Hardy et al., 2016). Also 
increased bacterial loads of both G. vaginalis and A. vaginae are observed in the biofilms 
(Swidsinski et al., 2005; Hardy et al., 2015). However, A. vaginae has not been identified 
without the presence of G. vaginalis and has only a 14% predictive value for BV diagnosis via 
quantitative PCR, further supporting the hypothesis that G. vaginalis colonization initiates an 
environment change inducive to other anaerobic bacteria (Menard, 2008; Hardy et al., 2015). 
Horizontal gene transfer between BV associated bacteria does transpire, possibly increasing 
virulence properties and contributing to disease state (Harwich et al., 2010).  
1.4 Virulence factors 
Virulence factors of G. vaginalis strains associated with BV were compared to non-BV 
associated strains, and showed several differences with respect to adhesion, cytotoxicity and 
biofilm formation (Castro et al., 2015). Overall, BV-associated G. vaginalis strains were found 
to be more virulent than non-BV associated G. vaginalis strains (Castro et al., 2015).  This was 
observed through findings of higher levels of cytotoxicity to HeLa cells, as well as greater 
adhesion to HeLa cells (Castro et al., 2015). BV-associated strains can adhere at an average of 
14.8 bacteria per HeLa cell, whereas non-BV G. vaginalis strains adhere at a rate of only 2.8 
bacteria per HeLa Cell (Castro et al., 2015).  These results were also supported by a trend 
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towards a higher biofilm forming index among the BV-associated G. vaginalis strains (Castro et 
al., 2015).  
Harwich et al. (2010) identified biochemical and genetic variations between BV-associated G. 
vaginalis isolates and commensal G. vaginalis isolates. It was observed that pathogenetic G. 
vaginalis induced vaginolysin (VLY)-dependent cytotoxicity compared to its commensal 
counterpart even though the vaginolysin amino acid sequence, encoded by vly gene, was only 
altered by one amino acid while its expression level was equivalent between strains. It is 
noteworthy that VLY requires direct contact with vaginal epithelial cells to induce cytotoxicity. 
The pathogenic G. vaginalis strain was observed to adhere to epithelial cells better and form a 
thicker biofilm, illustrating its significantly enhanced biofilm-forming capacity. This difference 
could further be due to sequence disparity in the biofilm associated protein (BAP) family gene 
identified in both isolates (Harwich et al., 2010).  
Vaginolysin is a cholesterol-dependent cytolysin (CDC), most closely related to Intermedilysin 
(ILY) and Pneumolysin (PLY) produced in Streptococcus spp, which form membrane embedded 
pores of 250-300 Å (Gelber et al., 2008; Dunstone and Tweten, 2012; Hotze and Tweten, 2012). 
CDCs are comprised of 4 domains; domains 1 and 3 form the head region that contains 
Transmembrane Helix 1 and 2 (TMH1/2), which unwind before insertion into the host bilayer 
membrane. Domain 2 links the head region to domain 4 through β-sheets (Rossjohn et al., 1997; 
Shepard et al., 1998; Shatursky et al., 1999; Tilley et al., 2005). Domain 4 is necessary for the 
completion of attachment to the host membrane, especially through binding of cholesterol 
(Soltani et al., 2007). The accepted pore forming model is that domain 1 undergoes a vertical 
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collapse and significantly alters domain 2 conformation before prepore formation to facilitate 
pore formation (Dunstone and Tweten, 2012; Hotze and Tweten, 2012). However, a new model, 
illustrates a less extensive conformational change could be responsible for the pore formation 
(Reboul et al., 2014). The monomer configurations alter the flexibility of the complex away from 
domain 4 and towards domains 1 and 3 (Reboul et al., 2014). Domain 2 then becomes more 
paralleled with the host membrane surface therefore when the vertical collapse of domains 1-3 
simultaneously occurs the TMH1/2 are pushed closer to the membrane surface allowing for 
insertion of their β-hairpins (Reboul et al., 2014). There are 3 modes of receptor recognition of 
CDCs based on binding affinity to membrane-bound cholesterol and human CD59 (hCD59).  
VLY falls into GROUP III: affinity for both cholesterol and hCD59 (Tabata et al., 2014). This 
cytolysin is species-specific, due to its dependence on the CD59, a complement regulatory 
molecule, which lyses human erythrocytes and human vaginal epithelial cells but is unable to 
lyse sheep, mouse, or horse erythrocytes (Gelber et al., 2008; Zvirbliene et al., 2010). However, 
Zilnyte et al. (2015) confirmed that high levels of VLY could lyse both wildtype Chinese 
hamster ovary (CHO) cells, and CD59-null CHO cells (CHO-hCD59) cells.  However, CHO 
cells lacking hCD59 expression required 32-fold more VLY than CHO cells containing hCD59.  
Further demonstrating that there are 2 pathways for oligomerization of the VLY complex; 
cholesterol alone or in the presence of hCD59.  Nevertheless, in humans attachment of VLY to 
CD59 may enhance VLY oligomerization resulting in increased lysis by the toxin (Budvytyte et 
al., 2013; Zilnyte et al., 2015). The presence of functional pores in vaginal epithelial cells, may 
be the basis of ultrastructural rearrangements, e.g. blebbing, of the epithelial cell membranes 
(Randis et al., 2013). However, VLY is also known to induce phosphorylation of the p38 
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mitogen-activated protein kinase (MAPK), inducing the epithelial cells immune response  
(Ratner et al., 2006; Gelber et al., 2008). An upregulation of the interlukin-8 (IL-8) pathway in 
epithelial cells was also observed in the presence of VLY (Gelber et al., 2008).  
Sialidases are considered to be virulence factors in G. vaginalis. Sialidases cleave sialic acid 
from glycoproteins, glycolipids and oligosaccharides by hydrolyzing α-glycosidic linkages 
between sugar residues and sialic acids (Moncla et al., 2015; Srinivasan et al., 2015). The 
sialidase produced by G. vaginalis has a molecular weight of 75000 Daltons and an optimum pH 
of 5.5 (von Nicolai et al., 1984). It was shown to contribute to enhanced pathogenesis and 
inhibition of host immune responses (von Nicolai et al., 1984; Cauci et al., 2008).  
The host’s protective mucosal layer is weakened as the result of desialylation of  mucin, 
providing a growth advantage for G. vaginalis on the vaginal epithelium (Wiggins et al., 2001; 
Cauci et al., 2008). This provides two advantages to GV and to the progression of infection. 
Firstly, the cleaved sialic acid can be utilized by bacterial cells as a carbon source, which further 
promotes their growth (Moncla et al., 2016); secondly, damage to the mucosal layer allows for 
other glycosidases, including the upregulated α-galactosidase, α- glucosidase and β-galactosidase 
to reach and cleave substrates that are exposed to the bacteria. This results in a significant 
decline in bound α-2,6 and α-2,3-linked sialic acid in BV-positive women (Lewis et al., 2013; 
Moncla et al., 2015, 2016). By destroying the mucosal membranes, as well as causing exfoliation 
of the epithelial cells, the bacterium can invade epithelial tissue further and establish the biofilm 
(Cauci et al., 2008; Onderdonk et al., 2016).  
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The adaptive immune system can also be affected by sialidase activity through the 
deglycosylation of immunoglobulins, IgA, Secretory IgA and IgM (Cauci et al., 1998; Lewis et 
al., 2012). This degradation is associated with increased sialidase levels, therefore increased 
susceptibility risks in BV positive women (Cauci et al., 1998; Cauci, Hitti, et al., 2002; Cauci 
and Culhane, 2011). Furthermore, high concentrations of sialidase and prolidase disrupt the 
adaptive immune system and increase induction of  interleukin -1β (IL-1β) (Cauci et al., 2008). 
However, despite the elevated concentrations of IL-1β, the IL-1β cascade activation is hindered 
by the possible degradation of cytokines following the IL-1β concentration increase (Cauci et al., 
2008). This degradation is hypothesized to be caused by sialidase and/or prolidase either in a 
direct or indirect manner (Cauci et al., 2008). Therefore, resulting in low levels of neutrophils, 
therefore reducing localized inflammation (Cauci et al., 2008). The IL-1β cascade inactivation 
also inhibits the induction of the proinflammatory chemokine interleukin-8, resulting in low 
levels of neutrophils and reduced localized inflammation (Cauci et al., 2008). The IL-1β cascade 
inactivation also inhibits the induction of the proinflammatory chemokine interlukin-8, limiting 
the presence of leukocytes in the vaginal environment further induces a local 
immunosuppression (Cauci, Guaschino, et al., 2002; Cauci et al., 2008). Another possibly 
method of host immune evasion is that some strains of G. vaginalis, including ATCC 14019, 
have genes encoding cell-surface expressed Rib-proteins, which provide protection from the host 
immune system (Yeoman et al., 2010).  
Carrying the genes for either virulence factors vaginolysin (vly) or sialidase (sld) does not seem 
to be indicative of a G. vaginalis strains association with BV, as both BV and non-BV associated 
G. vaginalis strains in Castro et al, (2015) study were shown to carry at least one of the genes 
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mentioned above, expect for the BV associated strain, G. vaginalis UM224 which was found to 
be negative for both genes. This was supported by non-BV and BV positive G. vaginalis isolates 
containing the vly gene in 100% and 98.3% of isolates, respectively (Knupp de Souza et al., 
2016). In contrary, Hardy et al. (2017) noted a higher probability of an increased Nugent score 
when high loads of sialidase A was present in G. vaginalis isolates. However when looking at the 
expression of the sld gene between BV and non-BV isolates no significant difference was 
observed (Castro et al., 2015).  Sialidase activity in a murine model has been established by 
Gilbert et el (2013) when sialidase was present in 67% of vaginal washes from G. vaginalis 
infected mice whereas only 14% of the control groups had sialidase activity from non-G. 
vaginalis bacterium. The sialidase activity was positively correlated with G. vaginalis bacterial 
load indicating a potential role in BV infection regardless of its presence in non-BV G. vaginalis 
isolates (Gilbert et al., 2013). As for VLY, however, there was a mean 2-fold difference in the 
expression of VLY by BV associated strains compared to non-BV associated strains. The 
expression of VLY, however, has been observed to be downregulated in BV associated G. 
vaginalis isolates within their biofilm (Castro et al., 2017). It has been hypothesized that this 
significant reduction in vly gene expression may be a means of evading immune response in 
chronic and recurrent BV infections (Castro et al., 2017).  
The transcriptomic profiles of BV associated G. vaginalis isolates in biofilm and planktonic 
states were characterized by Castro et al (2017). It was discovered that 78% of 1045 transcribed 
genes had differing expression levels with an overall conclusion that biofilm cultures induced a 
protective phenotype. Antibiotic resistance genes were upregulated while genes involved in 
metabolism and translation were downregulated (Castro et al., 2017).  G. vaginalis infection 
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alone can induce the BV sign of vaginal epithelial cell exfoliation (Clue cells) in a murine model 
consistent with the host response observed in BV positive women (Gilbert et al., 2013). As well, 
G. vaginalis biofilms are significantly less sensitive to hydrogen peroxide (H2O2) and lactic acid, 
produced by Lactobacillus species relative to planktonic cells by 5-folds and 4 to 8-folds, 
respectively, further illustrating the virulence factor nature of G. vaginalis biofilms in BV 
(Patterson et al., 2007). Other possible candidate virulence factors were identified via genome 
analysis of G. vaginalis strains. Among these candidates are the proteases and peptidases, which 
via proteolysis of host proteins can potentially provide a source of nitrogen for BVAB (Yeoman 
et al., 2010).  
Understanding the genetic basis of G. vaginalis virulence has been an area of interest. It was 
determined that G. vaginalis isolates carried a sialidase gene, although sialidase activity has only 
been found to be present among 40% of strains (Moncla and Pryke, 2009; Lopes dos Santos 
Santiago et al., 2011; Pleckaityte et al., 2012). Genotype 1, found to be predominantly 
represented by biotype 1 and to a less extent by biotypes 2 and 4, which were found to have no 
or weak sialidase activity, whereas all genotype 2 strains, exclusively represented by biotype 5, 
had strong sialidase activities (Pleckaityte et al., 2012). Contradictory results, demonstrated the 
genotype 1 and 3 were sialidase positive and genotype 2 was negative for sialidase activity 
(Lopes dos Santos Santiago et al., 2011). Opposing results, are potentially associated to 
population or geographical limitations or methodology (Moncla and Pryke, 2009; Lopes dos 
Santos Santiago et al., 2011; Pleckaityte et al., 2012; Schellenberg et al., 2016). No relationship 
among genotypes with vaginolysin production levels or HIV type 1 stimulatory activity were 
determined, however, this could be due to low sample sizes (Simoes et al., 2001; Pleckaityte et 
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al., 2012). However, genomic differences of pathogenic compared to commensal G. vaginalis 
strains have demonstrated that there is a potential for further investigation into virulence factors’ 
correlation with genotypes and biotypes (Harwich et al., 2010; Yeoman et al., 2010). Such 
pathogenic properties include bacterial toxins, antimicrobial resistance, strains ability to adhere 
to epithelial cells and evasion of immune detection (Harwich et al., 2010; Yeoman et al., 2010). 
1.5 Health risks associated with bacterial vaginosis  
BV has also been found to be a risk factor for other serious co-morbidities and health concerns. 
BV increases susceptibility to the acquisition of sexually transmitted diseases (STI). BV has been 
significantly linked to vaginal infections caused by Chlamydia trachomatis, Neisseria 
gonorrhoeae and Trichomonas vaginalis (Wiesenfeld et al., 2003; Rathod et al., 2011; Bautista, 
2017; Tosheva-Daskalova et al., 2017). It has been observed that BV-positive women can have a 
1.5 to 2.7-fold increased risk of acquiring trichomonas, gonococcal and chlamydial infections 
(Brotman et al., 2010; Allsworth and Peipert, 2011). Furthermore, these risks increase each time 
a women acquires a BV infection by 26% and 13% for gonococcal and chlamydial infection, 
respectively (Bautista, 2017). Additionally, BV has been linked to the increased rate of acquiring 
human Immunodeficiency Virus Type 1 (HIV-1) as well as being responsible for increased HIV-
1 virus load within the genital tract (Simoes et al., 2001; Msuya et al., 2002; Myer et al., 2005; 
Denslow et al., 2011). BV alone or in conjugation with T. vaginalis has also been linked with 
vaginal shedding of HIV-1 RNA (Fastring et al., 2014); further BV/HIV-1 co-infection leads to 
increased rate (>3 fold) of female-to-male HIV-1 transmission (Cohen et al., 2012). G. vaginalis 
and other BVAB additionally have the capability to hinder HIV preventative treatment, by 
metabolizing the antiretroviral drugs, e.g. Tenofovir, at a rate faster than the target cells can 
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uptake the drug and convert it to its active agent (Klatt et al., 2017). Herpes Simplex Virus Type 
2 (HSV-2) is another STI agent whose risk of acquisition is increased when an underlying 
chronic BV infection is present in the patient (Cherpes et al., 2003; Kirakoya-Samadoulougou et 
al., 2008). BV has also been linked to increased duration and persistence of high-risk human 
papillomavirus infection (HPV) when compared to BV negative women (Gillet et al., 2011; 
Caiyan et al., 2012; Guo et al., 2012; Magaña‐ Contreras et al., 2015). Bacterial vaginosis is 
therefore, considered a risk factor for several STI concurrent infections. Such co-morbidities 
complicate patient health and treatment outcomes.  
Prolonged BV infection is furthermore linked with several adverse health outcomes, which 
include pregnancy complications; induced spontaneous abortions, increased risk of preterm 
labour, late stage miscarriages and stillborn occurrences (Hay et al., 1994; Donders et al., 2000; 
Leitich et al., 2003; Bretelle, 2015; Shashikala et al., 2015). Infants born to mothers who suffer 
from BV are more likely to have low birth weights (Svare et al., 2006). Premature rupture of 
membranes (PROM) and chorioamnionitis, along with endometritis, and Pelvic Inflammatory 
Disease (PID) that can result in infertility, are other pregnancy related sequalae of bacterial 
vaginosis (McGregor et al., 1993; Haggerty et al., 2004; Ness, 2005; Svare et al., 2006). There is 
also a high occurrence of cervicitis in BV positive women (Marrazzo et al., 2006). Additionally, 
G. vaginalis colonization, comparable to BV infections, has been determined to have the 
capability of damaging the oviducts and triggering salpingitis (Taylor-Robinson and Boustouller, 
2011). BV is also significantly associated with cervical intraepithelial neoplasia, pre-cancerous 
lesions that are common in cervical cancer (Platz‐ Christensen et al., 1994; Caiyan et al., 2012; 
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Gillet et al., 2012). Premenstrual syndrome (PMS)-associated nausea also has been linked to G. 
vaginalis infections (Doyle, 2015). 
Moreover, non-reproductive organs can be adversely affected by chronic BV. There have been 
reported cases of G. vaginalis associated meningitis, retinal vasculitis, vertebral osteomyelitis, 
acute hip septic arthritis, balanoposthitis, acute encephalopathy and bacteremia (Kinghorn et al., 
1982; Berardi-Grassias et al., 1988; Amaya et al., 2002; Calvert et al., 2005; Graham et al., 
2009; Neri et al., 2009; Sivadon-Tardy et al., 2009; Tankovic et al., 2017). The mental health 
issues triggered or worsened by contraction of G. vaginalis infection are rarely discussed. 
Nevertheless, BV has negative psychological impact on women suffering especially from 
chronic infection (Bilardi et al., 2013). The self-esteem of women with BV plummet due to 
feelings of embarrassment and shame, which can severely impact the quality of their daily lives 
(Bilardi et al., 2013, 2016). Self-blaming for acquiring a BV infection has also been observed 
(Bilardi et al., 2016). Confusion in understanding how BV is transmitted and risk factors of 
acquiring the infection induce distress on BV positive women (Bilardi et al., 2017). The stressful 
state that BV positive women find themselves in may even increase the frequency of BV 
incidences, as it has been shown that there is a link between chronic stress and BV infection 
(Culhane et al., 2002; Nansel et al., 2006). Additionally, fear of judgement and safety has also 
been observed in female/female relationships in South Africa, which leads to women not seeking 
proper treatment for STIs thus worsening prognosis (Poteat, 2015). 
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1.6 Transmission and Risk factors  
There are many risk factors for the acquisition of BV infection among diverse populations of 
women. Most commonly stated risk factors are the use of broad spectrum antibiotics, resulting in 
vaginal microflora disruption, conducive to BV infection, as well as a history of multiple sexual 
partners (Barcelos et al., 2008; Caiyan et al., 2012; Mayer et al., 2015; Melkumyan et al., 2015). 
G. vaginalis has been isolated from up to 86.8% of asymptomatic women, who are the carriers of  
G. vaginalis clade 4 that lack the coding gene for sialidase, a GV associated virulence factor 
(Balashov et al., 2014; Janulaitiene et al., 2017). In contrast, Clades 1, 2 and 3 have been 
positively correlated with BV and carry the sialidase coding gene (Balashov et al., 2014; 
Janulaitiene et al., 2017). There appears to be consistency that certain clades are associated with 
the acquisition of BV (Balashov et al., 2014; Janulaitiene et al., 2017; Vodstrcil et al., 2017). 
Even if specific clades of G. vaginalis are commensal more evidence is suggestive of BV being a 
STI, as the transmission of BV through sexual partners is well documented (Fethers et al., 2008; 
Eren et al., 2011; Vodstrcil et al., 2015). Eren et al (2011) supported STI status of BV through 
heterosexual, monogamous couples colonized with G. vaginalis isolates that were of the same 
oligotype. BV infection of sexually experienced women has been strongly associated with 
penile-vaginal intercourse (Fethers et al., 2009). Since G. vaginalis has been isolated from semen 
consequently males can repeatedly transmit the infection to their female partners thus 
perpetuating a chronic infection or transmit the infection through multiple partners (Andrade-
Rocha, 2009). However, it is interesting to note that male circumcision has been linked to 
reducing the risk of transmission of G. vaginalis to female partners (Gray et al., 2009). A cross-
sectional study with homosexual women also supported BV as a STI through strong correlation 
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between sexual partners’ vaginal microflora (Vodstrcil et al., 2015). When comparing 
heterosexual couples to same sex female partners, reported BV rates are increased due to 
exchange of vaginal fluids (Fethers et al., 2000; Marrazzo, Thomas, Agnew, et al., 2010; 
Marrazzo et al., 2011), as well as a lower level of vaginal microbiome diversity when compared 
to heterosexual and or bisexual women (Muzny, Sunesara, Kumar, et al., 2013). Nevertheless, in 
a monogamous relationship female/female BV risk is reduced (Bradshaw et al., 2014; Vodstrcil 
et al., 2015). In contrast, Verstaelen et al. (2010) have suggested that BV is not a STI but is 
instead a sexually enhanced disease as BV have occurred in non-sexually active females (Vaca et 
al., 2010). 
The greater number of sexual partners, lack of condom protected sex, infidelity, frequency of 
intercourse and young age at first sexual experience increase the risk of BV transmission 
(Barcelos et al., 2008; Fethers et al., 2008, 2009; Verstraelen et al., 2010; Caiyan et al., 2012; 
Bradshaw et al., 2013; Durugbo et al., 2015; Marconi et al., 2015; Muzny et al., 2017). Sharing 
vaginal sex toys, the use of vaginal lubricants,  as well as participating in oral sex have also been 
associated with BV prevalence (Marrazzo, Thomas, Agnew, et al., 2010; Marrazzo, Thomas, 
Fiedler, et al., 2010). Also the presence of an already established urogenital infection increases 
the risk of BV infection; such infections include Chlamydia trachomatis, Neisseria gonorrhoeae, 
trichomoniasis, urinary tract infections, HSV-2 and other reproductive tract infections (Thorsen 
et al., 2006; Stoner, 2011; Li et al., 2014, 2015; Marconi et al., 2015). Also a previous extra-
vaginal infection with BVAB increases the likelihood of acquiring BV infection (Marrazzo et al., 
2012). Additionally, women who were diagnosed with tubal factor infertility have a 19-fold 
increased risk of acquiring BV (Durugbo et al., 2015). Other health related risk factors for BV 
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acquisition include abnormal cervical mucus, dysmenorrhea, 3 or more previous abortions, low 
levels of estradiol and vitamin D deficiency in pregnant women (Fang et al., 2007; Wilson et al., 
2007; Barcelos et al., 2008; Li et al., 2014; Skowrońska-Jóźwiak et al., 2014). However, the 
vitamin D deficiency has not been linked to BV prevalence in non-pregnant women (Turner et 
al., 2016). Contraceptive methods, oral pill vs intrauterine device (IUD) have also not been 
proven to increase the risk of acquisitioning BV and may even be protective (Castro et al., 1999; 
Alice et al., 2012; Vodstrcil et al., 2013; Marconi et al., 2015). However, more research in how 
hormonal contraceptive methods may affect the immune system of BV positive women needs to 
be conducted (Wang et al., 2015). Hormonal changes in Lactobacillus spp deprived women, 
during the first 2 weeks of menstruation may be partially responsible for microflora shifts that 
increase the risk of BV prevalence (Morison et al., 2005; Chaban et al., 2014). 
Another risk factor associated with BV infections is hygenic practices. Specifically, the act of 
frequent genital washing and vaginal douching as these acts result in the disruption of the vaginal 
microflora (Ness et al., 2002; Cottrell, 2006; Brotman et al., 2010; Vaca et al., 2010). Vaginal 
douching practice per month and per week increase the risk of BV by 2.5 and 2.75-folds, 
respectively (Cottrell, 2006). Additionally, douching is a significantly associated risk factor for 
preterm birth, between gestational weeks 32-34 (Luong et al., 2010). Women’s vaginal douching 
practices rates were reported as high as 76% (Cottrell, 2006). The main reasons provided for 
vaginal douching by participants was to “feel clean” including after intercourse and menstruation 
(50.5-87.7%). Additionally, 14% of women stated they preform vaginal douching as a treatment 
method against vaginal infections. Up to 49.9% of women have stated that they believed vaginal 
douching was beneficial to vaginal health (Ness et al., 2003). Vaginal tightening and drying 
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products have also been associated with increased BV risk (17-fold) (Durugbo et al., 2015). In 
contrast, the type of sanitary protection, sanitary pads vs traditional cloth pads, during 
menstruation were not found to be related to BV prevalence (Morison et al., 2005). Regardless, 
this continued use of harmful hygiene practices seems to be reliant on female relatives’ 
influences, media and even health workers. A lack of understanding of the health risks strongly 
associated with vaginal douching put women at risk for chronic BV infections. These practices 
may also have cultural basis, as African and Hispanic women have reported rates of douching 
higher than Caucasian women (Abma et al., 1997; Cottrell, 2006; Durugbo et al., 2015).  
Other studies have  indicated that specific ethnicities may be at increased risk of GV infection 
(Wenman et al., 2004; Dai et al., 2010; Li et al., 2014). Additionally, Goldenberg et al (1996) 
discovered that there was a significant difference between the colonization of BV associated 
microorganisms between ethnic groups. African and Hispanic women had the highest rate of 
colonization with 22.7% and 15.9%, respectively, while white (8.8%) and Asian-pacific islander 
(6.1%) women had lower colonization rates.  
Socioeconomic status has similarly been associated as a risk factor for BV (Kalinka et al., 2002; 
Bahram et al., 2009; Durugbo et al., 2015). Lower educational background, single marital status 
for both pregnant and non-pregnant women, smoking and younger maternal age have all been 
linked to increased prevalence of BV (Kalinka et al., 2002; Bahram et al., 2009; Desseauve et 
al., 2012; Bradshaw et al., 2014; Li et al., 2014; Durugbo et al., 2015; Marconi et al., 2015). 
However, increased age has also been indicated as a risk factor possibly due to increased 
likelihood of having multiple sexual partners and exposure to previously mentioned risk factors 
(Fang et al., 2007; Dai et al., 2010).  
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1.7 Epidemiology  
Bacterial vaginosis affects women on a global scale, however, despite its association with severe 
physical and psychological backlash, it is not currently considered as a reported infection by 
CDC and other health organizations. Therefore, all prevalence rates are estimated based on 
literature reports. As seen in Appendix A, the rates of BV can range from 0.4% in asymptomatic 
and symptomatic women to as high as 93%, with an overall trend of BV rates increasing over 
time. The BV prevalence rates in North America range from 9% to 93% depending on the study 
population (Alice et al., 2012; Schwebke et al., 2016). The Canadian estimated BV rates are only 
for Edmonton, Alberta and Toronto, Ontario at 14% and 9%, respectively (Wenman et al., 2002; 
Alice et al., 2012). The United States reported average rates typically stay around 30%, however, 
the asymptomatic BV incidence has been observed at rates as high as 70.5% and 93% (Cottrell, 
2006; Schwebke et al., 2016). Other North American countries have been shown to have similar 
rates as the United States; Grenada with 21.4% and Jamaica with 44.1% (Kamara et al., 2000; 
Brooks-Smith-Lowe and Rodrigo, 2013). In South America, most of the studies have occurred in 
Brazil. Between 1997 and 2013, BV rates in Brazil have doubled from 15.3% to 30.1% (De Lima 
Soares et al., 2003; Marconi et al., 2015). Chile, Ecuador, and Peru have similar reported rates, 
32%, 31.5% and 26.6%, respectively (Jones et al., 2007; Lillo G et al., 2010; Vaca et al., 2010). 
Table A.1 (Appendix A) also summarizes the bacterial vaginosis prevalence rates for 14 
countries, and their multiple cities, in Asia. Reported rates range from 5.9% in Shandong 
Province of China to 50% in Fars Province and 70% in Qom city of Iran (Keshavarz et al., 2001; 
Fang et al., 2007; Ghiasi et al., 2014). The literature from Africa reported BV rates ranging from 
6.4% to 58.4% with most of the studies reporting BV rates of 25% and higher (Frohlich et al., 
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2007; Kirakoya-Samadoulougou et al., 2008). South Africa’s rates are continually higher than 
the other African countries, illustrated with its lowest BV rating at 33.7% and the highest at 
58.4% (Frohlich et al., 2007; Dols et al., 2011).   
Across Europe BV prevalence is relatively low, averaging around 14.5%, ranging from 3.5% for 
asymptomatic BV positive women to 44.7% for symptomatic patients (Appendix A, Table A.1). 
However, few longitudinal studies have taken place in Europe, so a trend could not be 
established. Additionally, the most recent studies are from 2013, with the majority of data 
coming from 1990s, therefore, demonstrating the need for BV infection reporting. The Oceania 
Countries, Australia, Papua New Guinea and New Zealand, additionally have some of the lowest 
reported BV rates, all under 12% (Passey et al., 1998; Fethers et al., 2009; Lim et al., 2010; 
Bradshaw et al., 2013) (Table A.1). Nevertheless, it can be seen through Australian studies that 
the frequency of BV infection has increased over the time (Fethers et al., 2009; Bradshaw et al., 
2013). The rates reported in Table A.1 demonstrate that BV is a serious global health issue.  This 
vaginal infection is not tracked by world health organizations and to stress the importance of the 
issue, many records kept in private clinics remain inaccessible, leading to an underestimation of 
incidences. Even the studies shown in Table A.1 cannot provide accurate prevalence rates due to 
the specific nature of research reports. Limiting factors include inadequate population sizes, 
limited geographic locations of studies as well as criteria of studies based on socioeconomic 
status, pregnancy, antibiotic use and presence of sequelae, which results in data that cannot be 
generalized to the entire countries. The rates provided also do not include intermediate vaginal 
infections, where a women’s diagnosis score is not high enough to be considered BV positive, 
but is also not deemed to have a normal vaginal flora. Age is another limitation in acquiring 
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accurate BV rates since the presence of BV infection in postmenopausal women, with increased 
prevalence with age illustrate a misconception in the epidemiology of this infection when 
considering BV has been thought to affect only women of childbearing ages (Hoffmann et al., 
2014). This concept has also been a challenge through the isolation of G. vaginalis in 
premenarcheal females, demonstrating that G. vaginalis may be commensal as well as suggesting 
that BV infection could occur in prepubescent females (Myhre et al., 2010; Hickey et al., 2015). 
Additionally, in rare instances G. vaginalis has been isolated from rectum of preschool aged 
children of both male and females again establishing G. vaginalis as part of the normal 
microflora (Myhre et al., 2002). These studies are also limited due to reduced interest in 
participation and commitment to longitudinal studies (Forcey et al., 2014). In particular, Forcey 
et al. (2014) noted a link to attrition among women 30 years and under, as well as difficultly in 
recruiting participants without post-secondary education. Consequently, based on the reported 
BV rates and numerous limitations it is likely that bacterial vaginosis infection rates are being 
grossly underestimated.  
In summary, Bacterial vaginosis is a worldwide, womens’ health issue that has remained 
unreported and is significantly associated with many several health complications. Could the 
lack of attention placed upon BV be due to its taboo subject matter?  
1.8 Current therapies 
In the past other antibiotics e.g. Secnidazole (5-nitroimidazole derivative) and Garenoxacin (a 
quinolone antibiotic) were used to treat BV, however, the current standard clinical treatment for 
BV rely on metronidazole and clindamycin (Goldstein et al., 2002; Nunez, 2005). The primary 
antibiotic of choice is metronidazole that is delivered orally at 500mg/twice a day for 7 days. In 
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case of treatment failure with metronidazole, clindamycin is indicated at 100mg in 5g of cream 
for 7 days (Skidmore-Roth, 2015). Metronidazole is thought to be a cost-effective antibiotic used 
to target anaerobic bacteria, however, the effectiveness of this antibiotic has been called into 
question (Löfmark et al., 2010). Clindamycin, a broad-spectrum member of lincomycin class of 
antibiotics, can negatively affect the vaginal microflora leading to selection of resistant bacteria 
and outgrowth of yeast. Within 24-hours of treatment with metronidazole, a rapid decline in 
abundance of BVAB including G. vaginalis occurs at a slow rate; however, re-emergence of BV-
associated bacteria often occurs in 1 week post treatment (Mayer et al., 2015). Before G. 
vaginalis re-emergence an increase in lactobacilli is observed; however, their abundance declines 
again as BVAB re-emerge, leading to a recurring infection (Mayer et al., 2015; Swidsinski et al., 
2005; Gottschick et al., 2016). Recurrence of BV is considered to be due to development of 
metronidazole resistance at high rates (68.7%) in a short duration of time, which might 
potentially be due to its mutagenic capacity  (Tomusiak et al., 2011; Chaudhary, 2014; Mayer et 
al., 2015; Schuyler et al., 2016; Dingsdag and Hunter, 2018).   
The route of metronidazole administration only plays a minor role in effectiveness against BV 
treatment as no significant differences were observed between oral versus intra-vaginal 
administration (Mitchell et al., 2009). Furthermore, delivery of metronidazole via vaginal route 
only showed weak evidence (7.6%) that metronidazole can reduce the risk of upper genital tract 
infections following a dilation and curettage (Crowley et al., 2001). However, metronidazole 
administration by the intra-vaginal rings provided persisting drug availability over a longer 
period than systemic delivery via oral administration. This is due to the gradual release of 
antibiotic over 12 days after an initial release of 35-55% of the antibiotic over the first 24 hours 
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(Pathak et al., 2014).  
In addition to low efficacy of metronidazole treatment, patients treated with this antibiotic might  
suffer from side effects, e.g. dizziness, epigastric pain, nausea and dyspnea (Decena et al., 2006). 
Combination therapy with metronidazole and azithromycin was shown to be linked with 
increased adverse pregnancy outcomes (Tita, 2007).  
1.9 Alternative therapies 
1.9.1 Probiotics 
The most common alternative treatment strategy for BV relies on delivery of probiotics. 
Specifically Lactobacillus species are considered since they are often native to the vaginal 
environment, produce lactic acid and/or hydrogen peroxide as antimicrobials, and may 
competitively displace G. vaginalis from epithelial surfaces (Kaewsrichan et al., 2006; Saunders 
et al., 2007; Pessoa et al., 2017). Lactic acid and H2O2 production by Lactobacillus helvetiuc 
MTCC5463 and L. crispatus respectively, are examples of the members of lactobacilli that can 
control G. vaginalis. However, some Lactobacilli such as Lactobacillus plantarum do not kill G. 
vaginalis (Pessoa et al., 2017). Lactic acid is produced by the members of lactic acid bacteria 
(LABs) as a result of sugar fermentation process reduces the vaginal pH to acidic ranges as low 
as pH, 4.5 where G. vaginalis cannot thrive. This leads to inhibition of its colonization 
(Kaewsrichan et al., 2006; Mogha and Prajapati, 2017). However, for Lactobacillus species to 
increase the vaginal acidity they must be able to survive and replicate within a vaginal 
environment that already has alkaline pH due to the growth of G. vaginalis. Consequently, since 
Lactobacillus species are sensitive to alkaline pH, and a pH 6.3 can inhibit Lactobacilli survival 
by greater than 50%, this demonstrates a notable drawback to probiotic therapy (Pessoa et al., 
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2017). The limited inhibitory capacity of probiotics was supported in an ex vivo study where L. 
crispatus colonization prevented G. vaginalis colonization to different degrees depending on the 
environmental pH; i.e. within an alkaline environment L. crispatus was less effective as an 
inhibitor of G. vaginalis colonization (Breshears et al., 2015). However, when women are 
diagnosed with BV the initial colonization has already occurred, therefore it is important to 
determine how effective Lactobacillus probiotics are at destructing an established biofilm. It has 
been shown that G. vaginalis biofilm is 5-fold and 4.8-fold more tolerant to hydrogen peroxide 
and lactic acid, respectively, compared to G. vaginalis planktonic cells illustrating that the 
probiotics may not be effective treatment for BV with a persistent biofilm infection (Patterson et 
al., 2007). To lower the pH level within the vaginal environment, therefore allowing 
Lactobacillus species to thrive, bioadhesive polycarbophil gels and acidic douches were 
compared (Milani, 2000). Although polycarbophil gels were superior in lowering the vaginal pH 
to physiologic level (pH 4.5) as compared to acidic douches, it remains to be determined if such 
treatment could systematically restore the lactobacilli rich vaginal microflora and eliminate the 
BVAB (Milani, 2000).  
Probiotics have been considered as adjuvants for existing antibiotic treatments and assessed for 
the duration of recovery.  Delivery of EcoVag probiotic vaginal capsules containing  L. 
rhamnosus DSM 14870 and L. gasseri DSM 14869 in conjunction with metronidazole and 
clindamycin and/or fluconazole significantly prolonged the time before infection relapsed 
(Larsson et al., 2008, 2011; Pendharkar et al., 2015). The health benefit of the using L. 
rhamnosus DSM 14870 and L. gasseri DSM 14869 prompted further studies of these natural 
inhabitants of vagina by complete genome sequencing. Analysis of their genomes identified the 
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gene clusters coding for multiple adhesions, formation of thick exopolysaccharide capsule (EPS) 
that provided them with advanced competitive colonization properties leading to formation of 
thick biofilms (Marcotte et al., 2017).  
Nevertheless, different combinations of Lactobacillus probiotics have produced promising 
candidates for treatment of BV. Ingestion of yogurt containing the bacterial species such as L. 
crispatus, L. garrerii, L. jensenii and L. rhamnosus was shown to reduce symptoms of BV as 
well as improve the recovery rate (Laue et al., 2017). As well as the use of a slow release vaginal 
tablets containing probiotics L. plantarum LPO1 and L. fermentum LF15 was determined to be a 
promising form of treatment for acute cases of Gardnerella infections (Vicariotto et al., 2014). 
Another promising candidate is L. helvetiuc MTCC5463 that was incorporated into a vaginal 
cream and shown to produce inhibition zones (8-24mm) against G. vaginalis in vitro (Mogha and 
Prajapati, 2017). Additionally, L. fermentum L23, utilized in a mouse model, was determined to 
be a promising candidate as a probiotic against G. vaginalis although without evidence for 
recurrence rates following treatment, therefore, reservations for long term effectiveness should 
be considered (Daniele et al., 2014). There are also potential probiotics that do not directly affect 
the colonization of G. vaginalis, rather they lead to modulation of immune system. For example, 
the oral and intra-vaginal administration of L. rhamnosus HN001 and L. acidophilus La-14 
together with lactoferrin to a mouse model attenuated GV-induced vaginosis via up-regulation of 
the vaginal and gastrointestinal innate and adaptive immune responses (Jang et al., 2017). 
1.9.2  Pessary products 
Pessaries may be utilized to deliver therapeutics for BV treatment. Gottschick et al. (2016) 
showed that the pessary containing amphoteric tenside (WO3191) was more effective in 
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reducing G. vaginalis biofilms than the pessary containing lactic acid, however, three months 
post-treatment follow up showed that there was a 28% recurrence rate with the amphoteric 
tenside pessary. Another study using lactic acid gel in combination with metronidazole showed 
long-term outcome in treating BV, reducing recurrence, and promoting colonization of 
lactobacilli (Decena et al., 2006).  Although use of pessaries seems not to be effective in 
preventing infection recurrence, the health benefit and safety of using amphoteric tenside 
(WO3191) was tested in a controlled randomized clinical trial following metronidazole 
treatment, which showed promising restorative shift in microbiome composition among the test 
group (Gottschick et al., 2017). Interestingly, on the contrary, pessary products themselves have 
been blamed to increase the risk of developing BV (Alnaif and Drutz, 2000). Therefore, to treat 
the pessary associated-BV among pessary users, application of antimicrobial TrimsoSan gel 
(hydroxyquinoline based) was evaluated during standard pessary care. However, no significant 
difference in BV prevalence between patients treated with and without TrimsoSan gel was noted  
(Meriwether et al., 2015). 
1.9.3  Antiseptics 
Broad spectrum, local antiseptic, octenidine dihydrochloride in a spray application was tested for 
its cure rates for BV (Swidsinski et al., 2015). High initial cure rates were observed (87.5%), 
however, recurrence of infection was seen in 66.6% of women within 6 months post treatment. 
After an additional application of octenidine dihydrochloride, the cure rate was reduced to 75%, 
and then reduced further to 62.5% after a third treatment. Additionally, a subset of women was 
found to have 100% resistant bacteria to the antiseptic. This high resistance rate deterred 
Swidsinski et al. (2015) from further studying the antiseptic. Another side effect with this 
 33 
 
antiseptic was the side effect of vaginal burning and dryness associated with the application of 
the octenidine dihydrochloride product.  
1.9.4  Plant-derivatives 
Vaginal gels with metronidazole containing plant components, Myrutus communis L (2%) and 
Berberis vulgeris (5%) have been studied as possible therapeutics against BV (Masoudi et al., 
2016). These gels were shown to be more effective than a metronidazole (0.75%) vaginal gel 
treatment, however, they are still not promising candidates since after the trial ended 57.5-95% 
of women were not cured of their BV (Masoudi et al., 2016).  Brazilian pepper tree, Schinus 
terebinthifolius Raddi, extract (7.4%) gel was also compared to metronidazole (0.75%) vaginal 
gel treatment. The cure rate using the Brazilian pepper tree extract gel was significantly lower 
than the metronidazole with only 12.4% cure rate further supporting evidence that vaginal gels 
are not effective treatments for BV  (Leite et al., 2011). The side effects associated with the 
Brazilian pepper tree extract gel (vaginal burning, rash, heat and abdominal pain) were 
noteworthy limitation to this treatment since the treatment should not exacerbate discomfort in 
the patient (Leite et al., 2011).  
Thymol, a molecule in thyme essential oil has also been studied for its antimicrobial effect for G. 
vaginalis (Braga et al., 2010). It was determined that thymol could inhibit formation of G. 
vaginalis biofilm by up to 32.8%, but could not eliminate the biofilm (Braga et al., 2010). 
Likewise, another essential oil from Thymbra capitata had anti-biofilm activity significantly 
more specific to G. vaginalis biofilm than native vaginal lactobacillus spp exemplifying a 
potential candidate for further evaluation against G. vaginalis infection (Machado, Gaspar, et al., 
2017). 
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1.9.5  Antimicrobial peptides 
Subtilosin, a cyclic bacteriocin that is produced by Bacillus subtilis KATMIRA1933 was shown 
to prevent formation of G. vaginalis biofilm by targeting and inhibiting bacterial quorum sensing 
(Algburi, Zehm, et al., 2017). Additionally,  Bacillus amyloliquefaciens produces subtilosin A, a 
35 amino acid circular bacteriocin, which targets G. vaginalis cytoplasmic membrane causing 
pore formation (Noll et al., 2011). Subtilosin A in combination with clinically relevant 
antibiotics exerted synergistic effect on planktonic G. vaginalis cultures, while antagonistic 
effect on vaginal lactobacillus species was shown (Cavera et al., 2015). Similarly, subtilosin 
synergized with both metronidazole and clindamycin against G. vaginalis, while not affecting 
Lactobacillus biofilm (Algburi et al., 2015). Algburi et al. (2015) also studied the antimicrobial, 
lauramide arginine ethyl ester, which additionally synergized with both metronidazole and 
clindamycin against G. vaginalis, without disrupting Lactobacillus spp biofilms. Both studies 
indicate that subtilosin has a potential as a therapeutic agent for BV and can potentially be used 
in combination with other antimicrobials without significant detrimental effect on vaginal natural 
microflora. 
The bacteriocin lactocin 160, produced by Lactobacillus rhamnousus has a narrow spectrum 
affecting G. vaginalis and Prevotella bivia, but not bacteria native to the vaginal microflora 
(Turovskiy et al., 2009). Similar to subtilosin A, lactocin 160 targets the cytoplasmic membranes 
of bacterial cells resulting in cell death (Turovskiy et al., 2009; Noll et al., 2011). Lactosporin 
has also been isolated from Bacillus coagulans and was also identified as a potential 
antimicrobial against BV (Riazi, 2012). Additionally, human lysozyme has been suggested as a 
therapeutic agent for BV since alone or in combination with metronidazole the human lysozyme 
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inhibited the growth of G. vaginalis biofilm and degraded the already established biofilm 
(Thellin et al., 2016; Hukić et al., 2017).  
Some alternative therapies target specific aspects of a BV infection. The following studies use 
compounds specific against G. vaginalis biofilm formation. The use of inhibitors has been 
suggested to interfere with establishment of BV-associated biofilms. Retrocyclin RC-101, a 
synthetic cyclic peptide has been shown to have a broad antimicrobial activity and inhibitory 
effect on G. vaginalis’ vaginolysin cytotoxicity that reduces biofilm formation, however, it does 
not have a direct effect on planktonic cell growth. Therefore, its use as a therapeutic candidate 
for BV needs further in vivo studies (Hooven, 2012). Recombinant single-chain antibodies and 
polyclonal rabbit immune serum were also suggested to control the cytotoxicity of VLY (Randis 
et al., 2009; Pleckaityte et al., 2011). Although VLY antiserum could reduce VLY-mediated 
lysis of CD59 epithelial cells, the use of antibodies would only be considered a preventative 
approach instead of a treatment modality for BV (Randis et al., 2009). However, overall 
diminishing vaginolysin activity would result in limiting the virulence of G. vaginalis.  
G. vaginalis has been observed to release extracellular DNA during its early stationary growth 
phase that is essential for its structural integrity and might assist in colonization. It has been 
hypothesized that removal of extracellular DNA with DNases might have a potential to interfere 
with colonization of GV (Hymes et al., 2013). DNase was demonstrated by Hymes et al. (2013) 
to decrease G. vaginalis biofilm density by >10 fold in vivo using a murine model. It was shown 
that DNase treatment liberated the GV cells from the biofilm and increased the efficacy of 
antibiotics. Other anti-biofilm agents such as amphoteric tenside sodium cocoamphoacetate also 
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has been shown to decrease the GV biofilm by 51% (Gottschick et al., 2016), while, cationic 
amphiphiles (CAms) were shown to prevent and eliminate G. vaginalis ATCC 14018 biofilms by 
disrupting the bacterial cell membrane due to their membrane-lytic properties (Algburi, Zhang, et 
al., 2017). Additionally, CAms seem to have a narrower spectrum, needing a much higher 
concentration to affect Lactobacillus species (Algburi, Zhang, et al., 2017). They were also 
shown to be promising in combination with metronidazole in the treatment of BV (Algburi, 
Zhang, et al., 2017).  
In summary, the difficulty in treatment of BV is in part due to the polymicrobial nature of the 
BV biofilm to which G. vaginalis has the primary contribution as the progenitor of biofilm 
initiator and establishment, leading to progressive detrimental shift in healthy vaginal microflora. 
The problem is further potentiated by biodiversity inherent to G. vaginalis that might have been 
the basis for its plasticity with respect to its virulence capacity and response to treatment. 
Limitation in availabilities of treatment options and the menace of rapidly growing rates of 
antibiotic resistance has inevitably contributed to the chronic nature of infection and treatment 
failure leading to increased epidemiological prevalence of disease globally. Therefore, 
progressively increasing rates of treatment failure of BV using antibiotics has prompted the 
research toward discovery of alternative therapeutics and testing novel modalities in vitro and in 
vivo in the recent years.  Consequently, targeting G. vaginalis is fundamental for developing 
alternative therapies.  
A good alternative therapeutic candidate for treatment of GV-related BV must satisfy the 
following conditions: 
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i) it must have a narrow spectrum and specifically target G. vaginalis as the initiator of BV 
biofilm production preferably through bactericidal function. 
ii) it must not have a deteriorating effect on the vaginal healthy microflora; 
iii)  its bactericidal effect must not be discriminatory with respect to biological diversity 
among G. vaginalis;  
iv) it must show superiority to current antibiotics with respect to having novel mode of 
action, lack of toxicity and resistance development.  
1.10  Scope of the study 
We hypothesize that natural antimicrobial agents are promising candidates as future alternative 
therapeutics for the etiological agent of bacterial vaginosis. Proof of concept will be 
demonstrated by acquiring a collection of naturally occurring bacteria with potential for 
producing antimicrobials against a diverse population of G. vaginalis isolates resulting in a 
proposed minimal cocktail. We aim to accomplish this by first obtaining a diverse collection of 
G. vaginalis isolates and further characterizing the isolates based on their genotypic and 
antibiotic susceptibility profiles. Secondly, a collection of bacteria with antimicrobial activities 
against our G. vaginalis collection will be isolated and characterized. The nature of the 
antimicrobial active agents will be further studied to be able to propose a minimal cocktail 
formulation consisting of diverse antimicrobials with overlapping complimentary properties 
against the G. vaginalis collection. 
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2 Materials and Methods  
2.1 Materials 
2.1.1 Bacterial strains  
A total of fourteen G. vaginalis clinical isolates, collected from across Canada and confirmed to 
be G. vaginlais by 16S rRNA sequence, were obtained from the bacterial collection of National 
Microbiology Laboratory (NML), Manitoba, Canada (Table 2.1 ). The Gardnerella vaginalis 
ATCC 14018, 14019 and 45149 together with non-GV bacteria that were used for target spectra 
analysis were also acquired from ATCC and are listed in (Table 2.).  
2.1.2 Culture media, supplements, antibiotics, reagents, enzymes and kits 
Dehydrated nutrient media Brain-heart infusion broth (BHI) (Nutri-Bact, Terrebonne, Quebec, 
CA, Cat: QB-48-0305) , Columbia broth (CB) (Quelab, Montreal, Quebec, CA, Cat: QB-48-
1106), Mueller-Hinton (MH) broth (Oxoid Ltd., Basingstoke, Hampshire, England, Cat: 
CM0405), Difco Lactobacilli MRS broth (Becton, Dickson and Company, Le Pont de Claix, 
France, Cat: 288130), Tryptic Soy Broth (TSB) (Becton, Dickson and Company, Le Pont de 
Claix, France, Cat: 211825) were utilized to prepare broth culture media. Bacteriological Agar 
(Quelab, Montreal, Quebec, CA, Cat: QB-46-0221) was added to broth media at 1.5% and 0.7% 
to prepare solid culture plates and top agar, respectively. The following supplements were added 
to culture media as needed: 10% (v/v) fetal bovine serum (FBS) (Life Technologies Corporation, 
Grand Island, NY, USA, Cat:12483-020), soluble starch (Sigma-Aldrich, St. Louis, MO, USA, 
Cat: SLBP7458V), Hemin from bovine with ≥ 90% purity,  
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Table 2.1  Clinical G. vaginalis isolates given names, NML identification number and source of 
isolation.  
Name NML # Source 
cGV1 02-0045 Amniotic Fluid 
cGV2 02-0183 Urine 
cGV3 60420 Blood 
cGV4 100244 Uterine cavity 
cGV5 100570 Urine 
cGV6 110582 Blood 
cGV7 110707 Urine 
cGV8 120040 Urine 
cGV9 120093 Urine 
cGV10 120820 Tracheal aspirate  
cGV11 130068 Tracheal aspirate  
cGV12 130180 Deep Wound 
cGV13 130503 Urine 
cGV14 130786 Urine 
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Table 2.2 List of standard G. vaginalis and Non-G. vaginalis bacteria used for target spectra 
analysis of αGV isolates.  
Organism Strain Number (ATCC)  
G. vaginalis 14018 
G. vaginalis 14019 
G. vaginalis 45149 
Bifidobacterium adolescentis 15703 
Bifidobacterium animalis 700541 
Bifidobacterium longum 15707 
Clostridium difficile  9689 
Enterococcus durans 6056 
Enterococcus durans 11576 
Enterococcus durans 19432 
Enterococcus hirae 8043 
Enterococcus hirae 51686 
Lactobacillus acidophilus  4356 
Lactobacillus acidophilus  53544 
Lactobacillus casei 393 
Lactobacillus delbrueckii 11842 
Lactobacillus reuteri 23272 
Lactobacillus rhamnosus 53103 
Listeria monocytogenes  13932 
Listeria monocytogenes  19115 
Staphylococcus warneri  49454 
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(Sigma-Aldrich, Saint Louis, MO, USA, Cat:H9039-1G) and vitamin K1 (Sigma-Aldrich, Saint 
Louis, MO, USA, Cat: V3501-1G), Single Donor Human Whole Blood Unit CPD (Cedarlane, 
Burlington, NC, USA, Cat: IPLA-WB1-UNIT-CPD) or laked, defibrated sheep blood (Nutri-
Bact, Terrebonne, QC, CA). Preparation and final concentrations of supplements are listed in 
Appendix B. Selective G. vaginalis Human Blood Bilayer Plates were prepared in BHI agar with 
10% human blood supplement and by the addition of antibiotics, Nalidixic acid sodium salt 
(Sigma-Aldrich, St. Louis, MO, USA, Cat: N4382) and Amphotericin B (Sigma-Aldrich, St. 
Louis, MO, USA, Cat: A9528) as per Appendix B.  
Sterile plastic 1µL inoculation loops (Sartedt, Germany, Cat: 86.1562.010) were used to 
inoculate broth and plates with bacteria. Cell resuspension solution was from wizard Plus 
Midipreps DNA Purification kit that was used for preparation of bacterial DNA libraries 
(Promega, Madison WI, USA, Cat: A711F).  
The Epsilometer test (Etest) was applied for antibiotic susceptibility testing and the E-strips were 
purchased from bioMérieux Canada Inc (St. Laurent, QC, CA). The E-strips included: 
metronidazole MZ 256 US S30 (Cat: 412403), clindamycin CM 256 WW S30 (Cat: 412315, 
ampicillin AM 256 US (Cat: 501558), ciprofloxacin CI 32 WW S30 (Cat: 412311), linezolid LZ 
256 WW S30 (Cat: 412450), rifampicin RI 32 WW S30 (Cat: 412450), tetracycline TC 256 WW 
S30 (Cat: 412471), and vancomycin VA 256 US S30 (Cat: 412486).  
The following stock enzymes, chemicals and solutions were used for isolation of G. vaginalis 
genomic DNA (gDNA): pronase (20g/L) (Boehringer Mannheim GmbH, Germany), 
Ribonuclease (RNase) A/T1 (2mg/mL RNase A and 5000 U/mL RNase T1) (Thermo scientific, 
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Rochester, NY, USA, Cat: EN0551), EDTA disodium salt dihydrate biotechnology grade 
(Bioshop, Burlington, ON, CA, Cat: EDT001.500). Bacterial Genomic DNA Isolation Kit 
(Norgen biotek Corp. Cat: 17900) was used to isolated αGV bacteria gDNA.  
Taq DNA polymerase (Taq Pol) (50U/μl), 10mM deoxyribonucleotide triphosphates (dNTPs), 
polymerase chain reaction (PCR) buffer without Mg
+2
 (10X) and 50mM MgCl2 were used along 
with PCR primers (Section 2.1.3) were used in PCR reactions (Invitrogen, Carlsbad, USA). 
Restriction enzymes FastDigest HpaII (Thermo Scientific, Rochester, NY, USA Cat: FD0514) 
and TaqI (Thermo Scientific, Rochester, NY, USA, Cat: FD0674) were used in genotyping 
experiments. 
Agarose gels (0.7%–2%) were prepared in 1X tris-acetate-ethylenediaminetetraacetic acid (TAE) 
running buffer and were used for DNA gel electrophoresis (Appendix C). The DNA ladder 1 kb 
plus ladder (Invitrogen, Carlsbad, USA, Cat: 10787018) was used as marker in DNA 
electrophoresis experiments. RedSafe Nucleic Acid Staining Solution (20,000x) (FroggaBio 
scientific solutions, Toronto, Ontario, CA, Cat: 21141,) was used to direct visualization of DNA 
bands in agarose gels (BioShop, Burlington, ON, CA, Cat: 9012-36-6).  
The concentration or extraction of anti-GV active agent protein from the culture supernatants 
were completed with either chloroform extraction ACS, reagent grade (BioShop, Burlington, 
ON, CA, Cat: CCL402.1) or by precipitation in 100% methanol (Fisher Scientific (Fair Lawn, 
NJ, USA, Cat: BP1105-4).  
SDS-PAGE gels (12% or 15% separating; 4% stacking) were made with the following 
components (Appendix C): acrylamide, electrophoresis Grade, min 99.5% (BioShop, Burlington, 
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ON, CA, Cat: ACR002.500), bis-acrylamide (Sigma Chemical Company, St. Louis, MO, USA, 
Cat: M-2022), Tris base (BioShop, Burlington, ON, CA, Cat: TRS001.1), Sodium dodecyl 
sulfate (SDS) BioUltraPure electrophoresis grade (BioShop, Burlington, ON, CA, Cat: 
SDS001.500), ammonium persulfate electrophoresis grade (BioShop, Burlington, ON, CA, Cat: 
AMP001.10), β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA, Cat: M3148-25ML, 
bromophenol blue, glycerol certified ACS (Fisher Scientific, Fair Lawn, NJ, USA Cat: G33-
500), and TMED electrophoresis purity reagent (Bio-Rad Laboratories, Hercules, CA, USA, Cat: 
48411A) (Appendix C). High range, BLUeye prestained protein ladder (FroggaBio scientific 
solutions, Toronto, Ontario, CA Cat: PM007-0500) and Spectra Multicolor low range protein 
ladder (Thermo Scientific, Rochester, NY, USA Cat: 26628) were used in protein analysis in 
SDS-PAGE experiments.  
The Silver Staining Plus kit (Bio-Rad Laboratories, Hercules, California, USA Cat: 161-0449) 
was used to stain and visualize the protein bands in SDS-PAGE slabs. Glacial acetic acid ACS, 
reagent grade (BioShop, Burlington, ON, CA, Cat: ACE222.4) was used to preparation of 
protein gel distaining solution.  
2.1.3 PCR primers  
G. vaginalis specific oligonucleotide primers were synthesized by Sigma-Aldrich (Oakville, 
Canada). Primers were utilized in identification and genomic typing of G. vaginalis collection 
(Table 2.). 
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Table 2.3  G. vaginalis specific primers based on G. vaginalis ATCC 14018 reference strain (Genbank reference no. AP012332.1). 
Primer 
ID 
Direction Primer sequence (5’3’) 
Nucleotide 
Target 
Amplified Regions 
(5’3’) 
Fragment 
size (bp) 
Reference 
Ingia-F Forward TTCGATTCTGGCTCAGG 
16S rDNA 
96,453…97,886 
219,594…221,027 
1,434 
1,434 
Ingianni et 
al., 1997   
Ingia-R Reverse CCATCCCAAAAGGGTTAGGC 
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2.1.4 Equipment and other tools 
Bacterial cultures were incubated in the following incubators depending on atmospheric 
acquirements of bacteria: An 855-AC Controlled Atmosphere Chamber was used for anaerobic 
incubation (Plas Labs, Lansing, USA). Aerobic and 10% CO2 incubation was carried out in 
VWR 1545 Incubator (VWR) and Air-jacketed DHD Autoflow Automatic CO2 Incubator NU-
5510/E (NUAIRE), respectively. Candle jars (Oxoid, Basingstoke, UK) were used for storage of 
G. vaginalis culture plates in 5% CO2. Bacteria were visualized in Axio Scope.A1 fluorescent 
microscope (Carl Zeiss Microscopy, Thornwood, USA).  
Beckman Coulter Allegra X-12 Benchtop Centrifuge with SX4750A rotor (Palo Alto, USA) was 
used for centrifugation of volumes larger than 2mL. While for volumes of < 2mL, the Sorvall 
Legend Micro 21 Microcentrifuge with the 24 x 1.5/2.0 mL Rotor was used (Thermo Scientific, 
Germany). Centrifugation of supernatants during methanol extraction was completed in 
Beckman J2-21M with JA-20 rotor.  
CLASSIQswab swabs were used to create bacterial lawns for antibiotic susceptibility testing 
(Copan Flock Technologies, Brescia, Italy, Cat:138CS01). Target ranges of the αGV collection 
was determined on Nunc OmniTrays (Thermo Scientific, Rochester, NY, USA, Cat: 12565296) 
with the use of 96 Pin Long Replicators (Scinomix, Earth City, USA, Cat: SCI-5010-05). 
Bacterial gDNA purity and concentrations was determined using NanoDrop 2000c UV-Vis 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Overnight incubation for DNA 
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extractions were performed in Fisher Scientific Mini-Tube Rotator (Cat: 05-450-127). Optical 
densities (OD) of bacterial cultures were read on a computerized plate reader TECAN spectra.  
SnapGene software was used to construct the TaqI and HpaII restriction maps on an in silico 
generated PCR amplicon using the GV-specific 16S rDNA primers on G. vaginalis ATCC 14018 
genome (Genbank reference no. AP012332.1). 
A PTC-100 Programmable Thermal cycler (MJ Research Inc, Watertown, USA) was used for 
conducting PCR and genotyping of G. vaginalis isolates. Gel visualization and imaging were 
completed by the FluorChem FC3 imaging system using the AlphaView Software.  
Samples of gDNA of αGV isolates were prepared and contained in skirted/colourless Eppendorf 
twin Tec PCR Plate 96, (Fisher Scientific, Fair Lawn, NJ, USA, Cat: 951020401) and Pierceable 
Adhesive Foil, as per instructions by Genome Quebec Innovation centre, prior to shipment and 
sequencing by Illumia HiSeq platform.  
2.2 Methods  
2.2.1 Culture conditions, cryopreservation and preparation of bacterial gDNA 
libraries 
All bacterial strains and clinical isolates were grown at 37°C. G. vaginalis isolates were cultured 
on BHI human blood bilayer plates and/or grown in BHI broth supplemented with 10% FBS and 
1% soluble starch and incubated at 37°C and 10% CO2. Anti-GV isolates, Enterococcus faecalis 
ATCC 29212, and S. aureus ATCC 29213 were incubated anaerobically on CB plates. For 
antibiotic susceptibility testing, G. vaginalis isolates were grown on TSA plates (Tryptic Soy 
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Agar) plates supplemented with 5% laked, defibrated sheep blood and Enterococcus faecalis 
ATCC 29212 was cultured on Mueller Hinton (MH) agar plates. The non-G. vaginalis bacterial 
collection were cultured in an anaerobic chamber. Bifidobacterium ATCC strains were incubated 
in BHI supplemented with Hemin (5mg/L) and Vitamin K1 (1mg/L). The following bacteria 
were cultured on CB medium: Clostridium difficile ATCC 9689, Listeria monocytogenes (ATCC 
13932 and 19115), Enterococcus durans (ATCC 6056, 11576, and 19432), Enterococcus hirae 
(ATCC 8043 and 51686) and Staphylococcus warneri ATCC 49454. Lactobacillus spp. ATCC 
strains were cultured on MRS medium. Details of preparation of media and supplements are 
shown in Appendix B. 
Cryopreservation of bacterial strains was completed by growing 5mL broth cultures for 1-3 days 
under appropriate atmospheric conditions until a visible turbidity was reached. Cultures were 
pelleted by centrifugation at 3200xg for 30 minutes. Supernatants were removed, and the 
bacterial pellets were resuspended in 1mL 10% sterile glycerol. Concentrated cell suspensions 
were transferred to 2 cryovials, 500µL in each. The glycerol preserved cell stocks were stored in 
-80°C for long-term storage.  
For preparation of DNA libraries, bacterial cultures were established via inoculation of broth 
media (20mL for G. vaginalis collection, and 10mL for αGV collection). Cultures were 
incubated for 1-3 days under appropriate atmospheric conditions. Once turbid, broth cultures 
(full volume of G. vaginalis cultures and 2mL of 10mL αGV cultures) were centrifuged at 
3200xg for 30 minutes. Supernatants were removed, and pellets were resuspended and washed 
with 500µL of cell resuspension solution. Cells were transferred to 1.5mL sterile epitubes and 
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centrifuged at 14000xg for 5 minutes at 4°C. Supernatants were decanted and pellets were 
resuspended in 400µL of cell resuspension solution. Cell suspensions were stored in -80°C until 
DNA extraction was completed. Detailed procedures for preparation of buffers and reagents are 
shown shown in Appendix C. 
2.2.2 Morphological and biochemical testing 
2.2.2.1 Microscopy  
A volume of 7µL of turbid culture was pipetted onto a glass microscope slide and covered with a 
cover slip. The Axio Scope.A1 at 400X magnification was used to observe cell morphology and 
images were captured using the phase contrast setting of the microscope.  
2.2.2.2 Hemolysis 
G. vaginalis isolates were plated onto BHI bilayer plates and incubated under 10% CO2 at 37°C 
for 2 days. Hemolysis pattern was observed as clear zone around individual colonies.  
2.2.2.3 Catalase Test 
A volume of 5µL 30% H2O2 was pipetted onto a glass microscope slide. A sterile inoculation 
loop was used to select a colony from the G. vaginalis or αGV culture plates and placed into the 
H2O2. Catalase positive colonies showed bubbling pattern upon contacting hydrogen peroxide. S. 
aureus 29213 and G. vaginalis ATCC 14018 were used a negative and positive controls, 
respectively.  
2.2.3 Identification and genetic characterization of G. vaginalis collection 
2.2.3.1 Extraction of Genomic DNA from G. vaginalis isolates 
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The suspension of G. vaginalis bacterial cells prepared in section 2.2.1 for DNA library were 
thawed. Cells were pelleted from the suspension following centrifugation 14000xg for 2 minutes 
at 4°C. Pelleted cells where then washed with 1mL sterile ddH20 and resuspended in 240L lysis 
cocktail. Lysis cocktail consisted of 208L cell lysis buffer (Appendix C), 6L pronase 
(20g/L), 24L 10% SDS and 2L RNase A/T1 (2 g/L, 500U/mL). Cells/lysis cocktail 
mixture was mixed by pipetting up and down and then incubated overnight at 37°C in Mini-Tube 
Rotator (2 rpm). The lysed cells were incubated in 70°C water bath for 10 minutes. 
Subsequently, 120L of 3 M potassium acetate (pH 5.5) was added and mixed well by 
inversions. The cleared supernatant was collected by centrifugation at 17000xg for 15 minutes at 
4°C. The collected supernatant (300L) was then transferred to a sterile 1.5mL epitube, and 
1200uL of ethanol/0.16 M sodium acetate was added. Gentle inversion was used to mix the 
contents and to provide visualization of condensing chromosomal DNA. If chromosomal DNA 
was not visible, 2L of glycogen (20mg/mL) was added, and the contents were mixed by 
inversion and stored in -20°C for 1-2 hours followed by centrifugation at 17000xg for 15 minutes 
at 4°C. The supernatant was discarded, and the remaining DNA pellet was washed in 700µL of 
70% ethanol chilled to -20°C. The epitube was then inverted onto a clean Kimwipe absorbent 
surface for 2 minutes before fully dried in a vacuum evaporation chamber for 10 minutes. The 
DNA pellet was then resuspended in 200µL sterile ddH20.   
Purity and concentration of the extracted gDNA was verified by Nanodrop spectrophotometry, 
where 2µL of gDNA was read in triplicate and an average value was calculated. A 2µL sample 
of the gDNA with 5µL of 1X DNA loading dye was subjected to electrophoresis in a 0.7% 
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agarose gel containing RedSafe (2.5ul/25 ml of gel). Three microliters (0.25ug) of 1 KbP DNA 
ladder was also loaded and the gel electrophoresis ran for 40 minutes at 80V. The gDNA bands 
were visualized and imaged with the use of FluorChem FC3 imaging system with AlphaView 
Software. The prepared gDNA library was stored in -20°C until use.  
2.2.3.2   PCR based identification of G. vaginalis collection  
G. vaginalis specific 16S rDNA primers (section 2.1.3 and Table 2.) were used to amplify and 
genetically type the G. vaginalis collection. The concentrations of gDNA extracted in section 
2.2.3.1 were adjusted to 0.05µg/mL in each PCR reaction. A PCR mixture (50µL) containing: 
38.5µL of sterile ddH2O, 5µL of 10X Taq pol buffer without magnesium, 1.5µL magnesium 
chloride (50mM), 1µL dNTPs (10mM), 1µL Taq Pol (5U/L), 1µL Ingia-F primer (10µm), 1µL 
Ingia-R primer (10µm) and 1µL of gDNA (0.05µg). The PCR mixture was mixed via pipetting 
up and down and then ran on PTC-100 Programmable Thermal Cycler under optimized PCR 
conditions modified from Ingianni et al. (1997). Conditions are as follows: predwell at 94°C for 
3 minutes, 35 cycles of denaturation at 94°C for 30 seconds, annealing at 54°C for 30 seconds 
and extension at 72°C for 1 minute, followed by postdwell at 72°C for 5 minutes. A 4°C 
temperature was held until tubes were removed from PCR machine and stored in -20°C.  
The amplified single PCR product (Figure 3.4) was resolved by gel electrophoresis on 0.7% 
agarose gel with RedSafe and 1X TAE buffer as follows: Two microliters of PCR reaction 
mixture combined with 5µL 1X loading dye was loaded to the agarose gel. Three microliters of 1 
Kb DNA ladder was also included. Gel electrophoresis was run at 80V for 1 hour and the gel 
was photographed by FluorChem FC3 imaging system with AlphaView Software. 
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2.2.3.3   Genotyping of G. vaginalis collection  
Genotyping of the G. vaginalis collection was completed by two different restriction enzymes, 
FastDigest TaqI and HpaII (Thermo Scientific, Inc.), which provided two different genotyping 
patterns. One microliter of each of the restriction enzymes TaqI and HpaII were added to 5µL of 
PCR reaction mixture in separate tubes and mixed by pipetting followed by incubation for 15 
minutes in PTC-100 Programmable Thermal Cycler at 65°C and 37°C for TaqI and HpaII 
reactions, respectively.  
Entire volume of each of the restriction reaction was mixed with 1µL 6X loading dye and loaded 
into 2% agarose gel with RedSafe and ran against 3µL of 1 KbP DNA ladder. Gel 
electrophoresis was run at 80V for 1.5 hours. The gel was photographed in the FluorChem FC3 
imaging system with AlphaView Software. Images were analyzed, and genotypes were assigned 
for each isolated depending on the number and sizes of visible bands in comparison to known 
controls.  
2.2.4 Antibiotic susceptibility testing  
Antibiotic susceptibility testing was completed with E-tests based on bioMérieux and Clinical 
and Laboratory Standards Institute (CLSI) protocols (Clinical and Laboratory Standards 
Institute, 2004; bioMérieux, 2012b). G. vaginalis E-testing was completed on 150mm plates 
containing 4mm  thick TSA agar plates supplemented with 5% laked sheep blood. To make sure 
of the accuracy of the experimental conditions, the E. faecalis ATCC 29212 was used as the 
quality control strain that was plated on MH agar plates as per standard protocols (De Backer et 
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al., 2006; bioMérieux, 2012b; Schuyler et al., 2016). Expected and observed MIC values for 
quality control strain, E. faecalis ATCC 29212, is summarized in Appendix D. 
Cryopreserved E. faecalis ATCC 29212 was subcultured twice onto MH plates prior to E-testing. 
G. vaginalis isolates and quality control strain were grown in appropriate broth media and 
atmosphere. The turbidity of the G. vaginalis and E. faecalis ATCC 29212 cultures were 
adjusted to 1.0 and 0.5 McFarland turbidity index, respectively, as per standard protocols prior to 
plating (De Backer et al., 2006; bioMérieux, 2012b). The standardized bacteria suspensions were 
streaked onto the surface of the agar plates with sterile swabs three times. The swabs samples 
were taken three time from the bacterial suspension before each set of streaking, rotating the 
plate 90 degrees each time thus creating a uniform bacterial lawn. Lawns were allowed to dry 
before E-test strips were laid down on the plates. E-test strips were equilibrated to room 
temperature for 30 minutes before applying onto bacterial lawns according to recommendation 
by the manufacturer (bioMérieux, 2012b). Plates were then inverted and incubated under 10% 
CO2 or O2, no higher than 5 stacked plates for approximately 72 hours for G. vaginalis isolates 
and 16-20 hours for E. faecalis ATCC 29212 (bioMérieux, 2012b).  
Minimal inhibitory concentrations (MIC) for quality control from European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) (LZ, VA, RI, AM). CLSI for MIC ranges (CM, 
CI, TC) were considered for evaluation of the results for E. faecalis ATCC 29212 quality control 
strain (bioMérieux, 2012b, 2014; Clinical and Laboratory Standards Institute, 2015; EUCAST, 
2016).  MIC ranges for G. vaginalis isolates were extracted from the literature (De Backer et al., 
2006; Nagaraja, 2008; Clinical and Laboratory Standards Institute, 2015).  
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Colonies present within the zone of inhibition ellipse of cGV2 after exposure to antibiotics 
during E-testing were isolated from both sides of the E-test strip, starting from the lowest 
antibiotic concentration to the highest. Colonies isolated from the left-hand side of the E-test 
strip were labelled as presumptive mutants “a” while the colonies isolated from the righthand 
side of the strip were presumptive mutants “b”, additionally with identification by numbers 
increasing from lowest to highest based on the level of antibiotic concentration the colonies were 
exposed to. Ten colonies from either side of the E-strip were isolated and colony purified for 
further testing by genotyping and antibiotic susceptibility as previously described.  
2.2.5 Isolation of αGV bacterial collection  
A co-culture utilizing agar overlay method was employed in the isolation of the αGV collection. 
About 1-2 litre of raw sewage sample was collected on the April 25
th
, 2016 from Robert O. 
Pickard Environmental Centre (ROPEC) in Ottawa and stored at 4°C prior to usage. 
ROPEC samples were diluted by 100-folds in BHI broth. A volume of 200µL of diluted ROPEC 
sample was added, along with 500µL of turbid G. vaginalis ATCC 14018 or 14019 broth 
cultures, to 5mL of Columbia broth (CB) top agar (0.7%). Contents were mixed by inversion and 
overlaid onto BHI plates. Once top agar had solidified, plates were inverted and incubated under 
anaerobic conditions at 37°C. This was repeated for each of the G. vaginalis ATCC strain (14018 
and 14019) on 20 plates.  
Colonies which produced inhibition zones on the G. vaginalis lawns were isolated by a sterile 
inoculating needle and streaked on a BHI plate to isolate single colonies. A single colony from 
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each plate was picked and subcultured three times to make sure of the purity of the culture. Total 
of 34 pure isolates formed the αGV collection. αGV inhibition zones diameters (mm) on the 
primary plates were also noted. The αGVs were assigned alphanumerical identities on the basis 
of the G. vaginalis ATCC strain they were isolated on. For example, αGV18-12 denotes the 
isolate number 12 on G. vaginalis ATCC 14018, etc.  
2.2.6 Identification and characterization of αGV collection 
2.2.6.1 Genomic DNA extraction and sequencing  
αGV gDNA extraction was completed with Bacterial Genomic DNA isolation Kit (Norgen 
Bioteck Corp, ON, Canada). Alterations to protocol are as followed: RNase A/T1 (2 g/L, 500 
U/mL) instead of 10 Kunitz of RNase A, Pronase (20µg/µL) instead of Proteinase K and 
incubation during lysate preparation was extended from 2 hours to overnight at 37°C in Mini-
Tube Rotator (2 rpm). Sequencing of αGV gDNA was accomplished by 2 x 125 paired end reads 
in Illumina HiSeq platform (McGill University and Génome Québec Innovation Centre). The 
technical control for clustering reactions, sequence accuracy and sequencing diversity in low 
complexity libraries was phage ΦX174 genomic DNA. Samples were demultiplexed and fastq 
files were provided for each strand (R1-R2).  
2.2.6.2 Genome Assembly of αGV collection 
Contig assembly and further genomic analysis was completed by Dr. Gustavo Ybazeta. The 
provided sequences were checked for contamination from ΦX174 with the program BBsplit from 
the BBMap package through BBtools (Bestus Bioinformaticus, Inc.) (Mukherjee et al., 2015; 
Bushnell). The code used was as follows:  
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bbsplit in1 =foo_R1.fastq in2=foo_R2.fastq ref=phix.fa basename=out_%.fq 
outu1=foo_R1_phi.fastq outu2=foo_R2_phi.fastq 
Quality control of the sequences was completed using the program FastQC High Throughput 
Sequence QC report (version 0.11.5) (Andrews, 2010). Sickle sequence trimming tool was 
further utilized to complete a quality trimming of the 3’and 5’ ends of the sequence reads based 
on the quality scores and length parameters, which resulted in single sequences to be removed 
from the R1 and R2 paired trimmed sequences (Joshi and Fass, 2011). Parameters for 
considering the reads for trimming included, i) paired end sequences reads with an average 
quality score less than 20, ii) their lengths had to be greater than 10bp.  
Code used is as follows: Sickle pe –f R1.fastq –r R2.fastq –o trim.R1.fastq –p trim.R2.fastq –s 
singlets.fastq –q 20 –l 10 –t “sanger” 
De novo assembly of the paired reads was produced using the program Spades v. 3.9.0. Error 
corrections (k 21, 33, 55,77, 99) were used to improve alignment of the contigs (Bankevich et 
al., 2012; Nurk et al., 2013). Prokka, an annotation pipeline software, was used to annotate the 
assembled genomes with a parallel approach and multiple cores when available (Seemann, 
2014). The pipeline produced multiple outputs and outputs with the extension “txt” that were 
utilized in the production of the phylogenetic trees. 
Code used for annotation is as follows: for i in `cat list.txt`; do prokka –outdir $i/prokka –cpus 
40 –force –rnammer $i/prokka.fasta; done 
2.2.6.3 Phylogenetic analysis of αGV collection  
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To identify the taxonomic standing of each genome sequence, 16S rRNA and RNA polymerase 
subunit beta genes (rpoB) were extracted with the use of BLAST 2.6.0+ (Camacho et al., 2009).  
The code used is as follows: for i in `cat list.txt`; do blastn –query 16.fasta –subject 
PROKKA*.fasta –out $i/16S_tmp –evalue 0.0001 –perc_identity 70 –outfmt “6 sseqid sseq”; 
done 
The sequences used as general queries of the 16S rRNA and rpoB genes were extracted from the 
complete genomes of Enterococcus faecalis 62 (gb CP002491.1) and of Enterococcus faecium 
1352 (gb LN99984). Once sequences were identified for each αGV genome the files were 
formatted to fasta and an alignment for each gene was completed. Furthermore, the extracted 16S 
rRNA sequences were ran against the SILVA database (https://www.arb-silva.de/) to determine 
taxonomic similarity (Quast et al., 2013; Silva). Blast was performed locally and then upgraded 
to January 18, 2017.  
The code used is as follows: nice –n 40 update_blastdb.pl –passive –force –verbose –decompress 
nr nt taxdb >> nr_nt.updatedb.log 
Once the nucleotide and protein local database of blast were upgraded, blastn was used to extract 
the closest sequences to each one of the unidentified sequences and produced a phylogenetic 
analysis for the 16SrRNA and rpoB genes. Files were then changed from taxa ID to taxonomical 
identification using NCBI database. The files were again changed to fasta format and Seaview 
version 4 was used to align the sequences with the use of Clustal-omega and Muscle algorithms, 
with default settings (Edgar, 2004; Gouy et al., 2010; Sievers et al., 2011). For rpoB evaluation 
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of each αGV, sequences were translated to amino acid sequence view and aligned as proteins, 
and then converted into nucleotide view in Seaview version 4 (Gouy et al., 2010). Phylogenetic 
trees were produced by phyml software with αGV identifiers as the taxa description in NCBI 
database (Guindon et al., 2010).  
2.2.6.4 Pangenome analysis of a subset of αGVs 
The genome pipeline Roary v. 3.10.2 and Prokka were used to produce GFF3 files, which further 
used  to generate the pangenome matrix of the Lactococcus genera (Seemann, 2014; Page et al., 
2015). Alignment of core genes was used to produce phylogenetic tree and the matrix showing 
the absence or presence of core and accessory genes.  
The pipeline code used is as follows: Roary –p 40 –f Lactococcus_pangenome –e –n –i 70 –r –s 
–z –v  
2.2.6.5 Identification of bacteriocin genomic cassettes 
Genomes were analysed in the BAGEL3 program (http://bagel.molgenrug.nl/) to identify the 
potential bacteriocin cassettes (van Heel et al., 2013).  
2.2.7 Target Range of αGV bacterial isolates 
2.2.7.1 High throughput target range assay 
Preparation of αGVs for high throughput target range assay was completed by inoculating 20mL 
of BHI with each of αGV isolates and α523. Cultures were incubated anaerobically at 37°C until 
they became turbid. Five hundred microliters sample was taken from each culture to determine 
the turbidity via A405 readings in a TECAN computerized plate reader at the same time to verify 
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the cultures microscopically for expected cellular morphology and lack of contamination.  The 
turbidity of cultures was determined as follows: in a 96 well plate, 100µL of each culture, as well 
as a blank control (BHI) were pipetted in triplicate. The OD was read using a 405nm filter and 
the average and standard deviation values were calculated thereafter in excel. Remaining cultures 
underwent centrifugation at 3200xg for 20 minutes at 4°C. Supernatants were poured off and 
pelleted cell were resuspended in a volume of sterile 10% glycerol in order to attain 5x10
6 
cfu/mL. To estimate the volume of the glycerol to be used, a calibration curve originally 
developed for α523 by the former technician, Laura Douglas, was used. A volume of 100µL of 
each standardized culture, along with BHI as a negative control, was pipetted into a 96 well plate 
based on the layout (Appendix E). Nine plates in total were prepared with the same cultures. The 
96 well plates containing αGV cells were sealed with sterile adhesive foils and stored in -80°C 
until use. 
For the high throughput target range assay experiment, the prepared plate #1 of the nine 96 well 
plates containing αGV cells were removed from -80°C to thaw and then placed in ice. Depending 
on the indicator strain a volume of 28-500µL (approximately 10
7 
cells) was added to 5mL of 
0.7% top agar (BHI) and seeded on OmniTray plates containing reduced BHI agar (ie oxygen 
free). Once agar overlay solidified a 96-pin standard replicator was placed into the 96 well plate 
containing the αGV cells. The 96-pin standard replicator was then used to inoculate the 
OmniTray bacterial lawn with approximately 2µL of each αGV. Inoculated OmniTrays were 
then incubated under anaerobic conditions at 37°C for 2-4 days. Control OmniTrays of each 
media type, with no bacterial lawn were also inoculated with the αGV cells. The 96 well plate 
containing αGV cells were again sealed with adhesive foils and stored in -80°C.
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2.2.8 Target range analysis of αGV active agents 
2.2.8.1 Supernatant extraction  
Chloroform extraction of αGV isolates culture supernatants was performed using 25mL of 
supernatant and 17mL of chloroform (v/v ration of 1:0.7). The mixture was shaken for 45 
minutes at 300 rpm on a rotary shaker at 37°C. Centrifugation at 3200xg for 30 minutes at 20°C 
was performed to separate the organic and aqueous phases. The aqueous layer was pipetted off 
while the organic layer was removed by pouring it off without disturbing the accumulated 
whitish interphase matter that stayed stuck to the sides of the tube. The separated interphase 
matter was collected and transferred to a 1.5mL epitube and then centrifuged at 14000xg for 10 
minutes. Remaining aqueous and organic layers were removed via pipetting and the pellet was 
dried in vacuum drier chamber. The collected pellet was resuspended in 250µL of BHI broth and 
stored in a -20°C freezer.  
The protein content of the αGV isolates culture supernatants were precipitated with methanol by 
adding 21mL 100% pure methanol to 8.5mL supernatant (i.e v/v ratio of 1 supernatant: 2.5 
methanol). The solution was mixed by inversion and incubated at room temperature for 30-40 
minutes. Centrifugation at 12000 rpm for 20 minutes at 4°C was used to precipitate the protein 
content of the supernatants. The pellet was recovered by discarding the supernatant and the tube 
was inverted onto an absorbent surface to drain residuals of the supernatant. The pellet was dried 
under vacuum in a vacuum condenser chamber and resuspended in 100µL of BHI broth. The 
wall of the tube was rinsed with additional 50µL of BHI broth to make sure of resuspending any 
residual precipitate. Finally, the whole volume was collected at the bottom of the tube by second 
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centrifugation at 12000 rpm for 5 minutes at 4°C. The total volume 150µL of extracted 
supernatant was transferred to a 1.5mL epitube and stored in -20°C until use.  
2.2.9 Drop on the lawn testing  
One milliliter of turbid G. vaginalis culture was added to 7mL of 0.7% BHI top agar that was 
supplemented with 1% soluble starch. The bacterial suspension was inverted to mix and was 
evenly overlaid onto a BHI agar plate supplemented with 10% FBS and 1% soluble starch to 
form a bacterial lawn. Once top agar was solidified, the concentrated αGV supernatants (100x 
chloroform extract, 57x methanol extract) were pipetted onto the lawn (Appendix E). For the 
chloroform extracted supernatants 5µL drops were pipetted onto the lawns whereas 8µL of the 
methanol precipitated supernatants were applied to the lawns.  
2.2.10 αGV active agent protein analysis    
2.2.10.1 Silver staining and gel diffusion  
A volume equivalent to 10 µg, determined by Bradford protein assay, of each αGV methanol or 
chloroform concentrated supernatants was added to an equal volume of 2x SDS-PAGE loading 
buffer. Samples were heated in a water bath at 70°C for 5 minutes. Protein samples were then 
loaded into wells (5µg/well) of a 1.5mm thick, 12% or 15% SDS-PAGE gel; first in lanes 2-5 
and again in the same order in lanes 7-10. A high range BLUeye prestrained protein ladder (10 
µL) and Spectra Multicolour low range protein ladder (10 µL) were also loaded into lanes 1 and 
6, respectively. Electrophoresis of SDS gel at 100V for 1 hour and 45 minutes was completed. 
The gel was cut in half, through the low range ladder lane (lane 6). Silver staining of gel half 
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containing both protein ladder lanes was completed with Silver Staining Plus kit according to 
manufacturer’s protocol.  
The second half of the gel was washed three times in 200mL of sterile ddH2O for 1.5 hours with 
intermittent change of water. The washed gel half was transferred to a BHI agar plate (7mL total) 
supplemented with 10% FBS and 1% starch. Agar overlay technique was used to cover the gel 
with 10-15 mL of 0.7% BHI top agar with 1% soluble starch, mixed with 500µL of the G. 
vaginalis indicator strain. Incubation of plate was completed under 10% CO2 at 37°C for several 
days until a turbid lawn formed and cleared areas were visible. 
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3 Results 
3.1 Identification and characterization of G. vaginalis collection 
3.1.1 Morphological and biochemical properties 
The G. vaginalis clinical isolates exhibited expected morphological and biochemical properties. 
All G. vaginalis isolates were observed to have a coryneform cell morphology by microscopy 
(Figure 3.1). They were found also to be catalase negative and produced a representative clear β-
hemolysis clearing zone on the agar plates containing human blood (Figure 3.2). 
3.1.2 PCR identification and genotyping 
The correct identity of G. vaginalis clinical isolates was further and strongly supported through 
PCR experiments with the use of G. vaginalis-specific primers for 16S rDNA operons. PCR 
amplification of a portion of the16S rRNA gene of G. vaginalis produced a product of expected 
size (1434 bp Figure 3.3; Figure 3.4). Digestion of G. vaginalis 16S rRNA gene PCR products 
with TaqI restriction enzyme produced two distinct banding patterns representing genotypes A 
and B (Figure 3.5). The majority of G. vaginalis isolates were typed as B (82.4%) while 17.6% 
were determined to be of genotype A. Another restriction enzyme (HpaII) was used to 
characterize the G. vaginalis collection. Three genotypes were observed, indicated as genotypes 
1, 3 and 4 (Figure 3.6). Genotype 1 was the most prevalent (82.4%), followed by genotype 4 
(11.8%). Only 1 G. vaginalis isolate, cGV7, was determined to be genotype 3 (5.8% of the 
collection). 
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3.1.3 Antibiotic susceptibility testing of G. vaginalis collection 
Antibiotic susceptibility profiles were determined for the G. vaginalis collection and the 
reference strain E. faecalis ATCC 29212 using E-test strips for the following antibiotics: CM, 
LZ, VA, RI, MZ, CI, AM and TC (see section 2.1.2 and abbreviation list for the full names of the 
antibiotics). Metronidazole and clindamycin are clinically relevant as they are the primary and 
secondary treatments for BV, respectively.  
The application of E-strips onto a lawn of G. vaginalis or E. faecalis ATCC 29212 was as 
described in Section 2.2.4 and the minimal inhibitory concentrations were defined by the 
presence of an ellipse of an inhibition zone surrounding each E-strip (Figure 3.7). E-test 
procedural guidelines were utilized to read MIC values, where the MIC is read at the point of 
intersection of the E-strip with the bacterial lawn at the edge of the zone of inhibition 
(bioMérieux, 2011, 2012a, 2012c). MIC values for bactericidal antibiotics were read at 100% 
bacterial growth inhibition edge, while bacteriostatic antibiotics were read at 80% inhibition 
edge except for LZ, which was read at 90% of inhibition edge (bioMérieux, 2012b). 
 64 
 
 
 
 
 
 Figure 3.1  An example of coryneform cellular morphology of clinical G. vaginalis isolates 
observed at 400x magnification and photographed using phase contrast setting of the Axio 
Scope.A1 microscope. Here, the image of the cGV4 isolate is shown. 
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Figure 3.2  An example of the β-hemolysis pattern of G. vaginalis isolates on human whole 
blood agar plates. The hemolysis pattern of cGV1 is shown here. 
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Figure 3.3  Restriction map of 16S rRNA gene locus of G. vaginalis ATCC 14018. Taq1 and HpaII restriction sites are shown. The 
position of the primers Ingia-F and Ingia-R used in PCR amplification of 16S rDNA target are also shown. These maps are produced 
to provide a visual perception for the expected bands in genotyping experiments.  
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Figure 3.4  Agarose gel showing the PCR product of amplified 16S rRNA gene using GV 
specific primers. The expected amplicon size is 1434 bp for all isolates. G. vaginalis ATCC 
strains are included as controls. 1KbP: 1 Kb plus DNA ladder. 
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Figure 3.5  Electrophoretic restriction banding patterns of the 16S rRNA gene PCR products of 
G. vaginalis isolates digested with TaqI. G. vaginalis ATCC strains are included as controls. 
Two genotypes were noted: (A) Type A genotype. (B) Type B genotype. 1KbP: 1 Kb plus DNA 
ladder. 
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 Figure 3.6   Electrophoretic restriction banding patterns of the 16S rRNA gene PCR products of 
G. vaginalis isolates digested with HpaII. G. vaginalis ATCC strains are included as controls. 
Three genotypes were noted: 1, 3 and 4 represent genotypes 1, 3 and 4, respectively. 1KbP: 1 Kb 
plus DNA ladder. 
 
  
 70 
 
E. faecalis ATCC 29212 MIC values within the appropriate ranges defined by EUCAST and 
CLSI were used as internal quality controls in this study (bioMérieux, 2012b, 2014; Clinical and 
Laboratory Standards Institute, 2015; EUCAST, 2016). The MIC values for the quality control 
strain were determined to be within the acceptable ranges for the antibiotics used in this study, 
supporting the reliability of the applied procedures (Appendix D). Standard antibiotic 
susceptibility breakpoints for G. vaginalis have not been described by EUCAST or CLSI; 
therefore, our antibiotic susceptibility profiles are based on published breakpoints in the 
literature specifically for E-testing (De Backer et al., 2006; Nagaraja, 2008; Schuyler et al., 
2016).   
Metronidazole and Clindamycin  
For metronidazole activity against G. vaginalis, sensitivity has been defined as sensitive 
(<8µg/mL), intermediate as 8-16µg/mL, or resistant at either >16µg/mL or >32µg/mL, 
depending on the literature source (De Backer et al., 2006; Nagaraja, 2008; Schuyler et al., 
2016).  Based on these proposed breakpoint values, none of the isolates in our G. vaginalis 
collection were sensitive to metronidazole; 35.3% of isolates were intermediately susceptible and 
64.7% of the isolates were resistant (Figure 3.8). Additionally, the MIC50 and MIC90 values 
(median and 90
th
 percentile MIC values, respectively) were determined to be 32µg/mL and 
256µg/mL, respectively. These values suggested a high propensity for the G. vaginalis 
population to develop resistance to metronidazole (see the sections below). We also noted that 
there was a relatively broad distribution range for metronidazole MIC values even in this small 
collection. Compared to the lowest MIC value it was noted that the MIC values were different 
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from each other within the range of 1 to 16-fold (Table 3.1).  This observation is consistent with 
the genotypic diversity noted above in this collection.  
All G. vaginalis isolates were determined to be susceptible to the clinically relevant drug 
clindamycin, since the MIC values were all well below 2µg/mL (Table 3.1) with a MIC50 and 
MIC90 of  0.016µg/mL and 0.032µg/mL, respectfully (Nagaraja, 2008). Additionally, the 
susceptibility profiles of the G. vaginalis isolates showed a 1 to 4-fold difference.   
Non-clinically relevant antibiotics 
Similar to metronidazole and clindamycin the G. vaginalis isolates showed diversity with respect 
to the MIC values for antibiotics not typically used against GV clinically (Table 3.1). The MIC 
values for VA ranged from 0.25µg/mL to 0.5µg/mL, having only a1 to 2-fold difference. While 
the MIC values for LZ, RI and CI varied within the range of 1-4-fold. The antibiotics with the 
broadest MIC ranges were AM (1 to 30-fold) and TC (1 to 256-fold), respectively. The MIC50 
and MIC90, respectively, were as follows: LZ (0.25 and 0.5µg/mL), VA (0.5 µg/mL for both), 
RI (1 and 2 µg/mL), CI (2 and 4µg/mL), AM (0.064 and 0.35 µg/mL) and TC (0.5 and 
26.2µg/mL).  
3.1.4 Development of metronidazole resistance by G. vaginalis  
Following exposure of G. vaginalis isolates to metronidazole E-strips, within the ellipsoidal 
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Figure 3.7  Antibiotic susceptibility results of antibiotics CM, LZ, VA and RI on a lawn of 
cGV11. E-tests were performed as described in Section 2.2.4. MIC (µg/mL) values are indicated 
by white arrows. 
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Table 3.1  Antibiotic susceptibility profiles and MIC fold ranges for G. vaginalis collection.  
Bacteria Tested 
Etest: MIC values (ug/mL) 
CM LZ VA RI MZ CI AM TC 
G. vaginalis ATCC 14018 <0.016 0.25 0.25 2 >256 2 <0.016 0.50 
G. vaginalis ATCC 14019 <0.016 0.25 0.50 0.50 >256 4 0.016 0.50 
G. vaginalis ATCC 49145 <0.016 0.25 0.50 2 16 2 <0.016 64 
cGV1 0.016 0.25 0.50 1 64 2 <0.016 1 
cGV2 0.032 0.25 0.50 1 8 2 0.125 0.50 
cGV3 <0.016 0.125 0.50 1 32 2 0.064 0.50 
cGV4 <0.016 0.50 0.25 1 64 2 0.50 0.50 
cGV5 <0.016 0.25 0.50 1 128 1 0.032 1 
cGV6 0.064 0.25 0.50 1 32 2 <0.016 1 
cGV7 <0.016 0.50 0.25 1 32 2 0.064 0.50 
cGV8 <0.016 0.25 0.50 2 32 1 0.016 0.50 
cGV9 <0.016 0.25 0.50 1 16 2 0.032 0.50 
cGV10 0.032 0.25 0.50 2 16 4 0.064 128 
cGV11 <0.016 0.25 0.25 1 >256 1 2 0.50 
cGV12 0.032 0.50 0.50 1 >256 4 0.25 0.50 
cGV13 <0.016 0.125 0.50 2 16 2 0.125 0.50 
cGV14 <0.016 0.125 0.50 1 16 2 0.125 0.50 
Fold Range 1-4 fold 1-4 fold 1-2 fold 1-4 fold 1-6 fold 1-4 fold 1-30 fold 1-256 fold 
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Figure 3.8   Distribution and of Metronidazole MIC values (µg/mL) among G. vaginalis 
collection.   
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inhibition zones numerous growing colonies were observed (Figure 3.9). To determine whether 
these colonies were metronidazole-resistant, 10 were picked from either side of the E-strips on 
plates of the cGV2 isolate (section 2.2.4). The genomic DNA was isolated from these 20 isolates 
along with the parental strain cGV2 and G. vaginalis ATCC 45149. The genomic DNA was used 
to amplify the 16S rRNA gene using G. vaginalis specific primers. The PCR products were 
further analyzed for their genotypes with restriction enzyme TaqI. All isolates were observed to 
have the same genotype as the parental strain (Figure 3.10). The MZ MIC values of the mutant 
cGV2 isolates were determined together with their sensitivities to the killing effect by the αGV 
bacterial isolates. These results indicated that the 20 cGV2 mutant isolates were fully resistant to 
metronidazole with MIC values >256µg/mL (Figure 3.11). In addition, the isolates’ sensitivity 
profiles to the αGV bacterial collection did not differ from the parental cGV2 isolate. 
Similar to metronidazole strips, resistant isolates within the inhibition zones were noted for other 
antibiotics such as rifampicin and ciprofloxacin. Rifampicin resistant isolates were observed 
among 23.5% of the G. vaginalis collection, 53% of the collection when exposed to 
metronidazole and 11.8% when exposed to ciprofloxacin E-strips (Table 3.2). 
3.2 Isolation and characterization of αGV bacterial collection 
3.2.1 Isolation of αGV collection 
An αGV collection was isolated by using an agar overlay method containing ROPEC sewage 
samples and G. vaginalis ATCC 14018 and/or 14019 as indicator strains (as described in section 
2.2.5). 
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Figure 3.9  Metronidazole resistant colonies within ellipse of cGV2 inhibition zone.     
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Figure 3.10 TaqI digestion pattern of parental strain cGV2 and cGV2 metronidazole resistant derivatives. G. vaginalis ATCC 49145 
has been included as external control. All cGV2 metronidazole resistant derivative isolates showed TaqI genotypes similar to the 
parental cGV2 isolate.  
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Figure 3.11 An example of E-test results of metronidazole on cGV2 mutant isolates. The cGV2-
10b did not produce inhibition zone even at around the highest concentration of antibiotic on the 
E-strip.
 79 
 
 
 
 Table 3.2  Antibiotics that resistant G. vaginalis colonies were observed within their inhibition 
zones. “+” indicates the presence of resistant colonies; RI: rifampicin, MZ: metronidazole and 
CI: ciprofloxacin.  
 Etesting Antibiotics 
G. vaginalis Isolates RI MZ CI 
GV ATCC 14018 - - - 
GV ATCC 14019 + - - 
GV ATCC 49145 + + - 
cGV1 + - - 
cGV2 - + - 
cGV3 - - - 
cGV4 - + - 
cGV5 - - + 
cGV6 - + - 
cGV7 - + - 
cGV8 - + + 
cGV9 - + - 
cGV10 - + - 
cGV11 - - - 
cGV12 - - - 
cGV13 - - - 
cGV14 + + - 
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Colonies that produced inhibition zones on a lawn of G. vaginalis, as observed in Figure 3.12, 
were isolated and purified. A total of 33 bacterial isolates were recovered, 19 against G. 
vaginalis ATCC 14018 while 14 were isolated against G. vaginalis ATCC 14019. The αGV 
isolate identifiers are listed in Table 3.3. An additional bacterial isolate  previously isolated in 
Dr. Nokhbeh’s lab (523) was determined to be affective against G. vaginalis and therefore was 
added to the αGV collection (Ybazeta et al., 2017) (Figure 3.13).  
3.2.2 Characterization of αGV collection 
3.2.2.1 Morphological and biochemical testing 
Visual inspection of αGV collection members by phase contract microscopy revealed differing 
bacterial morphological properties. Except for two rod-shaped isolates (αGV18-14S and αGV18-
4L), the rest of the isolates were arranged as streptococci in short or long chains with varying cell 
sizes (Figure 3.14; Table 3.3). A catalase test of αGV collection members indicated that all αGV 
isolates were catalase negative. Gram staining of a subset of the αGV collection and α523 was 
completed. Of the subset, αGV18-1S, αGV19-4S, αGV18-8, αGV18-7aW, αGV18-11, αGV18-
14S were Gram-positive, while αGV18-4L was Gram-negative/variable. 
3.2.2.2 Genomics  
The genomes of αGV collection members were sequenced using an illumina HiSeq platform and 
assembled into 16-520 contigs as described in section 2.2.6.2.  None of the genomes could be 
closed. The genomes ranged in size from 2.1 Mbp to 3.1 Mbp with GC contents of 34.7% to   
 81 
 
 
Figure 3.12   Inhibition of G. vaginalis ATCC 14019 by an unknown bacterium (αGV) isolated 
from raw sewage.  
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Figure 3.13  Inhibition of the lawn of G. vaginalis ATCC 14019 by α523 bacterial colonies. 
α523 was originally isolated from sewage and co-cultured on the G. vaginalis ATCC 14019 
lawn.   
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Figure 3.14  Phase contrast microscopic images of αGV18-11, αGV18-17 and αGV19-12S isolates. Differences in morphological 
properties (short and long chain streptococci) among anti-GV collection indicate the diversity among this collection. Photographs 
were taken using 400x magnification and zoomed digitally to show the detailed morphological properties of each isolate
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Table 3.3  List of anti-GV isolates and their properties. Strep L: long chain streptococcus; Strep 
S: short chain streptococcus; rRNA: number of rRNA operons; tmRNA: number of transfer-
messengerRNA, CDS: number of coding segments in genome; nv: not verified  
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αGV18-11 Strep L - 2130140 38.67 85.87 2044 5 45 1 56 
αGV18-12S Strep L - 2186826 38.92 84.15 2154 6 46 1 141 
αGV18-13 Strep S - 2331233 38.7 85.92 2238 5 45 1 77 
αGV18-14S Rod - 2560328 35 86.36 2499 9 59 1 51 
αGV18-15 Strep L - 2264417 38.54 85.56 2206 6 47 1 77 
αGV18-16 Strep S - 2533569 34.99 86.77 2466 8 54 1 33 
αGV18-17 Strep L - 2303060 34.85 86.82 2224 7 53 1 16 
αGV18-18 Strep S - 2297125 38.73 86.54 2221 4 47 1 56 
αGV18-19W Strep S - 2325981 38.56 83.48 2269 6 44 1 175 
αGV18-19YW Strep S - 2849104 35.36 82.44 2742 7 53 1 240 
αGV18-1S Strep S - 2323323 39.77 86.81 2265 5 47 1 72 
αGV18-20 Strep L - 2283381 38.45 84.02 2199 6 44 1 116 
αGV18-2S Strep S - 2181522 38.55 85.29 2101 6 45 1 87 
αGV18-3 Strep S - 2307178 39.74 86.07 2230 7 46 1 119 
αGV18-5 Strep S - 2210287 38.46 83.86 2112 6 44 1 138 
αGV18-6L Strep S - 2350635 38.67 85.72 2256 5 45 1 79 
αGV18-7aW Strep S - 2186171 39.21 84.81 2133 5 40 1 108 
αGV18-7b Strep S - nv 47.47 82.2 nv 11 nv 2 nv 
αGV18-8 Strep S - 2413314 39.33 84.19 2283 5 45 1 194 
αGV18-9 Strep S - 3100738 35.62 80.22 2990 9 57 1 400 
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αGV19-1 Strep S - 2354650 38.8 85.18 2274 4 44 1 108 
αGV19-10L Strep S - 2566365 34.7 86.27 2436 8 54 1 37 
αGV19-11 Strep S - 2621397 36.72 86.02 2420 8 57 1 20 
αGV19-12S Strep S - 2459756 39.32 85.77 2350 5 37 1 112 
αGV19-13 Strep S - 2327210 39.79 87.31 2223 6 45 1 56 
αGV19-14 Strep S - 2790778 38.18 85.95 2671 8 63 1 40 
αGV19-2S Strep S - 2291593 38.54 85.3 2203 5 43 1 63 
αGV19-3 Strep S - 2276450 38.45 84.85 2188 6 47 1 105 
αGV19-4S Strep S - 2134436 38.65 85.43 2038 5 43 1 63 
αGV19-5 Strep S - 2301248 38.79 85.94 2206 5 45 1 75 
αGV19-6 Strep S - 2261830 38.73 83.75 2195 8 51 1 128 
αGV19-7 Strep S - 2672568 37.71 77.94 2608 7 56 1 520 
αGV19-9 Strep S - 2317193 38.65 85.92 2252 5 46 1 67 
CD523 α523 Strep S - 2779809 38.16 85.48 2680 8 62 1 81 
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39.8%. The nucleotide sequences with potential protein coding capacities accounted for 78-87% 
of the genomes corresponding to 2038-2990 CDS. They also contained 4-9 rRNA operons (rrn), 
a single tmRNA each, and 37 to 63 tRNAs (Table 3.3).  A phylogenetic tree based on 16S rRNA 
gene sequences of the αGV collection and NCBI reference strains was constructed as detailed in 
section 2.2.6.3. The two rod shaped isolates were grouped with endospore forming Gram-
variable Paenibacillus spp., however, they also erroneously clustered with lactococci probably 
due to partial sequence similarities and relatively low homology cutoff threshold or 
contamination of the DNA sources. The remainder of isolates were grouped in three main 
clusters with similarities to either of genera Enterococcus, Streptococcus and Lactococcus 
(Figure 3.15). However, the majority of isolates were in lactococcus group with the closest 
resemblance to L. raffinolactis followed by L. lactis. Only two isolates (αGV18-2S and αGV18-
16) fell within Enterococci with the closest match with E. faecium. Members of these genera are 
lactose fermenters (commonly referred to as lactic acid bacteria, LABs) and are known for 
production of short antimicrobial peptides. Two isolates (αGV18-19 and αGV18-3) were 
clustered closely with Streptococcus suis or Streptococcus lutetiensis that are considered newly 
emerging human pathogens. We excluded six isolates from further analysis due to their potential 
pathogenic status in addition to their weak αGV activities. These isolates that were excluded 
from analysis included two isolates in an Enterococci cluster, two rod shaped isolates in a 
Paenibacillus cluster and two isolates in a Streptococcus suis cluster.  
Bacterial isolates of the genus Lactococcus accounted for the majority of collection members (28 
of 34 isolates) with antiGV activities. They mostly contained potential cassettes for coding 
bacteriocins and were thus further analyzed in a pangenome comparison matrix detailed in 
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section 2.2.6.4 (Figure 3.16). Following pangenomic analysis, the isolates were grouped into 3 
clusters with clusters colored in blue and green having similarities to Lactococcus raffinolactis 
sp., while the red cluster was represented best by Lactococcus lactis sp. All clusters share 312 
core proteins (labeled in orange vertical lines). In addition to core proteins, a large number of 
proteins (2037-2990 proteins per αGV isolate) were considered in homology comparisons with 
an exclusion cutoff filter of 70% amino acid sequence similarity. The presence of a protein in 
any isolate was denoted by a vertical red line resulting in clustered patterns of isolates.    
Additionally, bacteriocin cassettes were identified for 27 out of 28 lactococcal αGV isolates in 
addition to the previously identified α523 isolate (Table 3.4). Seven cassettes were found, two of 
which were class I, ie. Lanthipeptide class I and Lanthipeptide class I orf013. The following 5 
cassettes were determined to be class II: orf10 HTCP (Head to Tail Cyclized Peptides), orf003 
HTCP, small ORF1 HTCP, Lactococcin putative class II and orf007 class II. It was also 
discovered that bacteriocin cassettes orf003 HTCP and small ORF1 HTCP were always found in 
tandem. The frequency of the presence of each cassette among the αGV isolates’ genome was 
64% for orf10 HTCP; 25% for orf003 HTCP and small orf1 HTCP; 21% for Lactococcin 
putative class II, orf007 class II and Lanthipeptide class I; 17.9% for Lanthipeptide class I 
orf013. The orf10 HTCP cassette was identified in 88% of blue cluster αGV, 40% of green 
cluster isolates and 16.7% of red cluster isolates. The tandem cassettes of orf003 HTCP and 
small orf1 HTCP were identified in 41% of blue cluster isolates but not within the αGV isolates 
of the other clusters. The Lactococcin putative class II was only identified in the blue (5.9%) and 
green (100%) clusters. While the remaining three cassettes, Lanthipeptide class I, Lanthipeptide 
class I orf013 and orf007 class II were only identified in the αGV isolates that are a part of the 
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red cluster. The prevalence of these cassettes within the red cluster ranged from 83-100% of 
αGV isolates. The molecular weights of the identified cassettes ranged from 2.32kD to 9.84kD 
(Table 3.4). Additionally, different molecular weights of cassettes (Lactococcin putative class II, 
Lanthipeptide class I, Lanthipeptide class I orf013 and orf007 classII) were observed among 
αGV isolates. However, αGV18-15 was not shown to carry any of the above-mentioned 
cassettes. This might be due to the incompleteness of the genome sequencing data or the lack of 
reference in the databases.  
3.3 Antibacterial activities of αGV isolates against G. vaginalis collection  
3.3.1 Target range of αGV bacteria against G. vaginalis collection  
A high throughput target range assay of αGV isolates (n=34) against the entire G. vaginalis 
collection (n=17) as well as an assortment of non-G. vaginalis bacteria (n=18) was completed 
(Figure 3.17) as described in section 2.2.7.1. Positive inhibition by αGV isolates against a G. 
vaginalis indicator strain was determined by the presence of a fully cleared inhibition zone 
around the αGV isolate in question. An example of the high throughput inhibition testing of αGV 
collection against G. vaginalis ATCC 4145 is shown in Figure 3.17. Differing inhibition zone 
diameters were observed for different αGV isolates against a given GV isolate, as well as 
differences between different GV isolates for a given αGV isolate. For the effect of αGV isolates 
against non-G. vaginalis bacteria, a positive result was considered if there was either full or hazy 
clearance zones of inhibition. Based on the zones of inhibition the target range of each αGV 
isolate against G. vaginalis and non-G. vaginalis collections were determined (Figure 3.18). The 
target range observed for the G. vaginalis collection was from 0% to 100%, with the majority of 
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αGV isolates (n=18) having the capability of killing at least 50% of the G. vaginalis isolates. 
While the αGV target range against the non-G. vaginalis collection ranged from 0% to 60%. 
Only six αGV isolates (17.6%) could inhibit the growth of greater than 40% of the non-G. 
vaginalis isolates. 
Sensitivity of the G. vaginalis collection to each of the αGV isolates was also determined based 
on the high throughput target range assay (Figure 3.19). Among the G. vaginalis collection 
76.5% were sensitive to more than 40% (n=12-24) of the αGV collection, with all isolates 
sensitive to at least 32% of the αGV collection. For the non-G. vaginalis collection, the growth 
of 33% of isolates was not affected by the presence of αGV bacteria. Of the isolates affected 
67% were fully sensitive to less than 30% of αGV isolates (Figure 3.20). The αGV isolates had 
limited inhibition of vaginal microbiome surrogates, Lactobacillus sp. (n=6). Contrarily, one of 
the non-G. vaginalis isolates, B. animalis ATCC 700541, was exceptionally inhibited by 91% of 
αGV isolates. It is noteworthy that B. animalis is not part of vaginal microflora.  
3.3.2 Target range of αGV concentrated supernatants and the sensitivity of G. 
vaginalis isolates   
A total of 29 αGV culture supernatants including α523 were concentrated using either 
chloroform extraction or methanol precipitation followed by “drop on the lawn” experiments as 
described in section 2.2.9. Twenty out of 29 αGV isolates produced concentrated supernatants 
with active agents verified by “drop on the lawn” experiments as detailed in section 2.2.8. 
Examples of “drop on the lawn” results for G. vaginalis ATCC 14018 and cGV7 are shown in 
Figure 3.21 and Figure 3.22, which correspond to chloroform extraction and methanol  
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Figure 3.15  Phylogenetic tree analysis of 16S rRNA of entire αGV collection.  
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Figure 3.16   Phylogenetic tree and pangenome matrix of a selected cluster of the αGV collection and 4 NCBI reference strains. The 
blue, green and red sections of the phylogenetic tree indicate the clusters within the pangenome matrix. Each vertical line represents 
the presence of a protein with at least 70% amino acid similarity. The orange vertical bars denote the 312 core proteins. The red 
vertical bars indicate accessory proteins. The last column refers to the number of ORFs analyzed.  
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Table 3.4   Bacteriocin cassette types with their respective molecular weights (kD) identified in 
αGV isolates. Blue, green and red is indicative of clusters identified in pangenome matrix.  
αGV isolates 
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aGV18-20 6.5 kD             
aGV18-1S 6.5 kD 8.61 kD 8.95 kD         
aGV18-5 6.5 kD             
aGV18-6L 6.5 kD             
aGV18-11 6.5 kD             
aGV19-10L 6.5 kD             
aGV19-11 6.5 kD             
aGV19-1 6.5 kD             
aGV18-15               
aGV19-9 6.5 kD 8.61 kD 8.95 kD         
aGV19-13 6.5 kD 8.61 kD 8.95 kD         
aGV18-8   8.61 kD 8.95 kD         
aGV18-18 6.5 kD 8.61 kD 8.95 kD 9.84 kD       
aGV18-17 6.5 kD 8.61 kD 8.95 kD         
aGV19-6 6.5 kD 8.61 kD 8.95 kD         
aGV19-12S 6.5 kD             
aGV19-3 6.5 kD             
aGV19-7       7.89 kD       
aGV19-4S 6.5 kD     7.89 kD       
aGV19-5       9.84 kD       
aGV19-14       7.89 kD       
aGV18-12S 6.5 kD     7.89 kD       
aGV19-2S         2.32 kD   2.32 kD 
aGV18-19YW         2.34 kD 5.82 kD 2.34 kD 
aGV18-9         2.34 kD 5.82 kD 2.34 kD 
aGV18-7b 6.5 kD       7.86 kD 5.82 kD 5.66 kD 
aGV18-7aW         7.86 kD 5.82 kD 5.66 kD 
aGV18-13         7.86 kD 5.89 kD 5.66 kD 
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precipitation methods, respectively. Differences in clearance zone sizes and full versus partial 
clearance zones are illustrated in Figure 3.21. Target ranges of αGV concentrated supernatants 
against the G. vaginalis collection were determined (Figure 3.23). The minimum target range 
was 5% while the maximum target range observed was 100% for 7 of the 20 isolates (35%). 
Overall, 60% of the αGV agents had target ranges greater than 45% indicating their inhibitory 
nature against 8 or more G. vaginalis isolates. Additionally, all G. vaginalis isolates (n=17) were 
shown to be sensitive to >30% of the 20 αGV concentrated supernatants, with a maximal 
sensitivity of 58% (Figure 3.24). It was concluded that the present collection of anti-GV isolates 
has the poteintail for formulation of minimal cocktails agaist GV collection; however, it would 
need to be expanded for larger collection of GV isolates. 
3.3.3 αGV active agent SDS-PAGE analysis  
Duplicate samples of the antiGV concentrated supernatants were fractionated in SDS-PAGE 
gels. Silver staining to observe protein banding patterns and diffusion of the bands from gel into 
indicator bacterial lawn are standard methods in screening for antimicrobial peptides, which are 
routinely applied to studying bacteriocins. Diffusion of peptide bands into the bacterial lawn 
results in localized clearance of bacteria corresponding to a band with antimicrobial activity as 
described in section 2.2.10. In practice, one half of the gel is cut and stained, and the other half is 
vigorously washed to remove the buffer and SDS and subsequently used in gel diffusion 
experiments. Alignment of the images of the gel halves using the low range protein ladder was 
used to identify the bands responsible for clearance of bacterial lawns. Several inhibitory bands 
were observed on the diffusion gel plates and matched to banding patterns on the silver stained 
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gel half (Figure 3.25, Figure 3.26, and Figure 3.27). The bands immediately corresponding to 
cleared areas in bacterial lawns were below 4.6 kD for αGV18-9 on the indicator strain G. 
vaginalis ATCC 14018 (Figure 3.25). On the G. vaginalis ATCC 14019 two clearance bands of 
different molecular weights, both between 4.6-10 kD, were observed for αGV19-2S and αGV19-
7 (Figure 3.26).  A band was also observed at approximately 35 kD for αGV19-7 on a lawn of 
cGV14 (Figure 3.27). It must be noted that the supernatant extract from αGV19-7 with clearance 
band at ~35 kD was active against 95% of GV isolates in drop on lawn experiments. This 
highlights the need for further thorough examination of the extracts in diffusion assays.  
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Figure 3.17  An example of high throughput target range assay of αGV bacterial collection 
against G. vaginalis ATCC 49145.  
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Figure 3.18  Target range of αGV bacteria against the G. vaginalis collection (n=17; blue bars) 
and non-G. vaginalis collection (n=19; red bars).  
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Figure 3.19  Sensitivity of G. vaginalis collection (n=17) to the αGV isolates (n=34).  
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Figure 3.20  Sensitivity of the non-G. vaginalis collection (n=18) to the αGV collection (n=34). 
Blue and red bars indicate full (clear zone of inhibition) and partial sensitivities (turbid zone of 
inhibition), respectively.  
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Figure 3.21  (A) An example of the “drop on lawn” target range assay results using αGV 
chloroform extracted supernatants against G. vaginalis ATCC 14018. (B) Transparency of 
clearing zone is illustrated by overlaying the plate on a paper with line patterns. 
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Figure 3.22  An example of the “drop on lawn” target range assay results using αGV methanol 
precipitated supernatants against cGV7. 
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Figure 3.23  Target ranges of twenty αGV concentrated supernatants against G. vaginalis 
isolates (n=17) as determined by “drop on the lawn” experiments. 
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Figure 3.24  Sensitivity of the G. vaginalis isolates (n=17) to twenty αGV concentrated 
supernatants as determined by “drop on the lawn” experiments. 
 
  
102 
 
 
Figure 3.25  Alignment of silver stained and gel diffusion half gels. Concentrated supernatants 
from αGV 19-11, 18-6L, 18-12S and 18-9 were fractionated in a 15% SDS-PAGE and diffused 
into G. vaginalis ATCC 14018 lawn. Multicolor low range protein ladder was used to align the 
gel images (lane 6). Arrows indicate position of silver stained protein band that correspond to 
clearance zone in gel diffusion.   
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Figure 3.26  Alignment of silver stained and gel diffusion half gels. Concentrated supernatants 
from αGV 18-8, 19-5, 19-2S and 18-7b were fractionated in a 15% SDS-PAGE and diffused into 
G. vaginalis ATCC 14019 lawn. Multicolor low range protein ladder was used to align the gel 
images (lane 6). Arrows indicate position of silver stained protein bands that correspond to 
clearance zones in gel diffusion.     
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Figure 3.27  Alignment of silver stained and gel diffusion half gels. Concentrated supernatants 
from α523, αGV 19-12S, 19-7, and 18-19YW were fractionated in a 15% SDS-PAGE and 
diffused into G. vaginalis cGV14 lawn. Multicolor low range protein ladder was used to align 
the gel images (lane 6). Arrows indicate position of silver stained protein band that correspond to 
clearance zone in gel diffusion.    
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4 Discussion 
4.1 Genotypic diversity among G. vaginalis isolates 
Consistent with the earlier reports as summarized in section 1.2, our collection of G. vaginalis 
(n=17) were determined to be genotypically diverse by ARDRA analysis via TaqI or HpaII 
digestion of a PCR product amplified from the 16S rRNA gene (Figure 3.5Figure 3.6). ARDRA 
analysis results using TaqI showed the existence of genotypes A and B but not C in our 
collection, suggestive of limited genotypic diversity among these G. vaginalis isolates (Ingianni 
et al., 1997). The majority of our isolates were genotype B (82.4%), while the remaining were 
found to be genotype A (17.6%). In Pleckaityte et al. (2012), the distribution of G. vaginalis 
genotypes was seen with 35% genotype A (n=6) and 64.7% genotype B (n=11) and no genotype 
C, indicating that genotype C may be a rare type. However, among clinical isolates from Kenya 
and Belgium the genotypic distribution differed with most isolates having genotype A (49%), 
followed by genotype B (26%) and C (25%) (Lopes dos Santos Santiago et al., 2011). Therefore, 
geographical location may play a role in diversity of the G. vaginalis genotypes. This observed 
genotypic diversity among our G. vaginalis collection was further supported by HpaII ARDRA 
analysis that revealed three genotypes 1, 2 and 4 but not genotype 3 (Ingianni et al., 1997). 
Genotype 1 made up 82.4% of the isolates. Interestingly, all previously identified genotype B 
isolates were determined to be genotype 1 by HpaII digestion. This pattern of correspondence 
between TaqI and HpaII genotypes, however, was not consistent, as the TaqI genotype A isolates 
appeared to be either genotype 3 (5.8%) or 4 (11.8%) by HpaII ARDRA analysis.  
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In conclusion, consistent with other reports, the members of our small collection of G. vaginalis 
isolates showed genotypic diversities that might also independently apply to their other traits 
such as virulence factors and antimicrobial sensitivities.  
4.2 Diversity in antibiotic susceptibility profiles 
Antibiotic susceptibilities of our G. vaginalis collection was determined for eight antibiotics: 
metronidazole (MZ), clindamycin (CM), vancomycin (VA), linezolid (LZ), rifampicin (RI), 
ampicillin (AM), ciprofloxacin (CI), and tetracycline (TC) (Table 3.1). The two clinically 
relevant antibiotics are metronidazole and clindamycin. Metronidazole MIC values for G. 
vaginalis isolates have been shown to be in the range of  0.125µg/mL to >1024µg/mL (Kharsany 
et al., 1993; Austin, 2006; De Backer et al., 2006; Nagaraja, 2008; Togni et al., 2011; Knupp de 
Souza et al., 2016). However, there are some contradicting reports. For example, G. vaginalis 
ATCC 14018 when assessed in VDMP medium (vaginally defined medium plus peptone) 
containing metronidazole showed growth stimulation at lower concentrations of antibiotic while 
at higher concentrations (1000-4000µg/mL) there was a gradual growth inhibition (Anukam and 
Reid, 2008). On the contrary, the G. vaginalis ATCC 14018 MIC value was said to be 16µg/mL 
(Knupp de Souza et al., 2016). There seems that the accuracy of MIC values is dependent on the 
method of evaluation, as well as the growth conditions. For example, incubation at strict aerobic 
versus microaerobic environments and the enriching supplements in the growth medium have 
dramatic effect on the growth kinetics of G. vaginalis. Suboptimal conditions can alter the 
growth kinetics of the G. vaginalis and therefore lead to reduced concentration of antibiotics 
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required to cause growth inhibition (MIC) and/or cell death. Gottschick et al. (2016) study 
demonstrated that the strict anaerobic condition was not optimal for G. vaginalis biofilm growth 
and that incubation should occur under 5% partial pressure for CO2. We conducted our E-testing 
for our G. vaginalis collection according to CLSI and EUCAST guidelines with optimal growth 
conditions for G. vaginalis and agar plates consistent with De Backer et al. (2006) and Schuler et 
al. (2016) (section 2.2.4). The quality control strain E. faecalis was used to validate test 
performance. Based on the E-test results (Table 3.1) the metronidazole MIC range for the G. 
vaginalis collection was 8µg/mL to >256µg/mL. This accounted for 1 to 8-fold differences in 
MIC values amongst the isolates, indicating diversity with respect to their susceptibilities to 
metronidazole. Differences in the levels of susceptibilities of different isolates might be related 
to the physiological differences among isolates in their antibiotic uptake rates, biological drug 
activation of antibiotic, and DNA repair functions that mitigate the genotoxicity of 
metronidazole. Nevertheless, our observations are congruent with previous literature results 
(Kharsany et al., 1993; Austin, 2006; De Backer et al., 2006; Nagaraja, 2008; Togni et al., 2011; 
Schuyler et al., 2016). The distribution of metronidazole MIC values for G. vaginalis collection 
is illustrated in Figure 3.8. Since there are no standard breakpoints defined by CLSI and 
EUCAST for G. vaginalis, the suggested breakpoints in the literature, <8µg/mL for susceptible, 
8-16µg/mL intermediate, and resistant is defined as either >16µg/mL or >32µg/mL, were used to 
interpret our results (Austin, 2006; De Backer et al., 2006; Nagaraja, 2008; Knupp de Souza et 
al., 2016; Schuyler et al., 2016). Based on the literature-stated breakpoints, none of the G. 
  
108 
 
vaginalis isolates were susceptible to metronidazole, whereas 35.3% were deemed to be 
intermediately resistant and 64.7% of the G. vaginalis isolates were resistant (Table 3.1). The 
isolates (n=4) that were not inhibited by metronidazole at the highest concentration available on 
the E-strips are most likely part of an emerging population of extremely resistant strains similar 
to what observed in Schulyer et al. (2016).  
4.3 Metronidazole resistance development 
Additionally, within the inhibition zones of metronidazole, rifampicin and ciprofloxacin E-strips 
several G. vaginalis singular colonies were observed (Figure 3.9; Table 3.2). The ARDRA 
analysis of 20 purified colonies picked from the inhibition zone of metronidazole E-strips on G. 
vaginalis cGV2 isolate showed similar banding patterns to their parental isolate consistent with 
genotype B. This suggested that resistant colonies were derived from the metronidazole sensitive 
parental cGV2 isolate. Further analysis of these 20 colonies for their susceptibilities to 
metronidazole by E-test showed elevated MIC values of >256µg/mL (Figure 3.11) indicating 
that an overnight exposure to metronidazole was sufficient to select for either existing 
spontaneous mutants in the population or mutants were induced via exposure to metronidazole. 
Although the latter seems an interesting postulation given the genotoxic and mutagenic capacity 
of metronidazole, however, determining the molecular basis of the mechanism involved in 
generation of mutants in G. vaginalis requires further experiments. It is noteworthy that 
involvement of nitroreductases in stepwise genotoxic bioactivation of the nitroaromatic 
compounds and further generation of induced resistant mutants has been mapped to mutations in 
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these enzymes in E. coli, S. thyphimurium and H. pylori (De Meo et al., 1992; Whiteway et al., 
1998; Carroll et al., 2002; Nokhbeh et al., 2002; Tanih et al., 2011). The observation that an 
overnight exposure/selection of the G. vaginalis metronidazole mutants did not result in 
incremental MIC values might be an indication of involvement of a single step mechanism 
leading to the highest MIC values. This rapid selection/induction of highly resistant isolates in G. 
vaginalis has obvious important clinical implications, which might be relevant to the reported 
20% relapse rates among BV patients within first month post-treatment with metronidazole and 
70% recurrences by the third month (Swidsinski et al., 2008; Mayer et al., 2015). This is not 
specific to G. vaginalis since a similar increasing trend of metronidazole treatment failure has 
become a common place for other infections such as C. difficile and H. pylori infections, which 
are also treated with metronidazole (Pandya et al., 2014; Barkin et al., 2017; Hu et al., 2017).  
Regardless of the mechanism through which the metronidazole resistance developed, we asked 
whether the metronidazole resistant cGV2 derivatives were still sensitive to the inhibitory/killing 
effects of antiGV isolates. We tested the sensitivities of 20 metronidazole resistant isolates to the 
antiGV collection by using a high throughput target range plate assay, as detailed in section 
2.2.7.1.  We found no difference in their susceptibilities to killing by specific antiGV isolates 
(data not shown). 
The diversity in the MIC values, rapid resistance acquisition rates and treatment failure further 
demonstrates the need for developing alternative therapeutics. Given the example of retaining the 
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target spectra of our αGV collection by the metronidazole-resistant mutants mentioned above 
highlights our approach of using bacteria against G. vaginalis isolates as one of the viable 
alternative trends that might lead to promising applications for combatting metronidazole-
resistant GV.  
Learning from the metronidazole experience, we were prompted to examine the susceptibilities 
of the G. vaginalis collection to other antibiotics. The MIC ranges determined by E-test for 
clindamycin were <0.016µg/mL to 0.064µg/mL, which is consistent with literature with most 
reported MIC values falling between <0.016µg/mL and 0.047µg/mL (Kharsany et al., 1993; De 
Backer et al., 2006; Nagaraja, 2008; Togni et al., 2011; Knupp de Souza et al., 2016). The 
suggested breakpoints in literature were <2µg/mL susceptible, 2-4µg/mL intermediate, and 
>4µg/mL resistant (Nagaraja, 2008). Based on these breakpoints all our G. vaginalis isolates 
tested (n=17) were determined to be susceptible to clindamycin.  
The MIC values for the six clinically not relevant antibiotics for our G. vaginalis collection are 
shown in Table 3.1. The MIC ranges for VA (0.25µg/mL to 0.5µg/mL), and CI (1µg/mL to 
4µg/mL) were consistent with MIC ranges previously reported for VA (0.12µg/mL to 
0.5µg/mL), and CI(0.75µg/mL to 4µg/mL) (Kharsany et al., 1993; De Backer et al., 2006). 
Whereas MIC ranges reported here for LZ (0.125µg/mL to 0.50µg/mL), RI (0.5µg/mL to 
2µg/mL), AM (<0.016µg/mL to 2µg/mL), were found to be slightly higher than the maxima of 
the literature-reported MIC ranges. The literature reported MIC ranges are as follows: LZ 
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(0.125µg/mL to 0.19µg/mL), RI (0.5µg/mL to 0.75µg/mL), and AM (<0.016µg/mL to 
0.5µg/mL) (Kharsany et al., 1993; De Backer et al., 2006; Knupp de Souza et al., 2016). There 
was a 2.6 fold, 2.7 fold, and 4 fold increase in MIC maxima values relative to literature values 
for LZ, RI, AM, respectively (Kharsany et al., 1993; De Backer et al., 2006; Knupp de Souza et 
al., 2016).  On the contrary, the MIC range for tetracycline (0.5µg/mL to 128µg/mL) in our 
collection was lower by 4 fold for minimum MIC value compared to the reported MIC range 
(2µg/mL to 128µg/mL) (Kharsany et al., 1993). Regardless of the antibiotic MIC value 
differences observed between our collection and the reported values, the susceptibilities to each 
antibiotic among the G. vaginalis isolates varied with an overall 2 to 256-fold difference in MIC 
values, which further demonstrated the diversity among G. vaginalis isolates (Table 3.1).  
In conclusion, it appears that our small collection of G. vaginalis isolates comprised of non-
homogenous members with respect to their genotypic characteristics and their antibiotic 
susceptibility properties. These observations are congruent with the reports from other labs 
around the world. In addition to limited efficacy of the available antibiotics, the genetic 
heterogeneity and diversity in biological properties of the members of G. vaginalis bacteria play 
a determining role in contributing to the treatment failure, acquisition of resistance and 
consequently to the ever-increasing prevalence of this infection globally. Therefore, developing 
effective antimicrobials for treatment of BV cannot simply rely on synthetic derivation 
technology by modifying the existing antibiotics for which there is a historical failure records. 
Moreover, vaginal colonization and formation of sessile biofilm of G. vaginalis, which plays a 
  
112 
 
primer role in establishing multi-bacterial biofilm, is greatly potentiated by the concomitant 
antibiotic induced severe damage to the otherwise protective vaginal microflora. Therefore, it 
would be beneficial to avoid developing and the use of broad spectrum antibiotics in the future. 
It makes a logical sense that for controlling a highly diverse and plastic pathogen such as G. 
vaginalis one must either rely on multiple narrow spectrum and highly specific therapies with 
additive or synergistic properties, or develop smart antimicrobials with dynamic adaptation 
properties, eg phage therapy.  
We considered the following principles in formulating our strategic approach to developing 
novel antibacterials against G. vaginalis. These principles are as follows, i) narrow spectrum and 
specificity against G. vaginalis, ii) indiscriminate inhibitory effect against metronidazole-
resistant variants, iii) multiplicity and diversity among candidate antibacterials, iv) overlapping 
modes of actions to provide additive or synergistic effects, v) advanced refinement through 
evolutionary selection to reduce the chance of resistance. 
One of the most attractive approaches in developing novel antibacterials is the use of bacteria 
against bacteria, as this has occurred throughout evolution in nature. Therefore, we screened for 
bacteria with potential direct antagonism against G. vaginalis.    
4.4 Isolation and characterization of a diverse collection of AntiGV isolates 
Screening raw sewage for bacteria against G. vaginalis ATCC strains 14018 and 14019 resulted 
in the isolation of a diverse group of 33 bacteria and one previously isolated bacterium (α523) 
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with direct inhibitory/killing effects against G. vaginalis (section 3.2.1). Except for two isolates 
that appeared rod-shaped, the majority of the αGV isolates belonged to streptococcal morphotype 
and differed from each other with respect to their individual cell sizes and the length of 
streptococcal chains, and all appeared to be catalase-negative (Figure 3.14 and Table 3.3). We 
used the catalase test not only as an additional phenotypic marker for diversity, but to be cautious 
about catalase-positive isolates, since catalase is considered to be a virulence factor for most 
pathogens, assisting them in avoding the immune system.   
We sequenced the genomes of these 34 αGV isolates and assembled into multiple contigs and 
annotated (see section 2.2.6.2 and 0), however, we could not close them. Closing any genome to 
its final circular representation of chromosome requires further long-range sequencing using 
PacBio or MinIon sequencing platforms and using the long scaffolds to fill-in the gaps between 
assembled contigs. Nonetheless, the available sequencing data (~90% recovery) provided useful 
information to proceed with taxonomic identification, and further analyses to detect genomic 
cassettes. In addition to morphological and varying levels of effect on G. vaginalis, a glance at 
the preliminary sequencing report indicates that the antiGV isolates were diverse with respect to 
their GC contents, number of rRNA operons and tRNA (Table 3.3). Using the nucleotide 
sequences and amino acid sequences of the predicted open reading frames (ORFs) the 
phylogenetic trees were constructed. Alignment of the 16S rRNA genes lead to construction of a 
phylogenetic tree (Figure 3.15). The majority of the isolates were clustered within lactococci (28 
out of 34 isolates) of which 22 of 28 lacococci were distantly related to L. raffinolactis that 
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appeared as an outgroup (Figure 3.15). The closest representative for 16 of 22 isolates in L. 
raffinolactis subgroup was identified as Lactococcus sp. YM05004 for which no complete 
genomic sequence is available, nor its accurate taxonomic binomial ID is defined. There seems 
that this group of 22 isolates are also divergent between each other that makes assigning accurate 
taxonomic identification challenging. Therefore, we speculate that these isolates might be either 
novel species or they might be defined as subspecies or strains of a common species. For the ease 
of communication, therefore, we suggest designating them as Lactococcus sp. followed by the 
numbers that we have already used in this report. The remaining 6 isolates out of 28 lactococcal 
group clearly clustered with Lactococcus lactis, a dairy fermenter (Figure 3.15). The third group 
of αGV isolates included two members that clustered with Enterococci and most closely with E. 
faecium and distantly with E. durans and our previously reported α523 isolate (Ybazeta et al., 
2017). For these two members we suggest assigning the representative E. faecium names and 
await full genome sequence when we can identify them at subspecies taxonomic levels, 
depending on the level of divergence they show compared to reference genome. The fourth 
group of isolates consisted of two that were clustered with Streptococcus suis and Streptococcus 
lutetiensis and the fifth group of two isolates were clustered with Paenibacillus lautus, a rod-
shaped spore bearing Gram-variable bacterium.  
The αGV isolates appear to be genetically diverse as shown by their 16S rRNA restriction maps; 
however, to gain more detailed information about diversities, we constructed a pangenomic 
phylogenetic tree using over 2000 protein amino acid sequences as explained in section 3.2.2.2 
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(Figure 3.16). Since the two rod-shaped bacteria had weak antiGV activities and the two 
members of Enterococci resembled by E. faecium (a pathogenic bacterium), and the other two 
isolates within Streptococcus suis cluster are considered emerging pathogens, we excluded these 
isolates from further analyses. We focused our pangenomic analysis on 28 lacotcoccal isolates. 
Pangenomic analysis identified three divergent clusters indicated by blue, green and red colors in 
Figure 3.16 and Table 3.4. As noted in the 16S rRNA phylogenetic tree, the closely related 
Lactococcus raffinolactic isolates represented the blue and green clusters, while the Lactococcus 
lactic isolates closely represented the red colored cluster.  L. piscium and L. garvieae, that were 
included as the outgroup controls, showed clear differences with the members of each cluster 
(Figure 3.16). While these clusters were different from each other, the αGV members within 
each cluster appeared not to be the same with respect to their banding patterns suggesting 
diversity among these isolates and consistent with previous genetic and morphological 
observations.   
It is noteworthy that 27 out of 28 of these isolates were also shown to carry genetic cassettes 
potentially coding for novel bacteriocins (Table 3.4). The predicted bacteriocin cassettes 
identified for each of the Lactococcus clusters also seemed to be linked to the pangenomic and 
16S rRNA clusters as illustrated in Table 3.4. The diversity of cassette types as well as cassette 
molecular weights indicated that there is a probability that the αGV isolates’ active agents are 
different from each other. Although, having an identified cassette does not indicate that the 
cassette is active, however, since 96% of isolates contain a cassette this might suggest that the 
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cassettes might have been conserved functionally. Therefore, the active agents’ natures needed to 
be studied. In addition, the αGV bacteria producing the active agent required further 
characterization for the specificity and sensitivity against G. vaginalis.  
4.5 Functional diversity of antiGV isolates against GV collection  
The functional diversity of the αGV collection was demonstrated via the high throughput target 
range assay against the G. vaginalis isolates (Figure 3.17). It was noted that not only the 
diameter of the zones of inhibition and clearance differed among αGV isolates against an 
individual G. vaginalis isolate, but also different G. vaginalis isolates showed different 
sensitivities to a given antiGV isolate. The overall sensitivity of G. vaginalis isolates varied from 
32% to 75% of αGV isolates (Figure 3.19). Since more than half of the αGV isolates were 
capable of killing at least 50% of the G. vaginalis isolates and only 17.6% affected more than 
40% of non-G. vaginalis bacteria, we concluded that the αGV isolates had a narrow spectrum of 
effect with a relative specificity biased for the G. vaginalis isolates (Figure 3.18). These 
observations stress the correct design and effectivness of our screeenig method. Due to the 
limited number of the G. vaginalis isolates the high sensitivity ranges are promising since there 
are multiple effective αGV isolates with overlapping target ranges that can be included in a 
minimal cocktail and tested against extended collection of GV isolated in the future. Thus 
expanding both collections is necessary to further refine the future cocktails to target a globally 
representative GV isolates. Additionally, sensitivity of the non-GV bacteria to the αGV isolates 
was biased toward bacteria that are not part of the vaginal microflora indicating that the 
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lactobacillus species that were used as surrogate representatives of vaginal lactobacilli were the 
least affected by antiGV bacteria (0 to <30% of entire antiGV collection). This observation is 
promising from the futuristic applied point of view indicating that it is less likely that the antiGV 
isolates or their active agents might damage the vaginal microflora. To fully define the target 
range and sensitivity of vaginal bacteria to the αGV collection, continued research would need to 
be completed utilizing commensal bacteria specific to the vaginal natural microflora in the high 
throughput target range assay. 
Overall, we concluded that the genetic diversity observed among antiGV isolates was also 
translated to their functional antimicrobial activities against GV isolates.  
4.6 Antimicrobial agents in the supernatants of antiGV isolates  
As mentioned earlier, members of a limited number of Bacillus sp. isolates, and many members 
of Lactococcus sp. and Enterococcus sp. isolates were found to carry cassettes coding for 
antimicrobial peptides collectively named bacteriocins, which are considered promising 
antimicrobials (van Belkum et al., 2011; Dischinger et al., 2014; Perez et al., 2014; Etayash et 
al., 2015). Bacteriocins are ribosomally synthesized and some are post translationally modified 
and exported via cell membrane to the extracellular environment where they deliver their 
antimicrobial functions. They are part of the arms-race phenomenon among bacteria to gain 
advantage against competitors in accessing limited resources and colonization surfaces. By virtue 
of their modes of action, which most often destabilize the integrity of the cell membranes of their 
  
118 
 
targeted microorganisms, they can be considered a new generation of antimicrobials. Therefore, 
searching for and studying the nature of such antimicrobial agents (found in the extracellular 
environment) was a logical next step to the projects goal of discovering alternative 
antimicrobials against G. vaginalis with the potential to be utilized in the furture as a bacterial 
vaginosis therapeutic treatment.   
Our analysis of the genomes of antiGV isolates pointed to the existence of multiple bacteriocin 
cassettes of different types among 27 out of 28 lactococcal isolates together with the previously 
identified α523 isolate (Table 3.4). Concentrating the supernatants from these 29 isolates 
produced 20 preparations with activity against GV isolates tested by drop on the lawn 
experiments.  
The lack of activity among 9 supernatants might be due to the inefficiency of the methods 
applied for concentrating the agents or inactivation of the active agents during extraction. It is 
necessary to repeat this procedure using an alternative method of extraction such as the salting in 
method using ammonium sulfate. It might also be that the activity of the bacteriocin is not 
compatible with extraction methods used here. If the active agent is not a peptide, then none of 
these methods would concentrate the agent in question. For example, overproduction of acids 
and hydrogen peroxide can exert antimicrobial activity and can be diluted out during the 
extraction process. Therefore, our attention will be focused on these isolates in the future.  
As previously described in section 3.3.2, the target ranges of the 20 concentrated supernatants 
were 5% to 100% with 12 of the αGV isolates with target ranges of at least 45% against the G. 
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vaginalis isolates (Figure 3.23). Interestingly, the target ranges of the αGV isolates in the high 
throughput target range assay, differed for some isolates compared to the extracted and 
concentrated active agents. In some cases, there was a decline in target range by using 
supernatants compared to inoculating the cells on the lawns. This is possibly due to a limited 
amount of active agent excreted to the supernatant environment as opposed to continuous export 
of the agent by the growing antiGV bacteria growing on the indicator lawn. Opposing results 
also occurred with increased target ranges in the extracted supernatant compared to the active 
bacterial growth on the indicator lawn. The αGV isolate with the greatest increase in G. vaginalis 
specific target range was αGV19-5. This αGV isolates’ target range increased by 76.5%, being 
able to inhibit growth of all G. vaginalis isolates within the collection. The reasoning for such a 
dramatic alteration in target range could be due to the growth rate of αGV19-5. As a slow 
grower, the bacteria may not have had enough time to produce a significant concentration of its 
active agent to effectively produce clear inhibition zone on a lawn of G. vaginalis. In contrast, 
since the active agents from the supernatants were concentrated by 57 times the active agent 
concentration would have greatly increased and therefore bacterial cell growth would not be the 
limiting factor anymore.  
The methods applied to concentrate the active agents from antiGV supernatants are standard 
methods of choice applied to bacteriocins and other antimicrobials that are short peptides or 
polypeptides. To further verify the peptide nature of the active agent in the supernatant 
concentrates, diffusion of the fractionated proteins and peptides from polyacrylamide gels into 
  
120 
 
the indicator bacterial lawn was used. We used this approach to test the supernatant extracts 
previously used in drop on lawn experiments. This approach is efficient in identifying the bands 
with antibacterial activities that can resist heat denaturation and resist the reducing agent used in 
these gels. Of note, class II circular bacteriocins and some class I lantibiotics typically fit this 
category and produce clearing zones upon diffusion to indicator bacterial lawn. Such molecules 
usually show slightly enhanced molecular rates on the gel due to retaining their folded structures 
and additionally due to the loss of stretch of amino acids at their N-terminus during 
circularization (van Belkum et al., 2011). As detailed in section 3.3.3, several bands matching 
the predicted bacteriocin molecules were detected on gels. All active bands but αGV19-7, had 
active agents within 1.7 to 10kD marker bands. However, αGV19-7 showed clearance on the 
indicator lawn at around 35kD region, highlighting the ability of this method in identifying 
unpredicted antimicrobial proteins. While bacteriocidins can be peptides, they can also be higher 
molecular weight proteins. For example, a family of heat-resistant high molecular weight 
bacteriocins have been described (Šmarda and Benada, 2005; Yang et al., 2014). There are also 
antibacterial enzymes, ie. enzybiotics, that target cell membranes or cell walls of bacteria that are 
large in size (Nelson et al., 2001; Hojckova et al., 2013; Maestro and Sanz, 2016). Thus, finding 
a large antibacterial protein, rather than being surprising, shows the power and efficiency behind 
the method applied for screening such antimicrobials.  
Although, application of SDS-PAGE for direct screening of active agents seems efficient, it can 
fail to detect some polypeptides or short peptides if they lose their function under the reducing 
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and denaturing conditions that these gels operate. Therefore, for further testing it is 
recommended to use non-denaturing gels. By no means are the gel diffusion assays complete, 
and we intend to expand this approach to identify further antimicrobials.  
4.7 Formulation of cocktails  
Based on the αGV collection, its genomic diversity, and the overlapping complimentary 
properties specific to G. vaginalis for its isolates, we are suggesting two minimal cocktail 
formulations for further study against a more globally representative G. vaginalis collection. The 
first cocktail formulation would consist of exponentially growing bacterial cells: αGV19-1, 
αGV19-6, α-GV18-12S and αGV18-7aW.  Isolates αGV19-1, αGV19-6 are part of the ‘blue’ 
pangenome matrix cluster, while α-GV18-12S and αGV18-7aW are part of the ‘green’ and ‘red’ 
clusters, respectively. The second proposed cocktail would consist of αGV purified and 
concentrated active agents. Suggested active agents to further characterize as potential minimal 
cocktail components include αGV18-11, αGV19-7, αGV19-5, αGV19-2S and α523. Each of the 
clusters identified in the pangenome matrix would be represented for this formulation. With this 
formulation a diverse combination of bacteriocin cassettes would be represented excluding only 
Lanthipeptide class I orf013. The active agent of α523 would also be a part of the cocktail as it is 
effective against all isolates in our G. vaginalis collection. Thus, the cocktail would be diverse in 
mechanistic nature and function and consequently be affective in eliminating even antibiotic 
resistant G. vaginalis growth in BV positive women (Turovskiy et al., 2009).  
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4.8 Future work 
As a pilot study, further experiments must be completed before highly defined and effective 
cocktail formulations can be established. Suggested future work for this project would be to first 
expand the G. vaginalis collection to be globally representative, and then to utilize an alternative 
supernatant extraction method for unidentified active agents such as ammonium sulfate 
precipitation. Additionally, not all the extractable αGV active agents were visualized via the 
SDS-PAGE gel diffusion assay. Possibly non-denaturing gels could be utilized to identify the 
protein bands responsible for the active agent. The active agent bands would also need to be cut 
from the gel and be sequenced to confirm their identities. Generation of knockout mutants of the 
identified bacteriocin cassettes for each αGV isolate followed by replications of the gel diffusion 
assay could be beneficial to making a direct link between the bacteriocin in question and its 
activity. Further toxicological studies and proper in vivo studies using animal models are among 
some of the important steps to be taken before a novel alternative treatment option could be 
introduced to clinic. Positive therapeutic outcomes are also subjects to successful human trials to 
examine the acceptable variations in responses of individual patients to the therapy.   
5 Conclusion  
Although our G. vaginalis collection is limited to 17 isolates, the isolates were shown to have 
diversity among their antibiotic susceptibilities and genotypes. Acknowledging the differing 
properties of these isolates allows us to better comprehend the difficulties in treatment of BV. 
Moreover, it is highly possible that the GV isolates would not be equally susceptible to a given 
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antimicrobial agent. Therefore, we searched for bacteria capable of producing diverse therapeutic 
agents. The αGV isolates were found to be diverse in their antimicrobial activities, their genetic 
construction, and the type of antibacterial agent they produce. The elucidation of these active 
agents is necessary to demonstrate that the active agents can be isolated and concentrated to 
potentially be used in a cocktail without the incorporation of non-commensal bacterium to the 
vaginal environment. However, we cannot say much about their differences in function and 
mechanism of action. The αGV collection was shown to be superior to metronidazole, as 
regardless of G. vaginalis antibiotic susceptibility profiles and rapid resistance acquisition, the 
αGV isolates worked successfully to inhibit G. vaginalis growth. The αGV isolates could 
potentially be used with low dose antibiotics, reducing antibiotic usage and exposure and thus 
potentially reducing the inclining resistance rates. We speculate that the use of multiple diverse 
αGV isolates in combination with antibiotics will have a potential to more effectively eliminate 
diverse G. vaginalis growth. As well, synergism among αGV isolates has yet to be determined, 
which could further eliminate BV at an advanced rate. The potential of these natural 
antimicrobial agents for the therapeutic treatment of G. vaginalis and therefore bacterial 
vaginosis is promising.   
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Appendix A Epidemiology  
A.1 Bacterial vaginosis prevalence   
Table A.1  Reported prevalence rates of Bacterial vaginosis by location, date and population. 
Continent Country Study Location Date Population 
Age Range 
or Mean 
Age 
BV Prevalence % Reference 
N
o
rt
h
 A
m
er
ic
a 
C
an
ad
a 
 
Edmonton, 
Alberta 
1994-
1995 
2047 pregnant women attending 1 of 4 
obstetrical office or the University of 
Alberta Hospital  
18-45 
14 
 
Wenman et al., 2002 
Edmonton, 
Alberta 
1995-
1996 
2047 pregnant women attending 1 of 4 
obstetrical office or the University of 
Alberta Hospital (4.3% Aboriginal, 95.7% 
non-aboriginal) 
NS 
13.6 Overall 
33 Aboriginal 
13 Non-
aboriginal 
Wenman et al., 2004 
Toronto, 
Ontario 
 
2008-
2009 
 70 women attending one of two Toronto 
University associated hospitals (St. 
Michael’s hospital and Sunnybrook Health 
Sciences Centre) for an IUD insertion 
(Alice et al., 2012) 
18-45 
7.1 Baseline                
9 Follow-up 
Alice et al., 2012 
G
re
n
ad
a 
 St. George’s 
2009-
2011 
2677 non-menopausal women, obtaining 
pap smears 
15-49 16.1 - 21.4 
Brooks-Smith-Lowe 
and Rodrigo, 2013 
Ja
m
ai
ca
 
Kingston  1999 
269 pregnant women in 4 prenatal clinics. 
(2nd or 3rd trimester) 
14-40 44.1 Kamara et al., 2000 
M
ex
ic
o
 
Villahermosa, 
Tabasco 
2013-
2014 
201 women attending outpatient clinic for 
routine gynecological checkups  
16-74 25.9 
Magaña‐ Contreras 
et al., 2015 
U
n
it
ed
 S
ta
te
s 
United States 
1984-
1989 
13,747 of predominantly low-
socioeconomic pregnant women (23-26 
weeks gestation) attending 7 urban medical 
centers based on ethnic origin 
NS 6.1-22.7 
Goldenberg et al., 
1996 
Alabama 
1995-
1998 
584 women at baseline and at follow-up 
visits while attending STD clinics  
18-35 16.1-16.6 Gallo et al., 2012 
Chicago 
1998-
1999 
117 woman attending Rush-Presbyterian-
St. Luke’s Medical Center’s gynecology 
clinic 
NS 27.4 
Aroutcheva et al., 
2001 
Pittsburgh, 
Pennsylvania 
1998-
2001 
255 women attending sexually transmitted 
diseases clinic 
15-30 46 
Wiesenfeld et al., 
2003 
US Marines 1999 1938 women entering Us Marines Corp  17-33 27 Yen et al., 2003 
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Philadelphia, 
Pennsylvania 
1999-
2001 
69 pregnant women attending antenatal 
clinic. (18-35 weeks gestation) 
15-46 5.8 Tolosa et al., 2006 
Birmingham, 
Alabama  
1999-
2002 
3,620 women 15-44 37.96 Brotman et al., 2010 
United States 
2001-
2004 
3739 women participating in the National 
Health and Nutrition Examination Survey 
14-49 29.2 
Koumans et al., 
2007 
Eight Florida 
Panhandle 
Counties 
2003-
2004 
483 women, self-proclaimed douching 
practices and medical records 
14-45 31.3 - 70.5 Cottrell, 2006 
Mississippi 
2009-
2010 
African American women attending 
Mississippi State Department of Health 
STD Clinic. 
18-45 47.4 
(Muzny, Sunesara, 
Austin, et al., 2013) 
United States 
2005-
2006 
&  
2010-
2011 
1,016 postmenopausal women at first time 
point and 883 at second time point  
57-85 
23.3 in 2005-
2006 
38.0 in 2010-
2011 
Hoffmann et al., 
2014 
United States  
2006-
2012 
463,496 United States Army Women.  NS 16.6 Bautista, 2017 
United States 
1994-
2015 
3,730 women participating in the Women’s 
Interagency HIV Study 
NS 48.7 cumulative Massad et al., 2017 
Baltimore, 
Maryland; 
Birmingham, 
Alabama; 
Durhamand 
Raleigh, North 
Carolina; 
Pittsburgh, 
Pennsylvania; 
and San 
Francisco, 
California 
Pre-
2016 
1,365 women attending 1 of 10 family 
planning clinics, obstetrics-gynecology 
clinics, clinical research clinics, or STD 
clinics. All women are asymptomatic for 
BV   
15-25 
87 baseline 
83-93 follow-up 
Schwebke et al., 
2016 
S
o
u
th
  
A
m
er
ic
a 
A
rg
en
ti
n
a Santa Fe 
2001-
2003 
400 women  15-55 13.5 Fosch et al., 2006 
Buenos Aires 
2012-
2013 
210 pregnant women attending ‘Ramon 
Sarda’ Maternity Hospital. (symptomatic 
n=80; asymptomatic n=130) 
10-42 
18.7 
symptomatic 
17.6 
asymptomatic 
Mucci et al., 2016 
B
ra
zi
l 
Alagoas 1997 341 women from 4 villages 15-63 15.3 
De Lima Soares et 
al., 2003 
Vitoria, 
Espirito Santo  
2003-
2004 
290 women attending Primary Health Unit 14-49 21.3 Barcelos et al., 2008 
Serra Pelada, 
Para State 
2004 209 women from mining village NS 18.7 
(Miranda et al., 
2009) 
Maringá, 
Paraná 
2004-
2006 
133,966 cytology examinations of women 
from public and private health system for 
the presences of clue cells  
13-80 4.8 
(Storti-Filho et al., 
2011) 
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Pacoti, Ceara 
Pre-
2007 
579 women from 7 hamlets in Pacoti 
municipality 
12-49 20 Oliveira et al., 2007 
Botucatu, Sao 
Paulo  
2006-
2007 
245 low-risk pregnant women (5-40 weeks 
gestation) attending 1 of 8 health clinics 
12-44 21.6 Gondo et al., 2010 
South-Eastern 
Brazil 
2012-
2013 
1519 women attending cervical screening 14-54 30.1 
(Marconi et al., 
2015) 
C
h
il
e Concepción 
 1997
-1998 
242 women attending family clinics NS 33.1 Castro et al., 1999 
Santiago  2006 
100 women attending family planning 
clinics 
15-49 32.0 Lillo G et al., 2010 
C
o
lo
m
b
ia
 
Bogota 
1999-
2001 
155 pregnant women attending antenatal 
clinic. (18-35 weeks gestation) 
14-43 9.0 Tolosa et al., 2006 
E
cu
ad
o
r 
La Concordia 
Pre-
2010 
213 adolescent females attending 1 of 2 
high schools 
13-17 31.5 Vaca et al., 2010 
P
er
u
 
 Lima 
Pre-
1998 
630 women attending family planning 
clinic and/or gynecologist 
15-35 30.0 
(Sánchez et al., 
1998) 
Coastal, 
Highlands, 
Jungle Regions 
1997-
1998 
754 women from 18 villages through 
community-based organization 
18-67 40.8 García et al., 2004 
Lima, Trujillo, 
Chiclayo 
 2001 
 
779 low-income women  18-30 26.6 Jones et al., 2007 
E
u
ro
p
e 
B
u
lg
ar
ia
 
Plovdiv 
Pre-
1998 
200 women attending dermatology and 
venereology clinics. 
17-34 17.5 
Tchoudomirova, 
1998 
C
ze
ch
 
R
ep
u
b
li
c 
Brno 1990 600 women NS 11.5 Unzeitig et al., 1991 
D
en
m
ar
k
 
Odense 
1992-
1994 
2,927 pregnant women (17-24 weeks 
gestation)  
NS 13.7 Thorsen et al., 2006 
Denmark 
1998-
2002 
3,526 pregnant women attending antenatal 
care (2nd trimester, <20 weeks gestation) 
NS 16.0 Svare et al., 2006  
E
n
g
la
n
d
 
Bristol & 
Taunton  
1996-
1998 
1111 women terminating a pregnancy at 1 
of 3 hospitals; Southmead Hospital 
(Bristol), St. Michael’s Hospital (Bristol) 
and Musgrove Park Hospital (Taunton)   
16-44 29.3 Crowley et al., 2001 
Paddington, 
London  
Pre-
1997 
38 women whose husbands attend 
genitourinary medicine clinics 
NS 44.7 Keane et al., 1997 
London 
1998-
2000 
1201 pregnant women attending 1 of 34 
general practices or 5 family planning 
clinics (<10 weeks gestation) 
16-48 14.5 
(Oakeshott et al., 
2002) 
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South 
Yorkshire  
 Pre-
2008 
1,073 asymptomatic pregnant women (15-
24 weeks gestation) 
11 - >40 3.5 Akinbiyi et al., 2008 
F
in
la
n
d
 
Aland Islands 
1993-
2008 
Cervical cancer screening for all women 
aged 20, 25, 30, 35, 40, 45, 50, 55, 60 the 
years of 1993 (n=819), 1998 (n=824), 2003 
(n=790) and 2008 (n=771) 
20-60 
15.6 in 1993 
11.9 in 1998 
8.7 in 2003                 
8.6 in 2008 
Eriksson et al., 2010 
F
ra
n
ce
 
Nord-Pas-de 
Calais 
2006-
2008 
 14,193 pregnant women (1st 
 trimester: before 14 weeks gestation) 
NS 7.1 
Desseauve et al., 
2012 
Ir
el
an
d
 
Dublin 
1999-
2001 
203 pregnant women attending antenatal 
clinic (18-35 weeks gestation) 
16-44 5.9 Tolosa et al., 2006 
It
al
y
 
Lombardo  
1989-
1994 
1,441 asymptomatic pregnant women (3rd 
trimester: 8-9 months gestation) 
NS 4.9 
Cristiano et al., 
1996 
L
it
h
u
an
ia
 
Vilnius & 
Marijampole 
Pre-
2017 
116 women attending private gynecology 
clinics (119 samples) 
22-53 24.4 
(Janulaitiene et al., 
2017) 
N
o
rw
ay
 
Tromso  1996 
168 pregnant women whom had applied 
for abortions in their 1st trimester  
NS 24.0 
Bjørnerem et al., 
1997 
P
o
la
n
d
 
Lodz region 
2001 196 pregnant women from 10 district 
maternity units (8-16 weeks gestation) 
NS 28.1 Kalinka et al., 2002 
Zabrze 
2001-
2003 
450 pregnant women attending antenatal 
clinics (6-36 weeks gestation)  
NS 19.1 
Kaźmierczak et al., 
2004 
South-Eastern 
Poland 
Pre-
2013 
161 women; Attending PARENS infertility 
centre in Cracow, Poland (n=101), fertile 
(n=60) 
20-40 
7 infertile 
women 
Tomusiak et al., 
2013 
P
o
rt
u
g
al
 Lisbon 
1993-
1994 
840 women attending clinics 22-39 7.0 
Guerreiro et al., 
1998 
Braga & 
Senhora da 
Hora 
2014-
2016 
Pregnant women attending either Hospital 
of Braga and Unidada Local de Saúde de 
Matosinhos.  
M=30 +/- 
5.16 
3.8 
Machado et al., 
2017 
S
co
tl
an
d
 
Aberdeen, 
Dundee & 
Glasgow  
1995-
1996 
1599 women obtaining abortions at 1 of 4 
Scotland hospitals (Aberdeen Royal 
Infirmary, Ninewells Hospital, Glasgow 
Royal Infirmary and Western Infirmary) 
NS 17.5 Penney et al., 1998 
S
p
ai
n
 Barcelona 
1995-
1996 
293 pregnant women attending hospital 
clinic  
M=29.9 7.5 
Martínez de Tejada 
et al., 1998 
Barcelona  1998 
492 pregnant women (<28 weeks 
gestation) 
M=27 +/- 
5.5 
4.5 Gratacós et al., 1999 
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S
w
ed
en
 
Stockholm & 
Eskilstuna 
1989-
1991 
956 women attending youth and family 
planning clinics  
M=25.7 +/- 
6.9 
13.7 
(Nilsson et al., 
1997) 
A
si
a 
B
an
g
la
d
es
h
 
Dhaka 
2001-
2002 
399 married women attending 1 of 5 
family planning clinics 
NS 23.2 
(Rahman et al., 
2008) 
C
h
in
a 
Sichuan 
2003-
2004 
2000 married women 20-49 15.4 Yongjun et al., 2009 
Shandong 
Province  
2004 4,039 married women from rural location 20-49 5.9 Fang et al., 2007 
Tibetan region 
of Sichuan 
2007 397 women 18-72 51.6 Dai et al., 2010 
Beijing 2009 6,339 married women from 12 districts  15-54 8.7 Caiyan et al., 2012 
Beijing 
Pre-
2010 
6,337 women from 137 communes   25-54 8.7 (Xu et al., 2010) 
Anhui Province 2010 
53,286 married women from rural Anhui 
Province, China 
18-49 11.9 (Li et al., 2014) 
Maanshan city, 
Anhui Province 
2012 
793 pregnant women attending prenatal 
care 
20-≥30 15.6 (Li et al., 2015) 
Shanghai 
2009-
2013 
3502 women attending Fengxian Hospital, 
Southern Medical University 
NS 9.3 (Lu et al., 2015) 
In
d
ia
 
Goa 
2001-
2003 
2494 women who lived near the Aldona 
primary health centre 
18-45 17.8 Patel et al., 2006 
Chennai 2002 487 women from urban slum area  18-40 24.6 Tolosa et al., 2006 
New Delhi 
2003-
2004 
502 pregnant symptomatic and 
asymptomatic women (14-28 weeks 
gestation)  
18-35 
11.2 
symptomatic 
7 asymptomatic 
Dadhwal et al., 2010 
Mysore 
2005-
2006 
898 women attending 1 of 2 reproductive 
health clinics  
15-30 19.1 
Madhivanan et al., 
2009 
Lucknow 
Pre-
2010 
200 pregnant women attending antenatal 
clinic in tertiary hospital 
18-45 13 Lata et al., 2010 
Meerut, Uttar 
Pradesh  
2009-
2010 
500 pregnant women attending either Lala 
Lajpat Rai Memorial Medical College or 
associated Sardar Vallabhbhai Patel 
Hospital (<28 weeks gestation) 
 
21-31 19.6 Gupta et al., 2013 
In
d
o
n
es
ia
 
Jakarta 
1989-
1990 
490 pregnant women attending 1 of 3 
hospitals (16-20 and 28-32 weeks 
gestation) 
NS 17 Riduan et al., 1993 
Manado 1999 
357 women with intrauterine devices, 
attending a family planning clinic 
NS 32.5 Joesoef et al., 2001 
Ir
an
 
Fars Province  
1996-
1997 
Married Qashqa’i women (n=839), married 
Mamasani Lor women (n=274) and 
married women from Shiraz 
NS 40-50 
Keshavarz et al., 
2001 
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Hamedan 2005 
540 women attending university hospital 
(Symptomatic n=270, control; 
asymptomatic n=270) 
NS 
28.5 
symptomatic 
0.4 
asymptomatic 
Shobeiri and Nazari, 
2006 
NS  
Pre-
2006 
425 pregnant women attending a prenatal 
clinic (37-42 weeks gestation) 
NS 30.5 Ziaei et al., 2006 
Zanjan 
Pre-
2009 
500 married women attending 1 of 5 
primary health care clinics 
15-45 16.2 Bahram et al., 2009 
Qom  
Pre-
2014 
73 women attending infertility clinics in 
Qom City 
21.1-38.5 70.3 Ghiasi et al., 2014 
Ja
p
an
 Otaru, 
Hokkaido 
1993-
2000 
6,038 pregnant women attending Otaru 
Kyokai Hospital   
14-46 
13.6 in 1993 
21.4 in 2000 
Shimano et al., 2004 
Gifu 1995 
118 pregnant women attending the prenatal 
clinic at Iwasa Hospital  
21-37 13.6 
Puapermpoonsiri et 
al., 1996 
K
en
y
a 
Mombasa 
Pre-
1999 
HIV-1 seronegative female sex workers 
attending an STD clinic. Enrollment 
(n=647); Follow-up visits (n=3685) 
18-48 
36 enrollment 
33 follow-up 
visit 
Martin et al., 1999 
L
ao
s 
Vientiane 
2000-
2001 
1125 women attending gynecology 
outpatient department at Sethathirath 
Hospital  
15-49 25 
Sihavong et al., 
2007 
Vientiane 
2001-
2002 
500 pregnant women attending 1 of 2 
hospitals for antenatal care (< 20 weeks 
gestation) 
17-40 22 
Thammalangsy et 
al., 2006 
M
al
ay
si
a 
Kuala Lumpur 2012 
207 women admitted to Hospital Kuala 
Lumpur. 
NS 30.9 Younus et al., 2017  
M
y
an
m
ar
 
Yangon 
1999-
2001 
227 pregnant women attending antenatal 
clinic (18-35 weeks gestation) 
11-42 15.6 Tolosa et al., 2006 
N
ep
al
 
Kathmandu  2006 
200 pregnant women attending Paropakar 
Maternity and Women’s Hospital 
NS 28 
(Shrestha et al., 
2011) 
P
ak
is
ta
n
 
Rawalpindi 
2007-
2008 
100 women who had preterm labour NS 21.0 Islam et al., 2009 
P
h
il
ip
p
in
es
 
Manila 
1999-
2001 
202 pregnant women attending antenatal 
clinic (18-35 weeks gestation) 
15-43 7.5 Tolosa et al., 2006 
T
h
ai
la
n
d
 Khon Kaen 1995 
208 pregnant women attending the clinic at 
Khon Kaen University’s hospital, 
Srinagarind Hospital  
15-40 15.9 
Puapermpoonsiri et 
al., 1996 
Khon Kaen 
1999-
2001 
200 pregnant women attending antenatal 
clinic (18-35 weeks gestation 
16-42 11.5 Tolosa et al., 2006 
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Bangkok 
1999-
2001 
227 pregnant women attending antenatal 
clinic (18-35 weeks gestation 
16-42 12.5 Tolosa et al., 2006 
Bangkok 2003 
300 women with IUDs, attending family 
planning clinic at Siriraj Hospital 
NS 20.3 
Harikarnpukdee et 
al., 2004 
V
ie
tn
am
 
Nghe An 
Province 
2004 
505 pregnant women attending antenatal 
clinics 
15-49 7.0 (Goto et al., 2005) 
Haiphong 
Pre-
2006 
197 women from rural village 18-49 27.4 Go et al., 2006 
Bavi District 2006 1012 married women from rural district 18-49 11.0 Lan et al., 2008 
A
fr
ic
a
 
B
o
ts
w
an
a 
Gaborone 2000 
703 pregnant women attending 1 of 13 
antenatal clinics 
15-43 38.1 
Romoren et al., 
2007 
B
u
rk
in
a 
F
as
o
 Boulgou, Poni, 
Seno and 
Yatenga 
Provinces 
2003 
2133 pregnant women from 96 antenatal 
clinics  
15-49 6.4 
Kirakoya-
Samadoulougou et 
al., 2008 
Ouagodougou 2003 
2018 pregnant women and 883 non-
pregnant women 
15-49 7.9 
Kirakoya-
Samadoulougou et 
al., 2011 
C
en
tr
al
 
A
fr
ic
an
 
R
ep
u
b
li
c 
Bangui 1996 
481 pregnant women attending 1 of 3 
antenatal clinics 
< 22 29.1 
Blankhart et al., 
1999 
 
E
g
y
p
t 
Assiut 
2001-
2002 
468 3rd trimester pregnant women who are 
at high-risk for Premature rupture of the 
membranes (PROM) and/or preterm labour 
NS 33.3 Darwish et al., 2005   
G
h
a
n
a Accra 2001 
100 women attending family planning 
clinic  
19-48 25 Lassey et al., 2005 
M
o
za
m
b
iq
u
e 
Maputo 
2002-
2003 
435 women attending SAAJ clinic at 
Maputo Central Hospital for the 1st time 
14-24 12.9 Melo et al., 2008 
N
ig
er
ia
 
 Lagos & 
Yaba-Lagos 
2000 
140 women with vaginal discharge 
Cervical Cytology Clinic of the Lagos 
University Teaching Hospital. 
18-50 18.6 Anorlu et al., 2004 
Araba, Lagos 
2012-
2013 
270 pregnant women attending antenatal 
clinic at Lagos University University 
Teaching Hospital (14-36 weeks gestation) 
22-40 26.0 Afolabi et al., 2016 
 Port Harcourt 2014 
356 women (178 fertile, 178 tubal factor 
infertility) 
NS 17.8 Durugbo et al., 2015 
S
o
u
th
 
A
fr
ic
a 
Durban 
1994-
1995 
168 pregnant women (30 weeks or less 
gestation) 
16-44 52.0 
(Govender et al., 
1996) 
Khayelitsha 2000- 5,110 women participating in cervical 35-65 58.3 Myer et al., 2005 
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2002 cancer screening trial, follow-up with 
3,199 women and 86 HIV seropositive 
women 
Rural KwaZulu 2002 
226 women attending family planning 
clinics and 48 women attending antenatal 
clinic 
14-52 58.4 
(Frohlich et al., 
2007) 
Johannesburg 
2005-
2009 
1,954 HIV-seropositive women attending 
Themba Lethu Clinic 
18-65 54.0 Denslow et al., 2011 
Elandsdoorn 
Pre-
2011 
101 women attending Ndlovu Medical 
Centre, an HIV testing centre 
NS 33.7 Dols et al., 2011 
T
an
za
n
ia
 
Moshi  1999 
382 women attending maternal child health 
and family planning clinics 
16-46 33.9 Msuya et al., 2002 
Moshi 
2002-
2004 
2654 pregnant women attending 1 of 2 
primary healthcare clinics. (3rd trimester) 
14-43 20.9 Msuya et al., 2009 
T
h
e 
G
am
b
ia
 
Farafenni 1999 1348 women from 20 villages 15-54 37 
Walraven et al., 
2001 
NS 2000 30 married women from 5 villages  20-53 37 
(Morison et al., 
2005) 
U
g
an
d
a 
Rakai 
Pre-
2006 
1,264 married women with circumcised 
and uncircumcised husbands  
NS 
30.5 
circumcised 
husbands               
38.3 
uncircumcised 
husbands 
Gray et al., 2009 
Z
im
b
ab
w
e 
Harare 
1999-
2001 
210 pregnant women attending antenatal 
care. (18-35 weeks gestation) 
12-41 24.4 Tolosa et al., 2006 
Harare 
2002-
2003 
678 pregnant women partaking in 
Prevention of Mother to Child 
Transmission program 
(36 weeks gestation) 
M=24.2 +/- 
5.1 
32.6 Kurewa et al., 2010 
NS 
Pre-
2016 
571 women attending family planning and 
general health care clinics utilized in in 
Hormonal Contraception and Risk of HIV 
Acquisition Study 
18-35 30.8 Turner et al., 2016 
A
u
st
ra
li
a 
A
u
st
ra
li
a Melbourne 2008 
528 women attending Melbourne 
University 
17-21 4.7 Fethers et al., 2009 
NS 
 Pre-
2013 
1,093 women attending 29 primary care 
facilities 
16-25 11.8 
(Bradshaw et al., 
2013) 
O
ce
an
ia
 
P
ap
u
a 
N
ew
 
G
u
in
ea
 
Asaro Valley 
1995 
 
201 women from 16 rural villages 15-45 9.0 (Passey et al., 1998) 
N
ew
 
Z
ea
la
n
d
 
Otago Region 
2005-
2007 
69 pregnant women attending Queen Mary 
Maternity Services  
M=32 8.7 Lim et al., 2010 
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Appendix B Supplements, Reagents and Culture Media  
B.1 Supplements and reagents  
5 mg/mL hemin working solution: 
A volume of 0.5g of hemin powder was added to 10mL of M NaOH and mixed until dissolved. 
A volume of 900mL of sterile ddH2O was added to the solution and sterilized by autoclave, 
using liquid cycle at 121°C for 15 minutes. Solution was allowed to cool to room temperature 
then stored in the dark at 4°C for a maximum of 30 days.   
95 % (v/v) ethanol working solution: 
A volume of 5mL sterile ddH2O was added to 95mL anhydrous ethanol and mixed well by 
inversion.  
10 mg/mL vitamin K1 stock solution: 
A volume of 0.2mLVitamin K1 solution was added to 20mL 95% EtOH and stored in the dark at 
4°C. 
1 mg/mL vitamin K1 working solution:  
A volume of 1mL Vitamin K1 stock solution (10mg/mL) was added to 9mL sterile ddH2O and 
mix by inversion. Solution stored in the dark at 4°C for a maximum of 30 days.  
20% (v/v) glycerol: 
A volume of 100mL glycerol was added to 400mL of sterile ddH2O. The solution was sterilized 
by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. 
Laked, defiberated sheep blood: 
Defibrinated sheep blood was frozen at -20°C for a minimum of 8 hours and then warmed to 
37°C.  
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B.2 Culture media  
BHI broth: 
Approximate formula per litre: 
Casein Peptone    15.0 g 
Meat peptone/brain heart infusion  12.0 g 
Dipotassium phosphate   2.5 g  
Dextrose     2.0 g 
Yeast extract     5.0 g 
Sodium chloride     5.5 g 
A total of 42g dehydrated BHI broth media and 1g soluble starch was dissolved in 1L ddH2O. 
The media was sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
 
BHI top agar (0.7%) supplemented with 1% starch: 
7g of agar was added with 42g of dehydrated BHI broth media and 1g soluble starch to 1L of 
ddH2O. Media was mixed and sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 
30 minutes.  
 
BHI agar (1.5%) supplemented with 1% starch:  
15g of agar was added with 42g of dehydrated BHI broth media and 1g soluble starch to 1L of 
ddH2O. Media was mixed with magnetic stir bar and sterilized by autoclave, using liquid cycle at 
121°C and 15 Psi for 30 minutes.  
 
BHI agar (1.5%) supplemented with 1% starch and 10% FBS: 
15g of agar was added with 42g of dehydrated BHI broth media and 1g soluble starch to 900mL 
of ddH2O. Media was mixed with magnetic stir bar and sterilized by autoclave, using liquid 
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cycle at 121°C and 15 Psi for 30 minutes. Once media cooled to approximately 50°C 100mL of 
FBS was added.  
BHI agar (1.5%) supplemented with hemin and vitamin K1: 
15g of agar was added with 42g of dehydrated BHI broth media 100mL of ddH2O. 1mL hemin 
working solution (5mg/mL) and 1 mL vitamin K1 working solution (1mg/mL) were added to the 
media. Media was mixed with magnetic stir bar and sterilized by autoclave, using liquid cycle at 
121°C and 15 Psi for 30 minutes. Once media cooled to approximately 50°C 100mL of FBS was 
added.  
 
BHI Bilayer plates (1.5%):  
For the bottom layer 7g of agar was added with 42g of dehydrated BHI broth media and 1g 
souble starch to 1L of ddH2O. Media was mixed with magnetic stir bar and sterilized by 
autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. Once media cooled to 
approximately 50°C antibiotic working solutions for, 1mL of nalidixic aid sodium salt 
(20mg/mL) and 150µL of amphotericin B (20mg/mL) were added to the media. In a 30mm petri 
dishes, 15mL of media was dispensed.  
For the top layer 7g of agar was added with 42g of dehydrated BHI broth media and 1g soluble 
starch to 900mL of ddH2O. Media was mixed and sterilized by autoclave, using liquid cycle at 
121°C and 15 Psi for 30 minutes. Once media cooled to approximately 50°C antibiotic working 
solutions for, 1mL of nalidixic aid sodium salt (20mg/mL) and 150µL of amphotericin B 
(20mg/mL) were added to the media. Additionally, 100mL of pre-warmed (37°C) human whole 
blood were added to the media and mixed with magnetic stir bar. Once bottom layer was 
solidified 10mL of media was dispensed into petri dishes. 
TSA supplemented with 5% sheep blood: 
Approximate formula per litre: 
Pancreatic digest of casein  17.0 g 
  
170 
 
Papaic digest of soybean  3.0 g  
Dextrose    2.5 g 
Sodium chloride    5.0 g 
Dipotassium phosphate  2.5g 
15g of agar was added with 30g of dehydrated TSA media was dissolved in 950mL ddH2O. The 
Solution was sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes. Once 
media cooled 500mL of pre- warmed (37°C) laked, defiberated sheep blood was mixed into the 
media with magnetic stir bar. In a 92mm petri dishes, 42mL of media was dispensed to create a 
nutrient agar depth of 4mm +/- 0.5mm. 
 
CB broth: 
Formula per litre: 
Special peptone mix  23.0 g 
Sodium chloride  5.0 g 
L-cysteine   0.1 g 
Sodium carbonate  0.6 g 
Dextrose   2.5 g 
Magnesium sulfate  0.1 g 
Ferrous sulfate  0.02 g 
Tris    0.83 g 
Tris, hydrochloride  2.86 g 
A total of 35g dehydrated CB broth media was dissolved in 1L ddH2O. The media was sterilized 
by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
  
CB agar (1.5%): 
15g of agar was added with 35g of dehydrated CB broth media to 1L of ddH2O. Media was 
mixed and sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
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MH broth: 
Approximate formula per litre: 
Dehydrated infusion from beef  300.0 g 
Casein hydrolysate    17.5 g 
Starch       1.5 g 
A total of 21g dehydrated MH broth media was dissolved in 1L ddH2O. Media was mixed with 
magnetic stir bar and sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 
minutes.  
 
MH agar (1.5%):  
15g of agar was added with 21g dehydrated MH broth media was dissolved in 1L ddH2O. Media 
was mixed with magnetic stir bar and sterilized by autoclave, using liquid cycle at 121°C and 15 
Psi for 30 minutes. In a 92mm petri dishes, 42mL of media was dispensed to create a nutrient 
agar depth of 4mm +/- 0.5mm. 
MRS broth: 
Approximate Formula per litre: 
 Proteose peptone no. 3  10.0g 
 Beef extract    10.0g 
 Yeast extract    5.0g     
 Dextrose    20.0g 
 Polysorbate 80   1.0g 
 Ammonium citrate   2.0g 
 Sodium Acetate    5.0g 
 Magnesium sulfate   0.1g 
 Manganese sulfate   0.05g 
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 Dipotassium phosphate  2.0g  
A total of 55g dehydrated MRS broth media was dissolved in 1L ddH2O. The media was 
sterilized by autoclave, using liquid cycle at 121°C and 15 Psi for 30 minutes.  
MRS agar (1.5%): 
15g of agar was added with 55g dehydrated MRS broth media was dissolved in 1L ddH2O. 
Media was mixed with magnetic stir bar and sterilized by autoclave, using liquid cycle at 121°C 
and 15 Psi for 30 minutes. 
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Appendix C Molecular Techniques: Buffer and Reagent Preparations 
C.1 Common buffers 
1M Tris-HCl, pH 8.0:  
121.1g Tris base was dissolved in 800ml sterile ddH2O.  Concentrated HCl was added dropwise 
until a pH 8.0 was achieved. Additional sterile ddH2O was added to bring the final volume to 1L 
and mixed well.  
0.5M EDTA, pH 8.0: 
186.12 g of EDTA.Na2.2H2O was mixed with 800 ml ddH2O.While mixing vigorously, NaOH 
was added into the solution until a pH 8.0 was achieved. Additional sterile ddH2O was added to 
bring the final volume to 1L and mixed well. 
C.2 Bacterial cell lysis  
Cell lysis buffer, pH 8.0: 
250 ml 0.1M Tris-HCl pH 8.0 was added to 735mL of sterile ddH2O. Additionally, 5mL of 0.5 
mM EDTA pH, 8.0 and 10 ml 100% Triton X-100 were added. Solution was mixed well.  
10% Sodium dodecyl sulfate (SDS):  
100g of SDS was added to 800 ml sterile ddH2O and stirred on a magnetic stirrer until dissolved. 
Additional sterile ddH2O was added to bring the final volume to 1L and mixed well. 
C.3 Agarose gel electrophoresis 
50X Tris acetate (TAE), pH 8.3:   
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242g of Tris base was dissolved in 500mL of sterile ddH2O. 57.1mL of 1M Glacial acetic acid 
and 100mL 0.5M EDTA pH, 8.0 were also added. Additional sterile ddH2O was added to bring 
the final volume to 1L and mixed well. 
1X TAE running buffer: 
80 mL 50X TAE concentrated stock solution was mixed with 3.92L of sterile ddH2O. 
0.7% (w/v) agarose gel: 
0.7g of electrophoresis grade agarose was added to 100mL of 1X TAE running buffer. Solution 
was mixted well and heated until boiling point reached, and agarose was dissolved.  
2.0% (w/v) agarose gel: 
2g of electrophoresis grade agarose was added to 100mL of 1X TAE running buffer. Solution 
was mixed well and heated until boiling point reached, and agarose was dissolved.  
6X DNA loading buffer pH 8.0: 
2mL of sterile ddH2O was combined with 6mL of glycerol, 1mL of 0.5M EDTA pH 8.0 and 
1mL of 1% bromophenol blue in ddH2O. A volume of 1mL was transferred to 2mL cryotubes 
and stored at -20°C.  
C.4 SDS-PAGE electrophoresis  
Acrylamide/Bis acrylamide (30%, 29:1): 
145g of acrylamide was added with 5g of bis-acrylamide in 500mL of sterile ddH2O. Solution 
was mixed until dissolved, filtered and stored at 4°C.  
4X buffer A (1.5M Tris-HCl, pH 8.8): 
54.51g of tris base was added to 150mL of sterile ddH2O. Concentrated HCl was added dropwise 
until a pH 8.0 was achieved. Additional sterile ddH2O was added to bring the final volume to 
300mL and mixed well. 
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4X buffer B (0.5M Tris, pH 6.8): 
6g of tris base was added to 60mL of sterile ddH2O. Concentrated HCl was added dropwise until 
a pH 8.0 was achieved. Additional sterile ddH2O was added to bring the final volume to 100mL 
and mixed well. 
10% Sodium dodecyl sulfate (SDS): 
Refer to B.2. Bacterial cell lysis 
10% Ammonium persulfate (APS): 
0.1g of ammonium persulfate was dissolved in 1mL of sterile ddH2O.   
 
Sample buffer 2X:  
A volume of 2.5mL of 4X buffer B, 2.0mL of glycerol, 2.5mL of 10% SDS, β-mercaptoethanol, 
0.2mL of 0.2% bromophenol blue and 2.3mL of ddH2O.   
5X Running Buffer: 
15.14g of tris base, 7g of glycine, 5g of SDS was dissolved into 1L of ddH2O.  
 
1X Running Buffer:  
A volume of 100mL of 5X running buffer was diluted to 400mL of ddH2O. 
 
12% separating gel:  
The following reagents are added in order of appearance:  
Acrylamide/Bis acrylamide (30%, 29:1)  4mL 
ddH2O      3.3mL 
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4X Buffer A     2.5mL 
10% SDS     100µL 
10% APS     50µL 
TEMED     5µL 
Mixed by inversion and pipette into gel apparatus.  
 
15% separating gel: 
The following reagents are added in order of appearance:  
Acrylamide/Bis acrylamide (30%, 29:1)  5mL 
ddH2O      2.345mL 
4X Buffer A     2.5mL 
10% SDS     100µL 
10% APS     50µL 
TEMED     5µL 
Mixed by inversion and pipette into gel apparatus.  
 
4% stacking gel:   
The following reagents are added in order of appearance:  
Acrylamide/Bis acrylamide (30%, 29:1)  533µL 
ddH2O      2.4mL 
4X Buffer B     1mL 
10% SDS     40µL 
10% APS     20µL 
TEMED     4µL 
Mixed by inversion and pipette into gel apparatus.  
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Appendix D Antibiotic Susceptibility  
D.1 Quality control standards 
 
Table A.2  Expected and observed MIC values and susceptibility ratings for quality control 
strain, E. faecalis ATCC 29212. S: Susceptible; I: Intermediate; R: Resistant; “-“: No Defined 
Standards. 
 
Expected Observed 
Antibiotic  
MIC Ranges 
(µg/mL) 
S  I R MIC (µg/mL) Susceptibility 
Clindamycin (CM) 4-16 - - - 12-16 - 
Linezoid (LZ) 1-4 ≤4 - >4 3 S  
Vancomycin (VA) 1-4 ≤4 - >4 3 S  
Rifampicin (RI) 0.5-4 - - - 0.5 - 
Metronidazole (MZ) - - - - >256 - 
Ciprofloxacin (CI) - - - - 0.38 - 
Ampillicin (AM) 0.5-4 ≤4 - 8 0.75 S  
Tetracycline (TC) 8-32 - - - 8-16 - 
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Appendix E Plate Layouts: Bacterial and Supernatant  
 
 
E.1 High throughput target range assay 
__ __ __ __ __ __ __ __ __ __ __ __ 
BHI __ α523 __ αGV18-
1S 
__ 
αGV18-
2S 
__ 
αGV18-
3 
__ 
αGV18-
5 
__ 
__ 
αGV18-
6L 
__ 
αGV18-
7aW 
__ 
αGV18-
7b 
__ 
αGV18-
8 
__ 
αGV18-
9 
__ 
αGV18-
11 
αGV18-
12S 
__ 
αGV18-
13 
__ 
αGV18-
14S 
__ 
αGV18-
15 
__ 
αGV18-
16 
__ 
αGV18-
17 
__ 
__ 
αGV18-
18 
__ 
αGV18-
19W 
__ 
αGV18-
19YW 
__ 
αGV18-
20 
__ 
αGV19-
1 
__ 
αGV19-
2S 
αGV19-
3 
__ 
αGV19-
4S 
__ 
αGV19-
4L 
__ 
αGV19-
5 
__ 
αGV19-
6 
__ 
αGV19-
7 
__ 
__ 
αGV19-
8 
__ 
αGV19-
9 
__ 
αGV19-
10L 
__ 
αGV19-
11 
__ 
αGV19-
12S 
__ 
αGV19-
13 
αGV19-
14 
__ __ __ __ __ __ __ __ __ __ __ 
Figure E.1  Layout of bacterial cultures in 96 well plate utilized in high throughput target range 
assay. 
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E.2 Drop on the lawn 
 
 
 
 
BHI α523 α523 (PBSU101) αGV18-20 αGV18-1S αGV18-5 
αGV18-6L αGV18-11 αGV19-10L αGV19-11 αGV19-1 __ 
αGV18-15 αGV19-9 αGV19-13 αGV18-8 αGV18-18 αGV18-17 
Plate 1 
BHI α523 α523 (PBSU101) αGV19-6 αGV19-12S αGV19-3 
αGV19-7 αGV19-4S αGV19-14 αGV18-12S αGV19-2S __ 
αGV18-19YW αGV18-9 αGV18-7b αGV18-7aW αGV18-13 __ 
Plate 2  
Figure E.2 Layout of chloroform extracted supernatants for drop on the lawn experiment.   
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BHI α523 (PBSU101) αGV18-20 αGV18-1S 
αGV18-5 αGV18-6L αGV18-11 αGV19-10L 
αGV19-11 αGV19-1 αGV19-15 αGV19-9 
Plate 1 
BHI αGV19-13 αGV18-8 αGV18-18 αGV18-17 
αGV19-6 αGV19-12S αGV19-3 αGV19-7 __ 
αGV19-4S αGV19-14 αGV18-12S αGV19-5 __ 
Plate 2  
Figure E.3  Layout of methanol extracted supernatants for drop on the lawn experiment. 
 
 
